

## **Curriculum Vitae**

Date Prepared: September 30, 2014

Name: Alan D. Michelson

Office Address: Boston Children's Hospital, 300 Longwood Avenue, Karp 08213, Boston, MA  
02115-5737

Work Phone: 617-919-2116

Work Email: [alan.michelson@childrens.harvard.edu](mailto:alan.michelson@childrens.harvard.edu)

Work Fax: 617-730-4631

Place of Birth: Melbourne, Australia

## **Education**

1974	MB, BS (Bachelor of Medicine, Bachelor of Surgery) with honors	Medicine	University of Adelaide, Australia
2010	Master of Arts	Honorary degree	Harvard University

## **Postdoctoral Training**

01/74-01/75	Intern	Medicine	Alfred Hospital, Melbourne, Australia
02/75-02/76	Resident Medical Officer	Pediatrics	Royal Children's Hospital, Melbourne, Australia
03/76-01/78	Registrar	Pediatrics	The Children's Hospital, Camperdown, Sydney, Australia
02/78-01/82	Registrar	Pediatric Hematology	The Children's Hospital, Camperdown, Sydney, Australia
02/82-06/84	Research Fellow	Hematology	Boston Children's Hospital, Brigham and Women's Hospital, Harvard Medical School

## **Faculty Academic Appointments**

07/84-06/88	Assistant Professor	Pediatrics	University of Massachusetts Medical School
1986-1987	Lecturer	Pediatrics	Harvard Medical School
07/87-06/88	Assistant Professor	Pathology	University of Massachusetts Medical

07/87-06/88	Assistant Professor	Immunology Program	School Graduate School of Biomedical Sciences, University of Massachusetts, Worcester
07/88-06/93	Associate Professor	Pediatrics and Pathology	University of Massachusetts Medical School
07/88-06/93	Associate Professor	Immunology Program	Graduate School of Biomedical Sciences, University of Massachusetts, Worcester
07/93-05/09	Professor	Pediatrics and Pathology	University of Massachusetts Medical School
11/00-05/09	Professor	Medicine	University of Massachusetts Medical School
11/04-05/09	Faculty Member	Clinical & Population Health Research	Graduate School for Biomedical Sciences, University of Massachusetts, Worcester
05/09 - present	Adjunct Professor	Pediatrics	University of Massachusetts Medical School
09/10 - present	Professor	Pediatrics	Harvard Medical School
09/11 - present	Professor	Medicine	Harvard Medical School

### Appointments at Hospitals/Affiliated Institutions

#### **Past**

07/84-05/09	Attending Physician	Pediatrics Hematology/Oncology	University of Massachusetts Medical Center/UMass Memorial Health Care
07/85-06/96	Courtesy Medical Staff	Pediatrics	The Medical Center of Central Massachusetts
1986-1996	Affiliate Medical Staff	Pediatric Oncology	Dana-Farber Cancer Institute
1987-1991	Assistant in Medicine	Hematology/Oncology	Boston Children's Hospital
1991-1997	Consultant in Medicine	Hematology/Oncology	Boston Children's Hospital
1993-1997	Consultant	Cardiac Unit	Massachusetts General Hospital
1996-1998	Consultant Medical Staff	Pediatrics	The Medical Center of Central Massachusetts

**Current**

04/09-present	Active Staff	Pediatric Oncology	Dana-Farber Cancer Institute
05/09-present	Attending Hematologist	Hematology/Oncology	Boston Children's Hospital
06/09-present	Pediatrician, Affiliate Medical Staff	Newborn Medicine	Brigham and Women's Hospital
06/11-present	Senior Physician (research)	Hematology	Brigham and Women's Hospital
11/11-present	Consulting Medical Staff	Neonatology	Beth Israel Deaconess Medical Center

**Major Administrative Leadership Positions****Local**

07/95-05/09	Director, Center for Platelet Function Studies	University of Massachusetts Medical School
01/01-05/09	Vice Chair for Academic Affairs	University of Massachusetts Medical School Department of Pediatrics Boston Children's Hospital
05/09-present	Director, Center for Platelet Research Studies	Boston Children's Hospital Division of Hematology/Oncology
05/09-present	Director, Thrombosis and Anticoagulation Program	Boston Children's Hospital Division of Hematology/Oncology
04/10-present	Director, Platelet Assay Research Core Facility	Boston Children's Hospital Division of Hematology/Oncology

**International**

1992-1993	Principal Investigator of Reference Laboratory, Platelet Section	V International Workshop on Human Leukocyte Differentiation Antigens ("the CD Conference"), Boston
1992-1993	Workshop Leader for CD42a/42b (GPIb-IX), Platelet Section	V International Workshop on Human Leukocyte Differentiation Antigens ("the CD Conference"), Boston
05/06	Co-Organizer and Co-Chair	Platelets 2006 International Symposium, Ma'ale Hachamisha, Jerusalem, Israel
10/08	Co-Organizer and Co-Chair	Platelets 2008: 5 <sup>th</sup> International Platelet Symposium, Woods Hole, Massachusetts
05/10	Co-Organizer and Co-Chair	Platelets 2010: 6 <sup>th</sup> International Platelet Symposium, Ma'ale Hachamisha, Jerusalem, Israel
06/12	Co-Organizer and Co-Chair	Platelets 2012: 7 <sup>th</sup> International Platelet Symposium, Beverly, Massachusetts
04/14	Co-Organizer and Co-Chair	Platelets 2014: 8 <sup>th</sup> International Platelet Symposium and Platelets 2014 Educational Course, Ma'ale Hachamisha, Jerusalem, Israel

09/16 Co-Organizer and Co-Chair

Platelets 2016: 9<sup>th</sup> International Platelet Symposium, Wellesley, Massachusetts

### Committee Service

#### **Local**

1984-1985	Pediatric Resident Selection Committee	University of Massachusetts Medical Center
	1984-1985	Committee Member
1984-1985, 1988-1991	Cancer Committee	University of Massachusetts Medical Center
	1984-1985, 1988-1991	Committee Member
1985-1987	Transfusion Review Committee	University of Massachusetts Medical Center
	1985-1987	Committee Member
1985-1987	Cancer Education Committee	University of Massachusetts Medical School
	1985-1987	Committee Member
1985-2000	Personnel Action Committee, Department of Pediatrics	University of Massachusetts Medical School
	1991-1996, 1999-2000	Chair
1987	Pediatric Student Curriculum Committee	University of Massachusetts Medical School
	1987	Committee Member
1987-1990, 2000-2002	Scientific Council	University of Massachusetts Medical School
	1987-1990, 2000-2002	Council Member
1987-1993	Interdepartmental Immunology Committee	University of Massachusetts Medical School
	1987-1993	Committee Member
1988-1989	Evaluation of Faculty Teaching Committee, Department of Pediatrics	University of Massachusetts Medical School
	1988-1989	Committee Member
1989-1991	Medical Student Research Committee	Graduate School in Biomedical Sciences, University of Massachusetts, Worcester
	1989-1991	Committee Member
1990-1995	Transfusion Medicine Research Committee	University of Massachusetts Medical School
	1990-1995	Committee Member
1991-1992	Technology Transfer Committee	University of Massachusetts Medical School
	1991-1992	Committee Member
1991-1995	Patent Policy Committee	University of Massachusetts Medical School
	1991-1995	Committee Member
1999-2009	Research Advisory Committee, Department of Pediatrics	University of Massachusetts Medical School
	1999-2009	Committee Member
2001-2009	Executive Committee, Department of Pediatrics	University of Massachusetts Medical School
	2001-2009	Committee Member

2002	Search Committee for Director of Transfusion Services	UMass Memorial Health Care
2002-2005	2002 Faculty Council	Committee Member University of Massachusetts Medical School
2003	2002-2005 Liaison Committee on Medical Education (LCME) Work Group on Composite Assessment of Clinical Departments	Council Member University of Massachusetts Medical School
2008	2003 Ad Hoc Committee on Revising the Vision Statement	Committee Member UMass Memorial Children's Medical Center
2009-2011	2008 Master of Medical Sciences thesis committee for Rachael Grace, MD	Chair Harvard Medical School
2009-2011	2009-2011 Scholars in Clinical Science Committee for Rachael Grace, MD (fellow in pediatric hematology/oncology)	Member Boston Children's Hospital
2009-2014	2009-2011 Participant and Clinical Interactions Resource (PCIR) Scientific and Resource Review Committee, Harvard Catalyst (Harvard Clinical and Translational Science Center)	Member Harvard Medical School
2011	2009-2014 Search Committee, Physician-Scientist at the Assistant Professor or Associate Professor level	Member Division of Hematology/Oncology, Boston Children's Hospital; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Dana-Farber/Children's Hospital Cancer Center; Harvard Medical School
2011	2011 Ad hoc committee to evaluate the proposed appointment of a Professor of Medicine at Brigham and Women's Hospital	Member Faculty Affairs, Harvard Medical School
2012	2011 Review Panel, Child Health Pilot Grant Program, Harvard Catalyst (Harvard Clinical and Translational Science Center)	Member Harvard Medical School
2012	2012 Venous Thromboembolism Hospital-Acquired Condition Team, Boston Children's Hospital	Member National Solutions for Patient Safety Network
2012-2014	2012 Review Panel for Pilot and Core Grants, Translational Research Program (TRP)	Team Leader Boston Children's Hospital
2012-2014	2012-2014 Search Committee, Physician/Scientist at	Member Division of Hematology/Oncology, Boston

	the Assistant Professor or Associate Professor level	Children's Hospital; Department of Pediatric Oncology, Dana-Farber Cancer Institute; Dana-Farber/Children's Hospital Cancer Center; Harvard Medical School
2013 - present	2012-2013 Mentorship Committee for Pavan Bendapudi, MD (fellow in hematology/oncology)	Member Dana-Farber Cancer Institute
2014	2013 – present Ad hoc committee to evaluate a proposed promotion to Associate Professor of Pediatrics at Harvard Medical School	Member Faculty Affairs, Harvard Medical School
	2014	Chair
<b>Regional</b>		
1999-2004	NIH Program Project Grant 5P01HL056949-14 (Adhesion Molecules in Transfusion Biology)	Immune Disease Institute, Harvard Medical School
	1999-2004	Advisory Board
<b>National</b>		
1995-2007	Consensus Conference on Antithrombotic Therapy and Thrombolytic Therapy	American College of Chest Physicians
	1995	Invited Participant, Fourth Consensus Conference on Antithrombotic Therapy
	1998	Invited Participant and Chair of Pediatric Section, Fifth Consensus Conference on Antithrombotic Therapy
	2000	Invited Participant, Sixth Consensus Conference on Antithrombotic Therapy
	2003	Invited Participant, Seventh Consensus Conference on Antithrombotic and Thrombolytic Therapy
	2007	Panel Member, Eighth Consensus Conference on Antithrombotic and Thrombolytic Therapy
2009	Platelet Disorders – Thrombosis Subcommittee, Hemostasis and Thrombosis Section	Transfusion Medicine and Hemostasis (TMH) Network, State of the Science Symposium (SoSS), National Heart Lung and Blood Institute
2010	2009 Trans-Agency Coagulopathy in Trauma Workshop	Co-Chair National Heart, Lung, and Blood Institute and US Army Medical Research and Materiel Command
2010	2010 Workshop on Defining Molecular Pathways	Invited Participant National Heart, Lung, and Blood Institute

	and Mechanisms that Predict Cardiovascular Disease Risk Associated with Sleep-Disordered Breathing	
	2010	Invited Participant
2011-2012	Guided Antithrombotic Therapy (ATT) Working Group	National Heart, Lung, and Blood Institute
	2011-2012	Working Group Member
2011-2012	Protocol H7T-MC-TACX: An Open-Label, Dose-Ranging Study of Prasugrel in Pediatric Patients with Sickle Cell Disease	Eli Lilly and Company
	2011-2012	Independent External Monitor
2011 – present	Anticoagulation Subcommittee, The Pumps for Kids, Infants, and Neonates (PumpKIN) Program	National Heart, Lung, and Blood Institute
	2011 – present	Subcommittee Member
2012 – present	Thrombosis in Pediatric Cardiology and Congenital Heart Disease Working Group	National Heart, Lung, and Blood Institute
	2012 – present	Working Group Member
2013	Workshop on Stem Cell-Derived Blood Products for Transfusion	National Heart, Lung, and Blood Institute
	2013	Working Group Member
<b>International</b>		
1996	Consensus Conference on the Flow Cytometric Characterization of Platelet Function	European Working Group on Clinical Cell Analysis
	1996	Invited Participant
1998	16 <sup>th</sup> Meeting of the BEST (Biomedical Excellence for Safer Transfusion) Working Party	International Society of Blood Transfusion, American Association of Blood Banks
	1998	Invited Participant
2002	Reticulated Platelets Task Force	International Society for Laboratory Hematology
	2002	Invited Participant
2002-2006	Pharmacodynamic Assessment Committee (PAC)	PICOLO (Platelet Aggregation Inhibition in Children On Clopidogrel) multicenter randomized controlled trial
	2002-2006	Committee Member
2003	International Advisory Board	Second International Conference on Cardiovascular Medicine and Science, Bethesda, Maryland
	2003	Advisory Board Member
2006-2008	Scientific Advisory Board	plateletNEWS.org
	2006-2008	Member
2006-2011	Data Monitoring Committee (DMC)	CLARINET (Clopidogrel to Lower Arterial Thrombotic Risk In Neonates and Infants Trial) multicenter randomized controlled

	2006-2011	trial Committee Member
2007-2008	Steering Committee, Antiplatelet Therapies section	<a href="http://www.theheart.org">www.theheart.org</a> from WebMD
2008	2007-2008 Scientific Committee	Committee Member TCT 2008 (Transcatheter Cardiovascular Therapeutics 2008), Washington, DC
2008-2009	2008 Executive Committee	Committee Member HORIZONS AMI 1.5 ( <u>H</u> armonizing <u>O</u> utcomes with <u>R</u> evascular <u>I</u> zati <u>O</u> N and <u>S</u> tents in <u>A</u> cute <u>M</u> yocardial <u>I</u> nfarction 1.5) study
2009	2008-2009 Scientific Committee	Committee Member TCT 2009 (Transcatheter Cardiovascular Therapeutics 2009), San Francisco, CA
2009	2009 PhD Thesis Committee for Fiona Newall	Committee Member Melbourne School of Graduate Research, University of Melbourne, Australia
2010-2011	2009 Data Monitoring Committee (DMC)	PhD Thesis Examiner A Double-Blind, Randomized Multicenter Study of Prasugrel Compared to Placebo in Adult Patients with Sickle Cell Disease (Eli Lilly study H7T-MC-TAEK)
	2010-2011	Committee Member
2013 - present	Data Monitoring Committee (DMC)	A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease (Eli Lilly study H7T-MC-TADO)
2014	2013 - present International Scientific Advisory Board	Chair ALPIC 2014 (Advanced Learning on Platelets and Thrombosis International Course), University of Ioannina, Metsovo-Ioannina, Greece
	2014	Board Member

### Professional Societies

1974-1982	Australian Medical Association	
	1974-1982	Member
1982 – present	American Heart Association	
	1987-1997	Member, Thrombosis Council
	1997 – present	Fellow (FAHA) of the Council on Arteriosclerosis, Thrombosis, and Vascular Biology
1983-1984	American Medical Association	



	1983-1984	Member
1983-1984	Massachusetts Medical Society	
	1983-1984	Member
1983-1989	New England Hemophilia Association	
	1983-1989	Member
1984-2002	American Association for the Advancement of Science	
	1984-2002	Member
1985-1999	American Federation for Medical Research (formerly American Federation for Clinical Research)	
	1985-1999	Member
1985-1994, 2009 - present	American Society of Pediatric Hematology/Oncology	
	1985-1994, 2009 - present	Member
1986 - present	American Society of Hematology	
	2000-2004, 2011 - present	Member, Scientific Committee on Platelets
1989-2009	Children's Oncology Group (formerly Pediatric Oncology Group)	
	1989-2009	Associate Member
1989 - present	Society for Pediatric Research	
	1989-present	Member
1991-present	International Society on Thrombosis and Haemostasis (ISTH)	
	2000-2006	Member, Scientific and Standardization Committee (SSC)
	2001	Member, International Advisory Board, XVIII Congress, ISTH, Paris, France
	2001-2004, 2007-2010	Co-Chairman, Scientific Subcommittee on Platelet Physiology, SSC
	2003	Member, International Advisory Board, XIX Congress, ISTH, Birmingham, United Kingdom
	2004-2005	Chair, Working Party on Aspirin Resistance, Platelet Physiology Scientific Subcommittee, SSC
	2004-2007	Chairman, Scientific Subcommittee on Platelet Physiology, SSC
	2005	Member, International Advisory Board, XX Congress, ISTH, Sydney, Australia
	2006-2013	Co-Chair, Working Party on Standardization of Light Transmission Aggregometry, Platelet Physiology Scientific Subcommittee, SSC
	2006 – present	Member, SSC Senior Advisory Council

2007		Member, International Advisory Board, XXI Congress, Isth, Geneva, Switzerland
2009		Member, International Scientific Advisory Board, XXII Congress of the Isth, Boston, MA
2009		Scientific Program Subcommittee on Platelets (Clinical), XXII Congress of the Isth, Boston, MA
2011		Scientific Program Committee (Platelets Clinical), XXIII Congress of the Isth, Kyoto, Japan
2011		International Scientific Advisory Board, XXIII Congress of the Isth, Kyoto, Japan
2015		Platelets-Clinical Subcommittee, XXV Congress of the Isth, Toronto, Canada
1992-1994	International Society for Analytical Cytology	
	1992-1994	Member
2000 - present	American Pediatric Society	
	2000 – present	Member
2002-2010	Australasian Society of Thrombosis & Haemostasis	
	2002-2010	Member

### Grant Review Activities

1988-1989	Research Peer Review Committee	American Heart Association, Massachusetts Affiliate
	1988-1989	Permanent Member
1996	Program Project in Transfusion Medicine	National Heart, Lung, and Blood Institute
	1996	Reviewer
1998-1999	Study Group 4 ( <i>Cell Transport and Metabolism, Immunology and Microbiology</i> )	American Heart Association, Northeast Affiliate Consortium
	1998-1999	Permanent Member
1999	Program Project	National Heart, Lung, and Blood Institute
	1999	Reviewer
2000-2001	National Thrombosis Peer Review Committee	American Heart Association
	2000-2001	Permanent Member
2009	Special Emphasis Panel, ZRG1 VH D 58 R, RFA-OD-09-003, Challenge Grants Panel 20 (RC-1)	National Institutes of Health
	2009	Member
2013	Small Business Hematology Special Emphasis Panel, ZRG1 VH-(F10) B	National Institutes of Health

## Editorial Activities

### **1. Ad hoc Reviewer**

New England Journal of Medicine  
 Proceedings of the National Academy of Sciences, U.S.A.  
 Journal of Clinical Investigation  
 The Lancet  
 Circulation  
 Blood  
 Journal of Pediatrics  
 Pediatrics  
 Arteriosclerosis, Thrombosis, and Vascular Biology  
 Journal of the American College of Cardiology  
 Journal of Thrombosis and Haemostasis  
 Thrombosis and Haemostasis  
 Pediatric Blood and Cancer  
 Journal of Pediatric Hematology/Oncology  
 Journal of Laboratory and Clinical Medicine  
 Cytometry  
 Communications in Clinical Cytometry  
 European Journal of Cell Biology  
 Pediatric Research  
 Thrombosis Research  
 Blood Coagulation and Fibrinolysis  
 Platelets  
 American Journal of Hematology  
 Australian and New Zealand Journal of Medicine

### **2. Other Editorial Roles**

1993	Abstract Reviewer	Platelet Section, V International Workshop on Human Leukocyte Differentiation Antigens (“the CD Conference”), Boston, MA
1997	Abstract Reviewer	Pediatric Academic Societies' Annual Meeting, American Pediatric Society/Society for Pediatric Research/Ambulatory Pediatric Association, Washington, DC
1997	Abstract Reviewer	39 <sup>th</sup> Annual Meeting of the American Society of Hematology, San Diego, CA
2001	Abstract Reviewer	XVIII Congress of the International Society on Thrombosis and Haemostasis, Paris, France
2003	Abstract Reviewer	XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, United Kingdom

2005	Abstract Reviewer	XX Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia
2005	Abstract Reviewer	XXX World Congress of the International Society of Hematology, Istanbul, Turkey
2006 - present	Editorial Board	<i>Platelets</i> (Informa)
2007	Abstract Reviewer	XXI Congress of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland
2008	Abstract Reviewer	Platelets 2008: 5 <sup>th</sup> International Platelet Symposium, Woods Hole, MA
2008	Abstract Reviewer	50 <sup>th</sup> Annual Meeting of the American Society of Hematology, San Francisco, CA
2009	Abstract Reviewer	XXII Congress of the International Society on Thrombosis and Haemostasis, Boston, MA
2010	Abstract Reviewer	Platelets 2010: 6 <sup>th</sup> International Platelet Symposium, Ma'ale Hachamisha, Jerusalem, Israel
2011	Abstract Reviewer	XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan
2011	Chapter Reviewer	<i>Hematology 2011</i> , the Education Program Book of the 53 <sup>rd</sup> Annual Meeting of the American Society of Hematology
2012	Abstract Reviewer	Platelets 2012: 7 <sup>th</sup> International Platelet Symposium, Beverly, MA
2013	Abstract Reviewer	XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands
2014	Abstract Reviewer	Platelets 2014: 8 <sup>th</sup> International Platelet Symposium, Ma'ale Hachamisha, Jerusalem, Israel
2014 - present	Editorial Board	<i>HemOnc Today</i>

### Honors and Prizes

1968-1973	Commonwealth Scholarship	Australian Government	Scholarship for medical school, based on academic achievement
1974	Graduated MB, BS with Honors	University of Adelaide, Australia	Academic achievement
1981	English-Speaking Union Scholarship	English-Speaking Union, New South Wales, Australia	Scholarship for postgraduate studies at Boston Children's Hospital, Brigham and

1982-1985	Fulbright Scholarship	United States Government	Women's Hospital and Harvard Medical School Scholarship for postgraduate studies at Boston Children's Hospital, Brigham and Women's Hospital and Harvard Medical School
2002	<i>Best Book in Medical Science</i> Award	Association of American Publishers	Awarded for Michelson AD (editor). <i>Platelets</i> . Academic Press/Elsevier Science, San Diego, 2002
2010	Master of Arts	Harvard University	Honorary degree
2013	<i>Highly Commended</i> Prize in the category of Internal Medicine	British Medical Association (BMA) Medical Book Awards	Awarded for Michelson AD (editor). <i>Platelets</i> , 3 <sup>rd</sup> edition. Elsevier/Academic Press, San Diego, 2013

## **Report of Funded and Unfunded Projects**

### **Funding Information**

1982-1983	Clinical Fellowship New South Wales State Cancer Council, Australia PI
1982-1984	Research Fellowship Post Graduate Medical Foundation, University of Sydney, Australia PI
1984	Glycocalicin/von Willebrand Factor Binding Samuel A. Levine Research Fellowship, #13-439-834 (declined) American Heart Association, Massachusetts Affiliate PI
1985-1987	Glycocalicin/von Willebrand Factor Binding Research Grant-in-Aid, American Heart Association, Massachusetts Affiliate, #13-523-845 PI
1986-1988	Human Blood Platelet Glycoprotein Ib Charles A. King Trust Research Fellowship/The Medical Foundation PI
1986-1989	Human Blood Platelet Glycoprotein Ib Basil O'Connor Starter Scholar Research Award, March of Dimes Birth Defects Foundation, , #5-582 PI
1986-1989	Human Blood Platelet Glycoprotein Ib New Investigator Research Award, National Heart, Lung, and Blood Institute, HL36809 PI
1987-1992	Human Blood Platelet Glycoprotein Ib FIRST Award, National Heart, Lung, and Blood Institute, HL38138 PI

1990-1997	Flow Cytometric Assays of Platelet Function Subcontract from Naval Blood Research Laboratory, Boston University School of Medicine under Contract from Office of Naval Research PI
1992-1993	The Effect of Cilostazol on Platelet Activatability and the Expression of Platelet Membrane Glycoproteins Otsuka Pharmaceutical Company (Tokushima, Japan) Individual investigator-initiated research project Co-PI
1994-1997	Effects of Radiologic Contrast Media on Platelet Activation Nycomed, Inc. (Princeton, NJ) Individual investigator-initiated research project PI
1995-1996	Equipment grant Newman's Own, Inc. (Westport, CT) PI
1995-1996	The Effects of TLC C-53 on Platelet and Leukocyte Function in Patients Receiving Thrombolytic Therapy for Acute Myocardial Infarction The Liposome Company, Inc. (Princeton, NJ) Individual investigator-initiated research project (as a substudy of a phase II trial) Co-PI
1995-2000	Adhesion Molecules - Mediators of Organ Injury Trauma Center Grant to Department of Surgery, Harvard Medical School (PI Hechtman) from National Institutes of Health, GM-52585 Collaborator
1995-2000	Local and Systemic Consequences of Ischemia Grant to Department of Surgery, Harvard Medical School, (PI Hechtman) from National Institutes of Health , GM-35141 Collaborator
1996	Effects of GP531 on Platelet Function Gensia, Inc. (San Diego, CA) Individual investigator-initiated research project PI
1997-2001	Effect of Aggrastat on Platelet Function Medical School Grant, Merck & Co., Inc. (West Point, PA) Individual investigator-initiated research project PI
1997-1998	Diagnosis of Acute Myocardial Infarction by Measurement of Circulating Monocyte-platelet Aggregates CompuCyte Corporation (Cambridge, MA) Individual investigator-initiated research project PI
1997-1998	Measurement of Platelet Activation by the P-selectin Profile and its Diagnostic Value in Acute Coronary Syndrome Centocor Diagnostics of PA, Inc. (Malvern, PA) Individual investigator-initiated research project PI
1998	Assays of Platelet Function by Laser Scanning Cytometry and Flow Cytometry

CompuCyte Corporation (Cambridge, MA)  
Individual investigator-initiated research project  
PI

1998 A Study to Assess the Equivalence of the Accumetrics Rapid Platelet Function Assay (RPFA) in Patients who are Undergoing Coronary Intervention Procedures to: 1) a GPIIb-IIIa Receptor Blockade Assay Using I<sup>125</sup> Abciximab and 2) Platelet Aggregation Using a Chrono-Log Aggregometer for Detection of Platelet Aggregation  
Accumetrics, Inc. (San Diego, CA)  
Individual research project  
PI

1998-1999 Prediction of Cardiac Events After Angioplasty by Measurement of Circulating Monocyte-platelet Aggregates  
CompuCyte Corporation (Cambridge, MA)  
Individual investigator-initiated research project  
Co-PI

1998-1999 The Effects of ReoPro on Platelet Activation *In Vitro*  
Centocor, Inc. (Malvern, PA)  
Individual investigator-initiated research project  
PI

1998-2000 Circulating Heterotypic Aggregates in Coronary Artery Disease  
CompuCyte Corporation (Cambridge, MA)  
Individual investigator-initiated research project  
PI

1999-2000 The Effects of Retaplast and Alteplase on Platelet Function in Acute Myocardial Infarction  
Centocor, Inc. (Malvern, PA)  
Individual research project  
Co-PI

1999-2000 GPIIb-IIIa Antagonist-induced Fibrinogen Binding to Platelets  
Centocor, Inc. (Malvern, PA)  
Individual investigator-initiated research project  
Co-PI

1999-2000 Evaluation of Coated Circuits  
Terumo Cardiovascular Systems Corporation (Ann Arbor, MI)  
Individual research project  
PI

1999-2000 Circulating Heterotypic Aggregates in Stroke  
CompuCyte Corporation (Cambridge, MA)  
Individual investigator-initiated research project  
PI

1999-2000 A Study to Evaluate Blood Samples Obtained from Patients Undergoing Cardiac Surgery for Platelet Function Assay Development  
Accumetrics, Inc. (San Diego, CA)  
Individual investigator-initiated research project  
PI

1999-2002 *In Vivo* Effects of Abciximab on Platelet and Leukocyte Activation, Platelet-Leukocyte Aggregation, Platelet Procoagulant Activity, Platelet-Derived Microparticles, and Platelet-Endothelial Cell Adhesion in Patients with Unstable Angina/Non-Q Wave Myocardial Infarction: A Case-Control Study

Centocor, Inc. (Malvern, PA)  
Individual investigator-initiated research project  
Co-PI

2000 Role of LDL Cholesterol in Mechanisms of Unstable Ischemic Syndromes  
Kaneka America Corporation (New York, NY)  
Individual investigator-initiated research project  
Co-PI

2000 *In Vivo* Effects of Aggrastat and TNK-tPA on Platelet and Leukocyte Activation and Platelet-Leukocyte Aggregation. A Substudy of the Fibrinolytics and Aggrastat with ST Elevation Resolution Trial (FASTER)  
Merck & Co., Inc. (West Point, PA)  
Individual investigator-initiated research project (substudy of phase III drug trial)  
Co-PI

2000-2001 Validation of PAC1 Assay For Use In Clinical Studies  
Accumetrics, Inc. (San Diego, CA)  
Individual investigator-initiated research project  
PI

2000-2001 Randomized Comparative Trial of Dalteparin versus Unfractionated Heparin in Conjunction with Abciximab Platelet GPIIb/IIIa Inhibition During and Following Elective Percutaneous Coronary Intervention  
Pharmacia (Peapack, NJ)  
Individual investigator-initiated research project  
Co-PI

2000-2001 Placebo Controlled Randomized Administration of Reduced Dose Abciximab Prior to Percutaneous Coronary Intervention in Patients Receiving Intravenous Abciximab Infusion Following Pharmacologic Reperfusion of Acute Myocardial Infarction  
Centocor, Inc. (Malvern, PA)  
Individual research project  
Co-PI

2000-2001 Assays for the Clinical Monitoring of DX-9065 Therapy in Humans; Effects of DX-9065a on Platelet Function  
Daiichi Pharmaceutical Co. Ltd. (Tokyo, Japan),  
Individual investigator-initiated research project  
PI

2000-2001 XaNADU: Xa Neutralization in Atherosclerotic Disease Understanding. A dose ranging trial of DX-9065a vs. placebo to determine the pharmacokinetics, pharmacodynamics, safety profile, and biochemical marker relationships in older patients with coronary artery disease  
Duke Clinical Research Institute, Durham, NC  
Individual research project (substudy of phase II drug trial)  
PI

2000-2001 Plavix Monitoring by Ultegra: PAC1 as a Gold Standard  
Accumetrics, Inc. (San Diego, CA)  
Individual investigator-initiated research project  
PI

2000-2001 PAC1 Assay Core Laboratory Assays  
Accumetrics, Inc. (San Diego, CA)  
Individual research project



	PI
2000-2001	A. Effects of different anticoagulants on eptifibatide inhibition of platelet function as determined by Ultegra RPFA and ADP-stimulated PAC1 binding. B. Validation of PAC1 flow cytometric assay vs. abciximab receptor binding assay. C. Validation of the use of PAC1 flow cytometric assay for use with clopidogrel inhibited samples. Accumetrics, Inc. (San Diego, CA) Individual investigator-initiated research project Co-PI
2000-2001	Molecular Mechanism of Abciximab Reversal of Platelet Aggregation Centocor, Inc. (Malvern, PA) Individual investigator-initiated research project Co-PI
2000-2001	Platelet Priming by GPIIb-IIIa Antagonists Centocor, Inc. (Malvern, PA) Individual investigator-initiated research project Co-PI
2000-2001	Effects of Hypothermia and GPIIb-IIIa Antagonists on Platelet Function Radiant Medical (Redwood City, CA) Individual investigator-initiated research project PI
2001	Porcine Studies American Immuno Tech, LLC (Costa Mesa, CA) Individual research project PI
2001-2002	Effects of the Medtronic Distal Protection Device on Platelet Activation: Pulsed Floating Perfusion Model Medtronic AVE, Inc. (Santa Rosa, CA) Individual investigator-initiated research project Co-PI
2001-2002	Dissolution of Preformed Platelet Aggregates Centocor, Inc. (Malvern, PA) Individual investigator-initiated research project Co-PI
2001-2004	Effects of GPIIb-IIIa Antagonists on CD40L Eli Lilly & Co. (Indianapolis, IN) Individual investigator-initiated research project PI
2002	Evaluation of Soluble CD40L Plasma Levels Centocor, Inc. (Malvern, PA) Individual investigator-initiated research project PI
2002-2003	D8/17 Assay for Obsessive-Compulsive Disorder Callisto Pharmaceuticals (New York, NY) Individual investigator-initiated research project PI
2002-2004	A Proposed Novel Mechanism of Action of Clopidogrel: Inhibition of Monocyte Procoagulant Activity Sanofi-Synthelabo/Bristol-Myers Squibb (Princeton, NJ)

Individual investigator-initiated research project  
PI

2002-2007 Correlation of *In Vitro* and *In Vivo* Determinations of Aspirin Resistance, including Clinical Outcomes  
Dade Behring (Miami, FL)  
Individual investigator-initiated research project  
Co-PI

2003-2004 An Assay for the Diagnosis and Prediction of Abciximab-induced Thrombocytopenia  
Centocor, Inc. (Malvern, PA)  
Individual investigator-initiated research project  
PI

2004 Inhibition of leukocyte-platelet aggregation by WAY-197697  
Wyeth Pharmaceuticals (Collegeville, PA)  
Individual investigator-initiated research project  
Co-PI

2004-2005 Use of IRMA in a Reticulated Platelet Assay  
Beckman Coulter, Inc. (Miami, FL)  
Individual investigator-initiated research project  
PI

2004-2005 Effects of Clopidogrel on Platelet Response Variability: A Clinical Trial of 633 Patients  
Bristol-Myers Squibb/Sanofi-Synthelabo (Princeton, NJ)  
Individual investigator-initiated research project  
PI

2004-2005 Utility of BioCytex VASP Phosphorylation and P2Y<sub>12</sub> Haplotype Assays in Aspirin Resistance and Clopidogrel Resistance  
BioCytex (Marseilles, France)  
Individual investigator-initiated research project  
Co-PI

2004-2006 Inhibition of Platelet P2Y<sub>12</sub> Receptor  
Eli Lilly & Co. (Indianapolis, IN)  
Individual investigator-initiated research project  
Co-PI

2004-2006 TRIUMPH (A Transfusion Avoidance Efficacy and Safety Clinical Investigation, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Using Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients) trial  
Alexion Pharmaceuticals, Inc. (Cheshire, CT)  
Core platelet function laboratory for phase III drug trial  
PI

2005 *In Vitro* Analysis of A-zyyme Effects on Platelets  
ZymeQuest, Inc. (Beverly, MA)  
Individual investigator-initiated research project  
PI

2005-2006 Clinical Study to Investigate the Efficacy and Safety of Purified C1 Esterase Inhibitor (Human) for the Treatment of Hereditary Angioedema (HAE) in Acute Attacks and as Prophylactic Treatment to Prevent HAE Attacks  
Lev Pharmaceuticals, Inc. (Merion Station, PA)  
Phase III drug trial  
PI

2005-2007 SHEPHERD (Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multicenter Open-label Research Design Study) trial  
Alexion Pharmaceuticals, Inc. (Cheshire, CT)  
Core platelet function laboratory for phase III drug trial  
PI

2005-2007 PNH EXTENSION (A Phase III, Open-Label, Extension Study of Eculizumab in Patients with Transfusion Dependent, Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Participated in the TRIUMPH, SHEPHERD or X03-001 Studies) trial  
Alexion Pharmaceuticals, Inc. (Cheshire, CT)  
Core platelet function laboratory for phase III drug trial  
PI

2005-2007 Effects of Aspirin on Platelet Response Variability  
McNeil Consumer & Specialty Pharmaceuticals (Fort Washington, PA)  
Individual investigator-initiated research project  
PI

2005-2007 Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel – Thrombolysis in Myocardial Infarction (TRITON-TIMI) 38  
TIMI Study Group, Brigham and Women’s Hospital (Boston, MA)  
Platelet function substudy of a phase III drug trial  
PI

2006-2007 Effects of Aspirin on Platelet Response Variability  
Accumetrics, Inc. (San Diego, CA)  
Individual investigator-initiated research project  
PI

2006-2007 Preservation of Platelets for Hemostatic and Wound Healing Bandages  
NIH STTR Phase I with Universal Stabilization Technologies (contract no. W81XWH-05-C-0164), PI Frelinger  
Research Scientist

2006-2007 Effects of M-118 on Platelet Function  
Momenta Pharmaceuticals, Inc. (Cambridge, MA)  
Individual investigator-initiated research project  
Co-PI

2006-2007 Phase I Trial of M-118  
Momenta Pharmaceuticals, Inc. (Cambridge, MA)  
Platelet function core laboratory of phase I drug trial  
Co-PI

2006-2007 The Effects of Platelet P2Y<sub>12</sub> Inhibition by R-138727 on Platelet Procoagulant Activities  
Eli Lilly & Co. (Indianapolis, IN)  
Individual investigator-initiated research project  
Co-PI

2006-2008 Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation – Thrombolysis in Myocardial Infarction 44 (PRINCIPLE-TIMI 44) trial  
TIMI Study Group, Brigham and Women’s Hospital (Boston, MA)  
Platelet function studies core laboratory for a phase II drug trial  
PI

2006-2008 Assessment of Platelet Activation, Degranulation and Adhesion with Biomaterials Under Shear  
Boston Scientific Corporation (Natick, MA)

Individual research project  
Co-PI

2006-2009 Effects of 5-HT<sub>2A</sub> Antagonist on Platelet Function  
Arena Pharmaceuticals (San Diego, CA)  
Individual investigator-initiated research project  
PI

2007-2008 Diadenosine Boranotetraphosph(on)ates as Antithrombotic Drugs  
NIH SBIR Phase I with GLSynthesis  
Subcontract, PI Frelinger  
Research Scientist

2007-2008 Novel Antithrombotic Diadenosine Tetraphosphate Analogs  
NIH SBIR Phase I with GLSynthesis  
Subcontract, Research Scientist  
Subcontract PI Frelinger  
Research Scientist

2007-2008 The Effect of the Thrombopoietic Agent Eltrombopag on Platelet Function  
GlaxoSmithKline (Collegeville, PA)  
Individual investigator-initiated research project  
PI

2007-2009 Preservation of Platelets for Hemostatic and Wound Healing Bandages  
NIH STTR Phase II with Universal Stabilization Technologies (contract no. W81XWH-05-C-0164), PI Frelinger  
Research Scientist

2007-2009 Can IPF Assist in Risk-stratification of Chest Pain Patients in the Emergency Department Setting?  
Sysmex (Kobe, Japan)  
Individual investigator-initiated research project  
PI

2007-2009 PACT (Platelet Activity after Clopidogrel Termination)  
Sanofi Aventis/Bristol-Myers Squibb (Bridgewater, NJ)  
Individual investigator-initiated research project  
PI

2008-2009 A Pharmacodynamic Comparison of Prasugrel (LY640315) versus High Dose Clopidogrel in Subjects with Type 2 Diabetes Mellitus and Coronary Artery Disease  
Eli Lilly & Co. (Indianapolis, IN)  
Phase II drug trial (both patient site and platelet function core laboratory)  
PI

2008-2009 Pathobiology of Thrombocytopenia and Bleeding in Patients with Wiskott-Aldrich Syndrome  
Weill Cornell Medical College (New York, NY)  
Collaborator

2008-2009 P-selectin-specific Aptamer in Sickle Cell Disease  
Archemix Corp. (Cambridge, MA)  
Individual investigator-initiated research project  
Co-PI

2009-2011 Novel Antithrombotic Diadenosine Tetraphosphate Analogs  
NIH SBIR (2R44HL088828-02) Phase II with GLSynthesis, PI Frelinger  
Research scientist

2009-2012 Prasugrel and Abciximab: Complementary and Synergistic Inhibition of Prothrombotic Activities  
Eli Lilly & Co. (Indianapolis, IN)  
Individual investigator-initiated research project  
Co-PI

2009-2013 Platelet surface P-selectin, Monocyte-Platelet and Neutrophil-Platelet Aggregates, Prothrombin Fragment 1.2, and Plasma Tissue Factor Antigen in Open-label, Multicenter Controlled Clinical Trials of Eculizumab in Patients with Atypical Hemolytic-uremic Syndrome (Protocols C08-002A, C08-002B, C08-003A, C08-003B)  
Alexion Pharmaceuticals (Cheshire, CT)  
Platelet function and coagulation studies core laboratory for a phase III drug trial  
Co-PI

2010-2011 ELEVATE-TIMI 56  
TIMI Study Group, Brigham and Women's Hospital  
Platelet function studies core laboratory for a phase IV drug trial  
PI

2010-2011 Multi-parameter Assay for Modulating Thrombotic Therapy  
Center for Integration of Medicine and Innovative Technology (CMIT) Innovation Grant  
Collaborator

2010-2011 A Phase 1, Open-Label, Parallel Add-on Design Study to Assess the Effects of Multiple Oral Doses of Lansoprazole, Dexlansoprazole, Omeprazole or Esomeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects  
Takeda Global Research and Development Center, Inc. (Lake Forest, IL)  
Platelet function studies core laboratory for a phase I drug trial  
PI

2010-2012 Platelet Activation and Inhibition in Sickle Cell Disease (PAINS): A Pilot Study of Monitoring Platelet Function in Adolescents with Sickle Cell Disease  
Eli Lilly & Co. (Indianapolis, IN)  
An investigator-initiated basic research study  
Co-investigator

2010-2013 Antiplatelet Therapy: Platelet Inhibition, Polymorphisms, and Protein Biomarkers  
NIH 1R01HL098082-01 research subaward no. 104962  
Research subaward PI

2011-2012 Platelet Function Substudy of Omthera protocol no. OM-EPA-007 (An open-label, randomized, 2-way crossover study to evaluate the effect of multiple doses of Epanova® on the multiple-dose pharmacokinetics of simvastatin in healthy normal subjects)  
Omthera Pharmaceuticals (Princeton, NJ)  
Platelet function studies core laboratory for a phase II drug trial  
PI

2012-2013 Platelet Function Substudy of E5501-G000-305 (A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 versus Eltrombopag, in Adults with Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura))  
Eisai Pharmaceuticals (Woodcliff Lake, NJ)  
PI

2012-2013 Sepsis-on-a-Chip Sepsis Therapeutics with Continuous Pathogen Detection  
Defense Advanced Research Projects Agency (DARPA) N66001-11-1-4180/Wyss  
Institute for Biologically Inspired Engineering, Harvard University

	Collaborator
2013	GDF-15 Inhibition of Platelet Function AVEO Oncology (Cambridge, MA) Platelet function studies core laboratory PI
2012-2013	Sizing of Thrombosomes Cellphire (Rockville, MD) Platelet function studies core laboratory PI
2012-2013	Mechanisms of Allergic Transfusion Reactions NIH grant 1R21HL107828-01A1 Collaborator
2013	Evaluation of the Effects of Pulse Electric Field on Human Platelets GE Global Research (Niskayuna, NY) An investigator-initiated basic and clinical research study PI
2010-2013	PEGASUS-TIMI 54 TIMI Study Group, Brigham and Women's Hospital Platelet function studies core laboratory for a phase III drug trial PI
2010-2013	Pilot Study to Evaluate the Safety and Efficacy of a Home Monitoring Program for Children on Chronic Warfarin Therapy Program for Patient Safety and Quality (PPSQ) grant, Boston Children's Hospital Investigator
2011-2013	Effects of Oxycyte on Platelet Function Oxygen Biotherapeutics (Morrisville, NC) and Department of Defense An investigator-initiated basic and clinical research study Co-PI
2013-2014	Mechanisms of Prolonged Platelet Inhibition Following Exposure to Reversibly Binding P2Y <sub>12</sub> Antagonists Eli Lilly & Co. (Indianapolis, IN) An investigator-initiated basic and clinical research study Co-PI
2013-2014	Omeprazole Drug-Drug Interaction Study: A Randomized, Multiple Dose, 2-Period Crossover Study to Assess the Effect of Coadministration of Omeprazole (CYP2C19 Inhibitor) on the Pharmacodynamics and Pharmacokinetics of AT-10 in Healthy Subjects Considered to be Normal Metabolizers of CYP2C19 Based on Genotyping (Alleles *1/*1) Celerion (Lincoln, NE) Platelet function core laboratory for a phase II drug trial Co-PI
2013-2014	A Randomized, Multiple Dose, 2-Period Crossover Study to Assess the Pharmacodynamics and Pharmacokinetics of AT-10 Compared to Clopidogrel in Heavy Smokers Considered to be Normal Metabolizers of CYP2C19 Based on Genotyping (Alleles *1/*1) Celerion (Lincoln, NE) Platelet function core laboratory for a phase II drug trial Co-PI
2013-2015	Platelet Function in E5501-G000-310 and E5501-G000-311 (Randomized, Global,

	Double-blind, Placebo-controlled, Parallel-group Studies to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to an Elective Procedure) Eisai, Inc. (Woodcliff Lake, NJ) An investigator-initiated clinical research study Co-PI
2013-2016	Novel Antithrombotic Diadenosine Tetraphosphate Analogs NIH R44 (SBIR Phase IIb) 9R44TR000983-04A1 funded by the Center for Advancing Translational Sciences Co-investigator
2013-2018	Brain and Related Studies in SIDS Infants NIH 2P01HD036379-16A1 Co-investigator
2014-2015	Decreased Platelet Function as a Cause of Increased Bleeding in Patients with Hemophilia A Baxter Healthcare (Westlake Village, CA) An investigator-initiated clinical research study PI

## **Report of Local Teaching and Training**

### **Teaching of Students in Courses**

1984-2001	Neoplasia and Blood Disease Block, Pathophysiology Course 2 <sup>nd</sup> year medical students	University of Massachusetts Medical School Four hours per year
-----------	-------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------

### **Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)**

1984-2009	Pediatric hematology/oncology	University of Massachusetts Medical School
	Pediatric residents	Two hours of lectures per year
2009 - present	Pediatric hemostasis/thrombosis	Boston Children's Hospital
	Pediatric hematology/oncology fellows	Four hours of lectures per year

### **Clinical Supervisory and Training Responsibilities**

1983	Medical Preceptor/Graduate Program in Primary Health Care Nursing/Simmons College-Brigham and Women's Hospital	Two hours per week
1984-1988	Attending Physician in General Pediatrics/ University of Massachusetts Medical Center	One month per year
1984-2008	Attending Physician in Pediatric Hematology-Oncology/ University of Massachusetts Medical Center	1 - 6 months per year
1984-2009	Pediatric Hematology-Oncology Clinic Preceptor/ University of Massachusetts Medical Center	2 - 4 clinics per month

2009 - present	Attending Physician in Pediatric Hematology/Boston Children's Hospital	2 - 4 weeks per year
2009 - present	Pediatric Hematology Clinic	2 clinics per month
2010 - present	Preceptor/Boston Children's Hospital	
	Founder and Organizer, Multidisciplinary Pediatric Thrombosis and Hemostasis Rounds/Boston Children's Hospital	1 hour per month

### **Laboratory and Other Research Supervisory and Training Responsibilities**

1984-2009	Supervision of research by residents, clinical fellows, post-doctoral research fellows, and visiting scholars/University of Massachusetts Medical School	Weekly mentorship
2004-2009	PhD Thesis Committee for Robyn Marty-Roix/University of Massachusetts Medical School	2 hours every 4 months
2009 - present	Mentor, <i>Research Methods in Pediatric Heart Disease</i> , NIH Institutional National Research Service Award (T32)/Boston Children's Hospital	5% of my professional effort

### **Formally Supervised Trainees and Faculty**

1988-1990	Goran Matic, MD/Transfusion Medicine Physician, Germany Published one manuscript	
1991-1992	William L. Breckwoldt, MD/ Vascular Surgeon, Winchester, Massachusetts Published two manuscripts	
1991-1994	Damodara Rajasekhar , MD/ Pediatrician, Apple Valley, California Published four manuscripts	
1991-2003	Michael J. Rohrer, MD/ Professor of Surgery, University of Tennessee Health Science Center, Memphis Published fourteen manuscripts	
1994-1995	Charles A. LaRosa, MD/ Vascular Surgeon, Bayshore, New York Published two manuscripts	
1995-1996	Robert S. Podolsky, MD/Vascular Surgeon, Reston, Virginia Published one manuscript	
1997-1998	Brian D. Peyton, MD/Assistant Professor of Surgery, University of Colorado at Denver Published two manuscripts	
1998-1999	Craig C. Powell, MD/Vascular Surgeon, Marshfield Clinic, Marshfield, Wisconsin Published two manuscripts	
1999-2001	R. Brannon Claytor, MD/Plastic Surgeon, South Portland, Maine Published three manuscripts	
2000-2001	Charles S.C. Garnette, MD/Vascular Surgeon, Orlando, Florida Published three manuscripts	
2003-2007	Matthew D. Linden, PhD/Associate Professor in the Centre for Microscopy, Characterisation and Analysis, University of Western Australia, Perth, Australia Published fifteen manuscripts	



2006	Inge Tarnow DVM, PhD/Associate Professor, University of Copenhagen Faculty of Life Sciences, Denmark Published six manuscripts
2007-2009	Hung Chang, MD/Hematologist, Chang Gung Memorial Hospital, Taiwan Published two manuscripts
2011-2013	Michelle A. Berny-Lang, PhD/Scientific Program Manager, Center for Strategic Scientific Initiatives, National Cancer Institute
2012-present	Anja Gerrits, PhD/Postdoctoral research fellow, Boston Children's Hospital
2014-present	Thomas Gremmel, MD/Visiting Assistant Professor, Harvard Medical School and Visiting Scientist, Boston Children's Hospital

## **Report of Regional, National and International Invited Teaching and Presentations**

### **Invited Presentations and Courses**

Those presentations below sponsored by outside entities are so noted and the sponsors are identified.

### **Local Invited Presentations**

2011	Advances in Antiplatelet Therapy/Grand Rounds Transfusion Medicine, Harvard Medical School
2013	Platelets: How They Stick Together in Sickness and in Health/Seminar Pediatric Hematology/Oncology, Boston Children's Hospital, Dana-Farber Cancer Institute, Harvard Medical School
2013	Antiplatelet Therapy: Aggregate Knowledge/Seminar Hematology Division, Brigham and Women's Hospital, Harvard Medical School

### **Regional**

1985	Flow Cytometric Assessment of Platelet Membrane Glycoproteins/Hematology Research Seminar Boston University School of Medicine, Boston, Massachusetts
1989	Modulation of Platelet Surface Receptor Expression/Seminar Genetics Institute, Cambridge, Massachusetts
1989	Thrombin-induced Changes in Platelet Surface Receptor Expression/ Biochemistry Research Seminar Boston University School of Medicine, Boston, Massachusetts
1990	Modulation of Platelet Membrane Glycoprotein Ib/Seminar Hematology Research Seminar , Massachusetts General Hospital, Boston, Massachusetts
1990	Transfusion Medicine Review Course/Moderator University of Massachusetts Medical Center, Worcester, Massachusetts
1991	New Insights on the Effect of Open Heart Surgery on Platelets/Invited Lecture <i>Topics in Transfusion Medicine</i> Seminar, University of Massachusetts Medical Center, Worcester, Massachusetts
1991	Structural Modulation of the Platelet Surface/Seminar Cardiovascular Research Seminar Series, West Roxbury Veterans Administration Medical Center/Harvard Medical School, Boston, Massachusetts
1992	The Platelet Defect Acquired During Cardiac Surgery/Invited Lecture

Massachusetts Medical Society, Committee on Blood Banks, Dedham, Massachusetts

1993 Analysis of Platelet Reactivity in Whole Blood/Seminar  
Instrumentation Laboratory, Lexington, Massachusetts

1993 Platelets and Flow Cytometry/Invited Lecture  
Core Lecture Series, Cardiac Unit, Massachusetts General Hospital, Boston, Massachusetts

1994 Activation-induced Down-regulation of the Platelet Surface GPIb-IX Complex/Seminar  
Division of Experimental Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts

1994 Clinical Studies of Platelet Activation/Seminar  
Maine Medical Center Research Institute, Scarborough, Maine

1997 Flow Cytometry: A Clinical Test of Platelet Function/Medical Grand Rounds,  
Maine Medical Center, Portland, Maine

1997 Platelet Surface Glycoproteins/Invited Lecture  
Maine Medical Research Institute, Scarborough, Maine

1998 Platelet Flow Cytometry/Invited Lecture  
Laboratory Medicine Conference, Massachusetts General Hospital, Boston, Massachusetts

1999 Platelet Function Testing by Flow Cytometry/Invited Lecture  
DAKO Discovery Series: Flow Cytometry Tools and Solutions, Boston, Massachusetts

2000 Circulating Platelet-Leukocyte Complexes in Cardiovascular Disease/Seminar  
Genetics Institute, Andover, Massachusetts

2000 Platelet Activation: From Bench to Bedside/Hematology Seminar  
Center for Blood Research, Harvard Medical School, Boston, Massachusetts

2001 GPIIb-IIIa Receptor Antagonists/ Hematology Grand Rounds  
Lahey Clinic, Burlington, Massachusetts

2004 Aspirin Resistance/Cardiology Grand Rounds  
Hartford Hospital, Hartford, Connecticut

2004 Platelet Function and Dysfunction in Cardiovascular Disease/ Cardiology Grand Rounds  
Boston University School of Medicine, Boston, Massachusetts

2006 Assessment of Platelet Function: Flow Cytometry and VASP/ TIMI Grand Rounds  
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

2006 Residual Arachidonic Acid-Induced Platelet Activation via an Adenosine Diphosphate-  
Dependent but Cyclooxygenase-1- and Cyclooxygenase-2-Independent Pathway: A 700-  
Patient Study of Aspirin Resistance/Invited Discussant  
Brigham and Women's Hospital Atherothrombosis eJournal Club, Boston, Massachusetts

2008 Antiplatelet Therapy: Aggregate Knowledge/Invited Lecture  
Harvard Blood Scholars Lecture Series, Boston Children's Hospital/Harvard Medical School, Boston, Massachusetts

2008 Platelets and Thrombosis: From Basic Mechanisms to Therapies/Research Seminar  
Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts

2009 Platelet Function Testing in Thrombosis: How, When, and Why?/Medical Grand Rounds  
Boston Scientific Corporation, Marlborough, Massachusetts

2011 Hormonal Contraception and Thrombotic Risk/Pediatric Grand Rounds  
University of Massachusetts Medical School, Worcester, Massachusetts

2012 Advances in Antiplatelet Therapy/Hematology-Oncology Grand Rounds  
UMass Memorial Health Care/University of Massachusetts Medical School, Worcester, Massachusetts

2012 Clopidogrel Pharmacokinetics and Pharmacodynamics/Cardiology Grand Rounds

- 2012 VA Boston Healthcare System, Boston, Massachusetts  
Advances in Antiplatelet Therapy/Invited Lecture  
GE Global Research, Niskayuna, New York
- 2012 Clopidogrel Pharmacokinetics and Pharmacology/Hematology-Oncology Grand Rounds  
UMass Memorial Health Care/University of Massachusetts Medical School, Worcester, Massachusetts
- 2012 Antiplatelet Therapy: Aggregate Knowledge/The Third Annual Peter H. Levine, M.D. Lecture  
UMass Memorial Health Care/University of Massachusetts Medical School, Worcester, Massachusetts

### **National**

- 1991 Activation-induced Downregulation of Platelet Membrane Glycoprotein Ib/ Grand Rounds  
Center for Blood Diseases, University of Miami School of Medicine, Miami, Florida
- 1991 Flow Cytometric Assays of Platelet Activation: Diagnostic Applications/Seminar  
Coulter Electronics, Inc., Hialeah, Florida
- 1991 Flow Cytometry in the Analysis of Platelet Antigens/Special Seminar  
Department of Medicine, Cornell University Medical College, New York, New York
- 1993 The Platelet Function Defect of Cardiopulmonary Bypass/Surgical Grand Rounds and Visiting Professor  
Albany Medical College, Albany, New York
- 1994 Procoagulant Activity of Platelet-derived Microparticles in Whole Blood: Differences Between Neonates and Adults/Invited Lecture  
Platelet Symposium, Miles Diagnostics, Inc., Tarrytown, New York
- 1994 The Hemostatic Defect of Cardiopulmonary Bypass/Invited Lecture  
*Cardiopulmonary Bypass in the 90s*, Annual Postgraduate Course, Division of Cardiothoracic Anesthesiology, Emory University, Atlanta, Georgia
- 1994 The Platelet Function Defect of Cardiopulmonary Bypass/Invited Lecture  
Cardiovascular Science and Technology Conference '94 (CVSTC '94), American Society for Artificial Internal Organs (ASAIO)/National Heart, Lung, and Blood Institute, Washington, DC
- 1995 Clinical and Research Applications of Flow Cytometry for Study of Platelet Function/Invited Lecture  
12<sup>th</sup> Annual Hemostasis and Thrombosis Update 1995, Temple University School of Medicine, Philadelphia, Pennsylvania
- 1995 Platelet Function in the Newborn/Invited Plenary Lecture  
Pediatric Academic Societies (American Pediatric Society/Society for Pediatric Research/Ambulatory Pediatric Association) Annual Meeting, San Diego, California
- 1995 Neonatal Immunology and Hematology/Moderator of Platform Session  
Pediatric Academic Societies (American Pediatric Society/Society for Pediatric Research/Ambulatory Pediatric Association) Annual Meeting, San Diego, California
- 1996 Flow Cytometry: A Clinical Test of Platelet Function/Seminar  
Coulter Corporation, Miami, Florida
- 1996 Flow Cytometry: A Clinical Test for Platelet Function/Invited Lecture  
Workshop: *Stem Cells and Platelets: Straight from the Source*, 38<sup>th</sup> Annual Meeting of the American Society of Hematology, Orlando, Florida (Becton Dickinson)
- 1997 Applications of Flow Cytometry for Study of Platelet Function/Invited Lecture  
14<sup>th</sup> Annual Hemostasis and Thrombosis Update 1997, Temple University School of

- Medicine, Philadelphia, Pennsylvania
- 1997 Clinical Use of Flow Cytometry to Assess Platelet Activation/Invited Lecture  
Clinical Applications of Cytometry 12<sup>th</sup> Annual Meeting, Clinical Cytometry Society,  
Charleston, South Carolina
- 1997 Guidelines for Antithrombotic Therapy/Invited Lecture  
*Hypercoagulable States* Symposium, American Society of Pediatric  
Hematology/Oncology, 10<sup>th</sup> Annual Meeting, San Francisco, California
- 1997 *Neonatal Immunology and Hematology*/Moderator of Platform Session  
Pediatric Academic Societies Annual Meeting, Washington, DC
- 1997 Platelet Activation Markers in Cardiovascular Disease/ Seminar  
Centocor, Inc., Malvern, Pennsylvania
- 1998 Flow Cytometry: A Clinical Test of Platelet Function/Invited Teleconference Lecture  
American Society of Clinical Pathologists (ASCP)
- 1998 Anticoagulation Therapy in Pediatric Patients/Invited Lecture and Chair of Pediatric  
Section  
Fifth Consensus Conference on Antithrombotic Therapy, American College of Chest  
Physicians Evidence-Based Clinical Practice Guidelines, Tucson, Arizona
- 1998 Antithrombotic Therapy in Children/State of the Art Plenary Invited Lecture  
Pediatric Academic Societies Annual Meeting, New Orleans, Louisiana
- 1998 Thromboembolic Disease in Children: A Product of Modern Technology/Moderator, State  
of the Art Plenary Session  
Pediatric Academic Societies Annual Meeting, New Orleans, Louisiana
- 1998 Platelet Surface Receptor Changes in Cardiovascular Diseases/Invited Lecture and Visiting  
Professor  
Fourth Annual Mayo Multidisciplinary Symposium on Platelets, Blood Vessels, and  
Extracorporeal Medicine, Mayo Clinic, Rochester, Minnesota
- 2000 Leukocyte Cathepsin G-Mediated Mechanism for the Loss of Surface P-Selectin from  
Circulating Degranulated Platelets/Seminar  
Thrombosis Research Center, Temple University School of Medicine, Philadelphia,  
Pennsylvania
- 2000 Validation of PAC1 Monitoring of Antiplatelet Therapy/Invited Lecture  
Becton Dickinson, San Jose, California
- 2000 GPIIb-IIIa Antagonists/Invited Lecture  
Education Program, 42<sup>nd</sup> Annual Meeting of the American Society of Hematology, San  
Francisco, California
- 2001 Platelets 'R Us: Clinical and Research Studies of Platelets/Seminar  
Cellular Analysis Division, Beckman Coulter, Inc., Miami, Florida
- 2001 Evaluation of Platelet Function By Flow Cytometry/Invited Lecture  
18<sup>th</sup> Annual Hemostasis and Thrombosis Update 2001, Temple University School of  
Medicine, Philadelphia, Pennsylvania
- 2002 Flow Cytometry for Platelet Function Assessment/Invited Lecture  
*Bleeding and Thrombosing Diseases: The Basics and Beyond*, Mayo Coagulation  
Conference, Mayo Clinic, Rochester, Minnesota
- 2003 How Platelets Work: Platelet Function and Dysfunction/Invited Lecture  
Seventh National Conference on Anticoagulant Therapy, Anticoagulation Forum, San  
Francisco, California
- 2003 Platelet Inhibitor Therapy: Mechanisms of Action and Clinical Use/Invited Lecture  
Seventh National Conference on Anticoagulant Therapy, Anticoagulation Forum, San

Francisco, California  
 2003 Platelet Function Testing and Variability of Response: Aspirin and Clopidogrel Resistance/Invited Lecture  
 EVEREST Scientific Advisory Council Meeting, New York, New York (Sanofi Aventis/Bristol-Myers Squibb)  
 2004 Platelets: How They Stick Together in Sickness and in Health/Invited Lecture  
 Hematology Speaker Series, Beckman Coulter, Inc., Miami, Florida  
 2004 Clopidogrel Response Variability/Invited Lecture  
 EVEREST Scientific Advisory Council Meeting, Washington, DC (Sanofi Aventis/Bristol-Myers Squibb)  
 2004 Measurement of Aspirin Resistance/Invited Lecture  
 Aspirin Resistance Roundtable Meeting, New Orleans, Louisiana (McNeil Consumer Healthcare)  
 2005 Platelet Function Testing in Cardiovascular Disease/Invited Lecture  
 EVEREST Scientific Council Meeting, New York, New York (Sanofi Aventis/Bristol-Myers Squibb)  
 2005 Aspirin Resistance/Invited Lecture  
 Dade Behring Hemostasis Fall Series, Scottsdale, Arizona  
 2006 Methods of Determining Platelet Function: Is there a 'Right' One?/Invited Lecture  
 Platelet Colloquium, University of Kentucky/Duke Clinical Research Institute, Miami, Florida  
 2006 Aspirin Resistance: State of the Art/Invited Lecture  
 Second Annual Hemophilia and Thrombosis Research Society (HTRS) Symposium, Chicago, Illinois  
 2006 The Spectrum of Point-of-Service Devices to Measure Antiplatelet Effects: Similarities, Differences, and Whether They Should be Standard of Care/Invited Lecture  
 TCT 2006 (Transcatheter Cardiovascular Therapeutics 2006), Washington, DC  
 2006 Emerging Insights Linking Platelet Biology and Clinical Outcomes/Invited Lecture  
 TCT 2006 (Transcatheter Cardiovascular Therapeutics 2006), Washington, DC  
 2006 Measurement of Platelet Function in Patients with Coronary Artery Disease: How and Why?/Research Seminar  
 Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania  
 2006 *Ex Vivo* Determination of Platelet Function: Is There a "Gold Standard?"/Invited Lecture  
 American Heart Association Scientific Sessions, Chicago, Illinois  
 2006 Late Stent Thrombosis After Drug-eluting Stents: Role of Platelet Function Testing/Invited Presentation  
 Circulatory System Devices Panel, Food and Drug Administration (FDA), Gaithersburg, Maryland  
 2007 *Aspirin and Clopidogrel Resistance: Fact or Fiction* Symposium/Co-chair  
 American College of Cardiology 56<sup>th</sup> Annual Scientific Session, New Orleans, Louisiana  
 2007 Measurement of Platelet Variability/Invited Lecture  
 American College of Cardiology 56<sup>th</sup> Annual Scientific Session, New Orleans, Louisiana  
 2007 P2Y<sub>12</sub> Antagonism: Promises and Challenges/Invited Lecture  
*Translational Therapeutics at the Platelet Vascular Interface* Symposium, Annual Conference 2007, Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Council of the American Heart Association, Chicago, Illinois (Boehringer Ingelheim)  
 2007 Thienopyridine Hyporesponsiveness: Definitions, Implications, and Monitoring

Considerations in ACS and PCI/Invited Lecture  
 2007 TCT 2007 (Transcatheter Cardiovascular Therapeutics 2007), Washington, DC  
 Antiplatelet Decisions in NSTEMI/Moderator  
 2007 TCT 2007 (Transcatheter Cardiovascular Therapeutics 2007), Washington, DC  
 Update on the New Antiplatelet Agents: Novel P2Y<sub>12</sub> Inhibitors/Invited Lecture  
 2007 TCT 2007 (Transcatheter Cardiovascular Therapeutics 2007), Washington, DC  
 What is the Prevalence of Aspirin Resistance Among Patients with Coronary Artery  
 Disease?/Invited Lecture  
 80<sup>th</sup> Scientific Sessions of the American Heart Association, Pre-Session Symposium: *Anti-  
 Platelet Drug Resistance: Phoenix Rising or Dead Duck*, Orlando, Florida  
 2008 Essentials of Platelet Function Testing/Invited Lecture  
 TCT 2008 (Transcatheter Cardiovascular Therapeutics 2008), Washington, DC  
 2008 Update on New Antiplatelet Agents/Moderator  
 TCT 2008 (Transcatheter Cardiovascular Therapeutics 2008), Washington, DC  
 2008 Aspirin Resistance: Role of Pre-existent Platelet Reactivity, Correlation Between Tests,  
 and Impact on Clinical Outcomes/Invited Lecture  
 TCT 2008 (Transcatheter Cardiovascular Therapeutics 2008), Washington, DC  
 2008 *Challenges in Anticoagulation Management in the Child with Heart Disease*  
 Cardiovascular Seminar/Moderator  
 81<sup>st</sup> Scientific Sessions of the American Heart Association, New Orleans, Louisiana  
 2008 *Thrombotic Thrombocytopenic Purpura and Heparin-induced Thrombocytopenia* Oral  
 Session/Moderator  
 50<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH), San Francisco,  
 California  
 2008 *Pathogenesis and Treatment of Idiopathic Thrombocytopenic Purpura* Oral  
 Session/Moderator  
 50<sup>th</sup> Annual Meeting of the American Society of Hematology (ASH), San Francisco,  
 California  
 2009 Response Variability and the Role of Platelet Function Testing/Invited Lecture  
 American College of Cardiology 58<sup>th</sup> Annual Scientific Session and the i2 Summit,  
 Orlando, Florida  
 2009 Platelet Disorders – Thrombosis/Invited Speaker  
 State of the Science Symposium in Transfusion Medicine and Hemostasis and Thrombosis,  
 National Heart Lung and Blood Institute, Bethesda, Maryland  
 2009 Platelet Function and Bleeding in ITP/Invited Lecture  
*Cytopenias Forum*, Orlando, Florida  
 2009 Platelet Function Testing in Patients with Thrombosis or Bleeding Disorders/Invited  
 Lecture  
 American Association of Blood Banks (AABB) Annual Meeting, New Orleans, Louisiana  
 2009 ADP Receptor Blockers: Will We Have a Choice?/Invited Lecture  
 American Heart Association Scientific Sessions, Orlando, Florida  
 2009 The Results of the CHAMPION PCI Trial/Invited Discussant  
 Late-Breaking Clinical Trials, American Heart Association Scientific Sessions, Orlando,  
 Florida  
 2010 Novel Oral Antiplatelet Agents in Acute Coronary Syndrome/Invited Panelist  
 ACC Meet the Experts, American College of Cardiology 59<sup>th</sup> Annual Scientific Session  
 and Innovation in Intervention: i2 Summit 2010, Atlanta, Georgia  
 2010 Platelet Activation/Invited Lecture

- Workshop on Defining Molecular Pathways and Mechanisms that Predict Cardiovascular Disease Risk Associated with Sleep-Disordered Breathing, National Heart, Lung and Blood Institute, Bethesda, Maryland
- 2011 Alternatives to Aspirin: Newer Antiplatelet Agents/Invited Lecture  
Symposium: *Beyond the Big Three (Heparin, Warfarin and Aspirin) – Newer Antithrombotic Agents in Development: Relevance to Pediatric Hematology*, American Society of Pediatric Hematology/Oncology (ASPHO), 24<sup>th</sup> Annual Meeting, Baltimore, Maryland
- 2011 Personalized Aspirin and Clopidogrel Therapy Based on Platelet Function Testing/Invited Speaker  
Working Group on Guided Antithrombotic Therapy: Current Status and Future Research Directions, National Heart, Lung and Blood Institute, Bethesda, Maryland
- 2011 Antiplatelet Therapy/Session Chair  
Education Program, American Society of Hematology 53<sup>rd</sup> Annual Meeting and Exposition, San Diego, California
- 2011 Advances in Antiplatelet Therapy/Invited Lecture  
Education Program, American Society of Hematology 53<sup>rd</sup> Annual Meeting and Exposition, San Diego, California
- 2012 Developmental Changes in Platelet Biology/Invited Lecture  
American Society for Artificial Internal Organs (ASAIO) 1<sup>st</sup> Annual Conference on Pediatric Circulatory Support, San Francisco, California
- 2012 Antiplatelet Therapy/Invited Plenary Lecture  
American Society for Artificial Internal Organs (ASAIO) 58<sup>th</sup> Annual Conference, San Francisco, California
- 2012 Laboratory & Translational Hematology/Invited Speaker  
Career Development Lunch, Committee on Training Programs, American Society of Hematology 54<sup>th</sup> Annual Meeting and Exposition, Atlanta, Georgia
- 2013 Functional Requirements for Manufactured Platelets: Testing Prior to Clinical Application/Invited Speaker  
Working Group on Stem Cell-derived Blood Products for Transfusion, National Heart, Lung and Blood Institute, Bethesda, Maryland
- 2013 Platelets: How They Stick Together in Sickness and in Health/Invited Speaker  
Biochemistry and Molecular Biology Faculty Seminar Series, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
- 2014 Clopidogrel Pharmacokinetics and Pharmacodynamics/Invited Speaker  
Keystone Symposium on New Frontiers in the Discovery and Treatment of Thrombosis, Keystone, Colorado

### **International**

- 1987 Platelet Receptors in Health and Disease/Invited Lecture  
Royal Children's Hospital, Melbourne, Australia
- 1987 Platelet Receptors in Health and Disease/Invited Lecture  
Continuing Education Meeting, The Children's Hospital, Camperdown, Sydney, Australia
- 1988 Disorders of Platelet Glycoprotein Ib: Diagnosis by Flow Cytometry and Immunoassay/Invited Lecture  
International Society on Thrombosis and Haemostasis (ISTH), Platelet Subcommittee Meeting, Washington, DC
- 1988 Platelet Glycoprotein Ib/Invited Lecture

- 1989 Special Seminar, Westmead Hospital, University of Sydney, Westmead, Sydney, Australia  
Role of Platelets in Pathomechanism of Defective Haemostasis During and After Extracorporeal Circulation/Invited Lecture
- 1993 International Symposium on Blood Use in Cardiac Surgery, Berlin, West Germany  
Thrombosis and Hemorrhage in the Newborn/Special Lecture  
The Children's Hospital, Camperdown, Sydney, Australia
- 1993 Human Platelets: How They Stick Together in Sickness and in Health/Special Lecture  
Hematology Society of Australia, New South Wales Red Cross Transfusion Service, Sydney, Australia
- 1993 Platelet Antigens: CD42 and Related Proteins/Moderator  
V International Workshop on Human Leukocyte Differentiation Antigens ("the CD Conference"), Boston, Massachusetts
- 1993 Characterization of Platelet Binding of Blind Panel Antibodies/Invited Lecture  
Workshop on *Concepts in Cross-lineage Antibody Analysis*, V International Workshop on Human Leukocyte Differentiation Antigens (the "CD Conference"), Boston, Massachusetts
- 1994 The Effects of Platelet Activation on the Glycoprotein Ib-IX Complex/Invited Lecture  
Platelet Physiology Subcommittee Meeting, 40<sup>th</sup> Annual Meeting of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH), Leuven, Belgium
- 1994 The Platelet Function Defect of Cardiopulmonary Bypass/Special Seminar  
Royal Perth Hospital, Perth, Australia
- 1994 Platelet Function in Neonates/Postgraduate Seminar  
King Edward Memorial Hospital for Women, Perth, Australia
- 1994 Flow Cytometric Assays of Platelet Function: Clinical and Research Applications/Invited Lecture  
Australasian Flow Cytometry Group, 17<sup>th</sup> Annual Meeting, Perth, Australia
- 1994 Haemostatic Defect in Cardiopulmonary Bypass/Invited Lecture  
Education Day, Australasian Society of Blood Transfusion, 32<sup>nd</sup> Annual Scientific Meeting, Perth, Australia
- 1994 Platelet Glycoproteins and Activation/Meet the Expert Breakfast Session  
Haematology Society of Australia, 28<sup>th</sup> Annual Scientific Meeting, Perth, Australia
- 1995 Differential Behavior of Platelet Membrane Glycoproteins During Platelet Activation/Invited Lecture  
Platelet Physiology Subcommittee Meeting, 41<sup>st</sup> Annual Meeting of the Scientific and Standardization Committee (SSC), XV Congress of the International Society on Thrombosis and Haemostasis (ISTH), Jerusalem, Israel
- 1995 Down-regulation of GPIb-IX-V/Invited Lecture  
*Bernard-Soulier Syndrome: GPIb-IX-V Complexes in Health and Disease*, Réunion en L'Honneur Du Professeur Jean Bernard, Institute des Vaisseaux et du Sang, Paris, France
- 1995 Methodological Considerations for Using Flow Cytometry to Measure Platelet Degranulation/Invited Lecture  
*Effects of Iodinated Contrast Media on Platelet Degranulation, Platelet Function, and Vascular Endothelium*, Symposium, St. Thomas, U.S. Virgin Islands (Nycomed)
- 1996 Antithrombotic Therapy/Invited Lecture  
Perinatal/Pediatric Hemostasis Subcommittee Meeting, 42<sup>nd</sup> Annual Meeting of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH), Barcelona, Spain



- 1996 Circulating Degranulated Platelets Rapidly Lose Surface P-selectin But Continue to Circulate and Function/Invited Lecture  
Consensus Conference on the Flow Cytometric Characterization of Platelet Function, European Working Group on Clinical Cell Analysis, Belgirate, Italy
- 1996 Use of Flow Cytometry to Assess Platelet Activation in Cardiovascular Diseases/Invited Lecture  
14<sup>th</sup> International Congress on Thrombosis, Montpellier, France
- 1998 The Clinical Relevance of Platelet CD62/Invited Lecture  
16<sup>th</sup> Meeting of the BEST (Biomedical Excellence for Safer Transfusion) Working Party, International Society of Blood Transfusion, American Association of Blood Banks, Philadelphia, Pennsylvania
- 1999 Flow Cytometric Assessment of GPIIb-IIIa Receptor Occupancy and Function/Invited Lecture  
Platelet Physiology Subcommittee Meeting, 45<sup>th</sup> Annual Meeting of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH), Washington, DC
- 1999 The Relevance of Platelet CD62 (P-Selectin) Testing/Invited Lecture  
24<sup>th</sup> International Symposium on Blood Transfusion, Groningen, The Netherlands
- 2000 New Diagnostic Methods/Chair  
*Platelets 2000* International Symposium, Ma'ale Hachamisha, Jerusalem, Israel
- 2000 Evaluation of Platelet Function by Flow Cytometry/State of the Art Invited Lecture  
*Platelets 2000* International Symposium, Ma'ale Hachamisha, Jerusalem, Israel
- 2000 Flow Cytometric Analysis of Platelets/ State of the Art Invited Lecture  
26<sup>th</sup> Congress of the International Society of Blood Transfusion, Vienna, Austria
- 2001 Platelet Physiology Scientific Subcommittee Meeting/Co-Chairman  
47<sup>th</sup> Scientific and Standardization Committee (SSC) Meeting, XVIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), Paris, France
- 2001 State-of-the-Art Lectures/Chairman  
XVIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), Paris, France
- 2001 *Platelet Markers and Activation* Oral Communications Session/Chair  
XVIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), Paris, France
- 2002 Platelet Physiology Scientific Subcommittee Meeting/Co-Chairman  
48<sup>th</sup> Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Boston, Massachusetts
- 2002 Circulating Monocyte-Platelet Aggregates as a Sensitive Marker of *In Vivo* Platelet Activation/Invited Lecture  
Platelet Physiology Scientific Subcommittee meeting, 48<sup>th</sup> Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Boston, Massachusetts
- 2003 Platelet Changes in Myocardial Infarction/Invited Lecture  
XVI International Symposium on Technical Innovations in Laboratory Hematology, International Society for Laboratory Hematology (ISLH), Orlando, Florida
- 2003 Platelet Physiology Scientific Subcommittee meeting/ Co-Chairman  
49<sup>th</sup> Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Birmingham, United Kingdom
- 2003 Detection, Standardization, and Clinical Correlates of Platelet-derived

	Microparticles/Invited Lecture
	Working Group on Vascular Biology, 49 <sup>th</sup> Annual Meeting of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH), Birmingham, United Kingdom
2003	Platelet Function: From Latest Research to Current Practice/Plenary State of the Art Invited Lecture
	2 <sup>nd</sup> Annual Expert Leaders in Thrombosis Evaluation (ELITE) Meeting, Paris, France (Sanofi Aventis/Bristol-Myers Squibb)
2004	The Central Role of Platelets in the Pathogenesis of Atherothrombosis/Plenary Session Invited Lecture
	4 <sup>th</sup> International Summit on Atherothrombosis, Copenhagen, Denmark (Sanofi Aventis/Bristol-Myers Squibb)
2004	<i>Focus on Atherothrombosis</i> Workshop/Moderator
	4 <sup>th</sup> International Summit on Atherothrombosis, Copenhagen, Denmark (Sanofi Aventis/Bristol-Myers Squibb)
2004	Overview of Aspirin and Clopidogrel Resistance/Invited Lecture
	Platelet Physiology Scientific Subcommittee meeting, 50 <sup>th</sup> Annual Meeting of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH), Venice, Italy
2004	Platelet-derived Microparticles in Vascular Disease/Invited Lecture
	Working Group on Vascular Biology, 50 <sup>th</sup> Annual Meeting of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH), Venice, Italy
2004	Platelet Physiology Scientific Subcommittee Meeting/Co-Chairman
	50 <sup>th</sup> Scientific and Standardization Committee Meeting (SSC), International Society on Thrombosis and Haemostasis (ISTH), Venice, Italy
2004	The Significance of Microparticles in Thrombus Formation/Special Guest Speaker
	2 <sup>nd</sup> Daiichi Symposium for Thrombosis Update, 27 <sup>th</sup> Congress of the Japanese Society of Thrombosis and Haemostasis, Nara, Japan
2005	Platelet Response Variability to Aspirin And Clopidogrel/Invited Lecture
	Platelet Physiology Scientific Subcommittee meeting, 51 <sup>st</sup> Annual Meeting of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH), Sydney, Australia
2005	Platelet Physiology Scientific Subcommittee Meeting/Chair
	51 <sup>st</sup> Annual Meeting of the Scientific and Standardization Committee (SSC), International Society on Thrombosis and Haemostasis (ISTH), Sydney, Australia
2005	<i>Perinatal/Paediatric Haemostasis and Thrombosis</i> Oral Communications Session/Chair
	XX Congress of the International Society on Thrombosis and Haemostasis (ISTH), Sydney, Australia
2005	<i>Bleeding Disorders</i> Oral Session/Chair
	XXX World Congress of the International Society of Hematology, Istanbul, Turkey
2005	Platelet Function Testing in Cardiovascular Diseases/Invited Lecture
	XXX World Congress of the International Society of Hematology, Istanbul, Turkey
2006	Flow Cytometry/Invited Lecture
	Platelets 2006 International Symposium, Ma'ale Hachamisha, Jerusalem, Israel
2006	Platelet Function Analyzer (PFA)-100/Invited Lecture
	Platelets 2006 International Symposium, Ma'ale Hachamisha, Jerusalem, Israel
2006	Aspirin Resistance/Invited Lecture

- 2006 Platelets 2006 International Symposium, Ma'ale Hachamisha, Jerusalem, Israel  
Platelet Function Testing/Moderator
- 2006 Platelets 2006 International Symposium, Ma'ale Hachamisha, Jerusalem, Israel  
*Novel Methods for Evaluation of Hemostasis* State of the Art Lectures/Co-Chair
- 2006 19<sup>th</sup> International Congress on Thrombosis, Tel Aviv, Israel  
Clinical Applications of the Platelet Function Analyzer (PFA)-100/State of the Art Invited Lecture
- 2006 19<sup>th</sup> International Congress on Thrombosis, Tel Aviv, Israel  
Evaluation of Platelet Function by Flow Cytometry/State of the Art Invited Lecture
- 2006 19<sup>th</sup> International Congress on Thrombosis, Tel Aviv, Israel  
Aspirin Resistance/Invited Plenary Lecture
- 2006 19<sup>th</sup> International Congress on Thrombosis, Tel Aviv, Israel  
Optimizing Clinical Outcomes Through Platelet Function Testing: An Achievable Goal?/Satellite Symposium Chair
- 2006 52<sup>nd</sup> Annual Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Oslo, Norway (Lilly/Daiichi Sankyo)  
Measurement of Platelet Function in Patients/Chair
- 2006 Platelet Physiology Subcommittee, 52<sup>nd</sup> Annual Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Oslo, Norway  
Overview: Measurement of Platelet Function in Patients/Invited Lecture
- 2006 Platelet Physiology Subcommittee, 52<sup>nd</sup> Annual Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Oslo, Norway  
Flow Cytometry/Invited Lecture
- 2006 Platelet Physiology Subcommittee, 52<sup>nd</sup> Annual Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Oslo, Norway  
The Use of Flow Cytometry in the Monitoring of Antiplatelet Drug Therapy/Invited Lecture
- 2006 ADP 2006, P2 Receptors: From Basic Science to Clinical Practice, 4<sup>th</sup> International Meeting, Bischoffsheim, France  
Laboratory Methods of Potential Interest to Monitor Antiplatelet Therapy/Session Chair
- 2006 ADP 2006, P2 Receptors: From Basic Science to Clinical Practice, 4<sup>th</sup> International Meeting, Bischoffsheim, France  
Variability of Response to Antiplatelet Agents/Workshop Moderator
- 2006 Expert Leaders In Therapeutic Evidence (ELITE) Forum, Paris, France (Sanofi Aventis/Bristol-Myers Squibb)  
Variability of Response to Antiplatelet Agents/Invited Lecture
- 2006 Expert Leaders In Therapeutic Evidence (ELITE) Forum, Paris, France (Sanofi Aventis/Bristol-Myers Squibb)  
Monitoring Antiplatelet Therapy/Invited Lecture
- 2007 30<sup>th</sup> Sysmex Hematology Seminar, Kobe, Japan  
Standardization of Turbidometric Platelet Aggregation/Session Chair
- 2007 Platelet Physiology Subcommittee, 53<sup>rd</sup> Annual Scientific and Standardization Committee (SSC), Meeting of the International Society on Thrombosis and Haemostasis (ISTH), Geneva, Switzerland  
Overview: Standardization of Turbidometric Platelet Aggregation/Invited Lecture

- Platelet Physiology Subcommittee, 53<sup>rd</sup> Annual Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Geneva, Switzerland
- 2007 New Point-of-Care Methods for Monitoring Antiplatelet Therapy/Satellite Symposium Chair  
XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH), Geneva, Switzerland (Lilly/Daiichi Sankyo)
- 2007 Point-of-Care Methods for Monitoring Antiplatelet Therapy: Potential Clinical Applications/Invited Lecture  
New Point-of-Care Methods for Monitoring Antiplatelet Therapy, Satellite Symposium, XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH), Geneva, Switzerland (Lilly/Daiichi Sankyo)
- 2007 Recent Advances in the Measurement of Platelet Inhibition/Invited Lecture  
Redefining the Unmet Needs of Platelet Inhibition in Acute Coronary Syndrome Patients, Satellite Symposium, European Society of Cardiology (ESC) Congress 2007, Vienna, Austria (Lilly/Daiichi Sankyo)
- 2008 Is There a Need for Monitoring Antiplatelet Drug Treatment?/Invited Lecture  
ADP 2008, 5<sup>th</sup> International Meeting – Platelet P2 Receptors: From Basic Science to Clinical Practice, Bormio, Italy
- 2008 Laboratory Methods Potentially Useful for Monitoring Antiplatelet Drug Treatment/Chairperson  
ADP 2008, 5<sup>th</sup> International Meeting – Platelet P2 Receptors: From Basic Science to Clinical Practice, Bormio, Italy
- 2008 Welcome and Overview of the SSC Working Party on Platelet Aggregation/Co-Chair  
Platelet Physiology Subcommittee, 54<sup>th</sup> Annual Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Vienna, Austria
- 2008 Consensus of Experts on Standardization of Light Transmission Aggregometry/Co-Chair  
Platelet Physiology Subcommittee, 54<sup>th</sup> Annual Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Vienna, Austria
- 2008 Clinical Applications of Platelet Function Testing in Cardiology/Satellite Symposium Chair  
54<sup>th</sup> Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Vienna, Austria (Lilly/Daiichi Sankyo)
- 2008 Hyporesponsiveness to Antiplatelet Therapy: Mechanisms and Potential Solutions/Invited Lecture  
Clinical Applications of Platelet Function Testing in Cardiology, Satellite Symposium, 54<sup>th</sup> Scientific and Standardization Committee (SSC) Meeting, International Society on Thrombosis and Haemostasis (ISTH), Vienna, Austria (Lilly/Daiichi/Sankyo)
- 2008 Platelet Function Testing/Moderator  
Platelets 2008: 5<sup>th</sup> International Platelet Symposium, Woods Hole, Massachusetts
- 2008 Platelet Function Testing in Patients with Thrombosis/Invited Lecture  
Platelets 2008: 5<sup>th</sup> International Platelet Symposium, Woods Hole, Massachusetts
- 2009 Consensus of Experts on Standardization of Light Transmission Aggregometry/Moderator  
Platelet Physiology Subcommittee, 55<sup>th</sup> Annual Scientific and Standardization Committee (SSC) Meeting, XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH), Boston, Massachusetts

- 2009 Consensus of Experts on Standardization of Light Transmission Aggregometry/Invited Lecture  
Platelet Physiology Subcommittee Program, 55<sup>th</sup> Annual Scientific and Standardization Committee (SSC) Meeting, XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH), Boston, Massachusetts
- 2009 Platelet Function as a Guide to Thrombotic Risk/Education Program Invited Lecture  
Platelet Physiology Subcommittee Program, 55<sup>th</sup> Annual Scientific and Standardization Committee (SSC) Meeting, XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH), Boston, Massachusetts
- 2009 Platelet Inhibition/State-of-the-Art Session Chair  
XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH), Boston, Massachusetts
- 2010 The Relationship Between Platelet Function and Subsequent Major Adverse Clinical Outcomes/Invited Lecture  
Platelets 2010: 6<sup>th</sup> International Platelet Symposium, Ma'ale Hachamisha, Jerusalem, Israel
- 2010 Platelet Function Testing/Moderator  
Platelets 2010: 6<sup>th</sup> International Platelet Symposium, Ma'ale Hachamisha, Jerusalem, Israel
- 2010 The Varying Effects of Antiplatelet Agents on *In Vivo* Platelet Function/Invited Lecture  
6<sup>th</sup> International Meeting, ADP 2010: Platelet Receptors: From Basic Science to Clinical Practice, Gazzada Schianno, Italy
- 2011 Emerging Antiplatelet Drugs/Symposium Chair  
XXIII Congress of the International Society on Thrombosis and Haemostasis (ISTH), Kyoto, Japan
- 2011 Advances in Antiplatelet Therapy/Grand Rounds  
The Children's Hospital at Westmead, Sydney, Australia
- 2012 Clopidogrel Pharmacokinetics and Pharmacodynamics: Effects of the *CYP2C19* Gene and Proton Pump Inhibitors/Invited Lecture  
Platelets 2012: 7<sup>th</sup> International Platelet Symposium, Beverly, Massachusetts
- 2012 Pharmacology 1/Moderator  
Platelets 2012: 7<sup>th</sup> International Platelet Symposium, Beverly, Massachusetts
- 2013 Clinical Practice 1/Chairperson  
7<sup>th</sup> International Meeting, ADP 2013, Platelet Receptors: from Basic Science to Clinical Practice, Callian, France
- 2013 Clopidogrel Pharmacokinetics and Pharmacodynamics/Invited Lecture  
7<sup>th</sup> International Meeting, ADP 2013, Platelet Receptors: from Basic Science to Clinical Practice, Callian, France
- 2013 The Clinical Utility of the Immature Platelet Fraction/Invited Lecture  
Sysmex Symposium: Shaping the Future of Hematology, International Society of Laboratory Haematology (ISLH) 2013, XXVI International Symposium on Technological Innovations in Laboratory Hematology, Toronto, Canada
- 2013 Platelet Dysfunction: How to Investigate/Invited Lecture  
Education Session, Pediatric/Neonatal Hemostasis and Thrombosis Subcommittee Program, 59<sup>th</sup> Annual Scientific and Standardization Committee (SSC) Meeting, XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands
- 2013 Antiplatelet Therapy/Invited Lecture

	New Antithrombotics: Practical Aspects for the Clinician and the Laboratory, Satellite Symposium, XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH), Amsterdam, The Netherlands
2014	Clotidogrel Response Variability: Contributing Factors, Expectations and Reality/Distinguished Lecture ALPIC 2014 (Advanced Learning on Platelets and Thrombosis International Course), University of Ioannina, Metsovo-Ioannina, Greece
2014	Antiplatelet Therapy/Invited Lecture Platelets 2014 Educational Course, Ma'ale Hachamisha, Jerusalem, Israel
2014	Randomized Human Studies of Clotidogrel Pharmacokinetics and Pharmacodynamics/Invited Lecture Platelets 2014: 8 <sup>th</sup> International Platelet Symposium, Ma'ale Hachamisha, Jerusalem, Israel
2014	Platelet Function Testing/Moderator Platelets 2014: 8 <sup>th</sup> International Platelet Symposium, Ma'ale Hachamisha, Jerusalem, Israel

## **Report of Clinical Activities and Innovations**

### **Current Licensure and Certification**

1979 - present	Membership of the Royal Colleges of Physicians of the United Kingdom (MRCP [UK], Pediatrics)
1983 - present	Fellowship of the Royal Australasian College of Physicians (FRACP, Pediatrics)
1983-present	Fellowship of the Royal College of Pathologists of Australasia (FRCPA, Pediatric Hematology)
1984 – present	Massachusetts Medical License

### **Practice Activities**

1984-1988	Inpatient Attending	Pediatrics, University of Massachusetts Medical Center	One month per year
1984-2008	Inpatient Attending	Pediatric Hematology/Oncology, University of Massachusetts Medical Center	1 – 6 months per year
1984-2009	Ambulatory Care	Pediatric Hematology/Oncology, University of Massachusetts Medical Center	2 – 4 sessions per month
2009 - present	Inpatient Attending	Hematology, Boston Children's Hospital	1 – 2 weeks per year
2009 - present	Ambulatory Care	Hematology, Boston Children's Hospital	4 – 7 sessions per month

## **Report of Technological and Other Scientific Innovations**

Platelet Analysis in Whole Blood	U.S. Patent Number 5,246,832/September 21, 1993/ <a href="http://patft.uspto.gov">http://patft.uspto.gov</a>  Method of determining, in a blood sample containing unwashed platelets and fibrinogen, the state of thrombin reactivity of the platelets by adding thrombin to the sample in the presence of an agent for inhibiting fibrin polymerization, and then detecting activated platelets.
Detection of Procoagulant Platelet-derived Microparticles in Whole Blood	U.S. Patent Number 5,552,290/September 3, 1996/ <a href="http://patft.uspto.gov">http://patft.uspto.gov</a>  A flow cytometric method for determining procoagulant platelet-derived microparticles in whole blood is described. The invention also provides a method for measuring platelet reactivity in whole blood by measurement of platelet-derived microparticles generated in vitro in the presence of an inhibitor of fibrin clot formation.

## Report of Education of Patients and Service to the Community

### Educational Materials for Patients and the Lay Community

No educational materials below were sponsored by outside entities.

2008 Aspirin resistance	<a href="http://www.abc.net.au/rn/healthreport/stories/2008/2212983.htm">www.abc.net.au/rn/healthreport/stories/2008/2212983.htm</a> (posted April 14, 2008)	Interview, The Health Report, ABC Radio National (Australia)
-------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------

## Report of Scholarship

### Publications

#### Peer reviewed publications in print or other media

##### **Research investigations**

1. Adelman B, **Michelson AD**, Loscalzo J, Greenberg J, Handin RI. Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. *Blood* 1985;65:32-40. PMID: 3155489
2. Adelman B, **Michelson AD**, Handin RI, Ault KA. Evaluation of platelet glycoprotein Ib by fluorescence-activated flow cytometry. *Blood* 1985;66:423-427. PMID: 3160414
3. **Michelson AD**, Loscalzo J, Melnick B, Collier BS, Handin RI. Partial characterization of a binding site for von Willebrand factor on glycocalicin. *Blood* 1986;67:19-26. PMID: 3000477.
4. Adelman B, **Michelson AD**, Greenberg J, Handin RI. Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. *Blood* 1986;68:1280-1284. PMID: 2946332
5. **Michelson AD**. Flow cytometric analysis of platelet surface glycoproteins: Phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. *Journal of Laboratory and Clinical Medicine* 1987;110:346-354. PMID: 3475397.
6. **Michelson AD**, Barnard MR. Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. *Blood* 1987;70:1673-1678. PMID: 3663949.

7. **Michelson AD**, Adelman B, Barnard MR, Carroll E, Handin RI. Platelet storage results in a redistribution of glycoprotein Ib molecules: Evidence for a large intraplatelet pool of glycoprotein Ib. *Journal of Clinical Investigation* 1988;81:1734-1740. PMC442618.
8. **Michelson AD**, Barnard MR. Plasmin-induced redistribution of platelet glycoprotein Ib. *Blood* 1990;76:2005-2010. PMID: 2146979.
9. **Michelson AD**, Gore JM, Rybak ME, Cola CA, Barnard MR. Effect of *in vivo* infusion of recombinant tissue-type plasminogen activator on platelet glycoprotein Ib. *Thrombosis Research* 1990;60:421-424. PMID: 2150730.
10. **Michelson AD**, Ellis P, Barnard MR, Matic GB, Viles AF, Kestin AS. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, ADP or an *in vivo* wound. *Blood* 1991;77:770-779. PMID: 1704263.
11. Yamamoto N, Greco NJ, Barnard MR, Tanoue K, Yamazaki H, Jamieson GA, **Michelson AD**. Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation. *Blood* 1991;77:1740-1748. PMID: 2015400.
12. Matic GB, Jaspers SR, Miller TB, **Michelson AD**. Platelet glycogen synthase: Further characterization and effect of insulin. *Thrombosis Research* 1991;63:427-432. PMID: 1754995.
13. Rohrer MJ, Kestin AS, Ellis PA, Barnard MR, Rodino L, Breckwoldt WL, Li J, **Michelson AD**. High dose heparin suppresses platelet alpha granule secretion. *Journal of Vascular Surgery* 1992;15:1000-1009. PMID: 1375966.
14. Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, Birjiniuk V, Ouimet H, Pasche B, Nelson MJ, Benoit SE, Rodino LJ, Barnard MR, **Michelson AD**. The platelet function defect of cardiopulmonary bypass. *Blood* 1993;82:107-117. PMID: 7686785.
15. Kestin AS, Ellis PA, Barnard MR, Errichetti A, Rosner BA, **Michelson AD**. Effect of strenuous exercise on platelet activation state and reactivity. *Circulation* 1993;88:1502-1511. PMID: 8403298.
16. Orchard MA, Goodchild CS, Prentice CRM, Davies JA, Benoit SE, Creighton-Kemsford LJ, Gaffney PJ, **Michelson AD**. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. *British Journal of Haematology* 1993;85:533-541. PMID: 7510990.
17. Grabowski EF, Head C, **Michelson AD**. Nonionic contrast media. Procoagulants or clotting innocents? *Investigative Radiology* 1993;28:S21-S24. PMID: 8282498.
18. LaRosa CA, Rohrer MJ, Benoit SE, Rodino LJ, Barnard MR, **Michelson AD**. Human neutrophil cathepsin G is a potent platelet activator. *Journal of Vascular Surgery* 1994;19:306-319. PMID: 7509416.
19. **Michelson AD**, Benoit SE, Kroll MH, Li J, Rohrer MJ, Kestin AS, Barnard MR. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. *Blood* 1994;83:3562-3573. PMID: 8204882.
20. LaRosa CA, Rohrer MJ, Benoit SE, Barnard MR, **Michelson AD**. Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb $\alpha$  and by a cytoskeletal-mediated redistribution of the remainder of the complex. *Blood* 1994;84:158-168. PMID: 7509416.
21. **Michelson AD**, MacGregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Reversible inhibition of human platelet activation by hypothermia *in vivo* and *in vitro*. *Thrombosis and Haemostasis* 1994;71:633-640. PMID: 7522354.
22. **Michelson AD**, Wencel-Drake JD, Kestin AS, Barnard MR. Platelet activation results in a redistribution of glycoprotein IV (CD36). *Arteriosclerosis and Thrombosis* 1994;14:1193-1201. PMID: 7517184.
23. Grabowski EF, Head C, Michail HA, Jang IK, Gold H, Benoit SE, **Michelson AD**. Effects of contrast media on platelet activation using flowing whole blood aggregometry and flow cytometry of platelet membrane glycoproteins. *Investigative Radiology* 1994;29:S198-S200. PMID: 7928228.
24. Rajasekhar D, Kestin AS, Bednarek FJ, Ellis PA, Barnard MR, **Michelson AD**. Neonatal platelets are



- less reactive than adult platelets to physiological agonists in whole blood. *Thrombosis and Haemostasis* 1994;72:957-963. PMID: 7740470.
25. Shaw S, Luce GG, Gilks WR, Anderson K, Ault K, Bochner BS, Boumsell L, Denning SM, Engleman EG, Fleisher T, Freedman AS, Fox DA, Gailit J, Gutierrez-Ramos JC, Hurtibise PE, Lansdorp P, Lotze MT, Mawhorter S, Marti G, Matsuo Y, Minowada J, **Michelson AD**, Picker L, Ritz J, Roos ED, van der Schoot CE, Springer TA, Tedder TF, Telen MJ, Thompson JS, Valent P. Leucocyte differentiation antigen database. *Leucocyte Typing V* (eds. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein RL, Springer TA, Tedder TF, Todd RF), Oxford University Press, Oxford, p 16-198, 1995
  26. **Michelson AD**, Barnard MR, Benoit SE, Mitchell J, Knowles C, Ault KA. Characterization of platelet binding of blind panel mAb. *Leucocyte Typing V* (eds. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein RL, Springer TA, Tedder TF, Todd RF), Oxford University Press, Oxford, p 1207-1210, 1995
  27. **Michelson AD**, Benoit SE, Barnard MR, MacGregor H, Valeri CR. A panel of platelet mAb for the study of haemostasis and thrombosis in baboons. *Leucocyte Typing V* (eds. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein RL, Springer TA, Tedder TF, Todd RF), Oxford University Press, Oxford, p 1230-1231, 1995
  28. **Michelson AD**. CD42 cluster workshop report. *Leucocyte Typing V* (eds. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein RL, Springer TA, Tedder TF, Todd RF), Oxford University Press, Oxford, p 1309-1310, 1995
  29. **Michelson AD**, Benoit SE, Barnard MR, MacGregor H, Valeri CR. Blood bank storage of platelet concentrates results in a loss of platelet surface GPIb (CD42b) and GPV (CD42d) but not GPIX (CD42a). *Leucocyte Typing V* (eds. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein RL, Springer TA, Tedder TF, Todd RF), Oxford University Press, Oxford, p 1331-1333, 1995
  30. **Michelson AD**, Benoit SE, Barnard MR. Platelet activation results in a reversible decrease in the platelet surface expression of CD42d. *Leucocyte Typing V* (eds. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein RL, Springer TA, Tedder TF, Todd RF), Oxford University Press, Oxford, 1333-1334, 1995
  31. Kamat SG, **Michelson AD**, Benoit SE, Moake JL, Rajasekhar D, Hellums JD, Kroll MH, Schafer AI. Fibrinolysis inhibits shear stress-induced platelet aggregation. *Circulation* 1995;92:1399-1407. PMID: 7664419.
  32. Grabowski EF, Jang I-K, Gold H, Palacios IF, Boor SE, Rodino LJ, **Michelson AD**. Platelet degranulation induced by some contrast media is independent of their nonionic vs. ionic nature. *Acta Radiologica* 1995;399:182-184.
  33. **Michelson AD**, Benoit SE, Furman MI, Barnard MR, Nurden P, Nurden AT. The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible cytoskeletal-mediated redistribution to the surface-connected canalicular system. *Blood* 1996;87:1396-1408. PMID: 8608229.
  34. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, **Michelson AD**. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. *Journal of Clinical Investigation* 1996;97:979-987. PMC: 507144.
  35. Li J-M, Podolsky RS, Rohrer MJ, Cutler BS, Massie MT, Barnard MR, **Michelson AD**. Adhesion of activated platelets to venous endothelial cells is mediated via GPIIb/IIIa. *Journal of Surgical Research* 1996;61:543-548. PMID: 8656640.
  36. Grabowski EF, Boor SE, Rodino LJ, Jang IK, Gold H, **Michelson AD**. Platelets are degranulated by some, but not all, contrast media. *Academic Radiology* 1996;3:S328-330. PMID: 8796594.
  37. **Michelson AD**, Benoit SE, Furman MI, Breckwoldt WL, Rohrer MJ, Barnard MR, Loscalzo J. Effects of

- nitric oxide/EDRF on platelet surface glycoproteins. *American Journal of Physiology* 1996;270:H1640-H1648. PMID: 8928869.
38. Upchurch GR, Valeri CR, Khuri SF, Rohrer MJ, Welch GN, MacGregor H, Ragno G, Francis S, Rodino LJ, **Michelson AD**, Loscalzo J. Effect of heparin on fibrinolytic activity and platelet function in vivo. *American Journal of Physiology* 1996;271:H528-534. PMID: 8770093.
  39. **Michelson AD**, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, Valeri CR. *In vivo* tracking of platelets: Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. *Proceedings of the National Academy of Sciences, U.S.A.* 1996;93:11877-11882. PMC: 38152.
  40. Vander Salm TJ, Kaur S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, Leone L, Li J-M, Valeri CR, **Michelson AD**. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. *Journal of Thoracic and Cardiovascular Surgery* 1996;112:1098-1107. PMID: 8873738.
  41. Grabowski EF, Jang I-K, Gold H, Head C, Benoit SE, **Michelson AD**. Variability of platelet degranulation by different contrast media. *Academic Radiology* 1996;3:S485-487. PMID: 8883525.
  42. Rajasekhar D, Barnard MR, Bednarek FJ, **Michelson AD**. Platelet hyporeactivity in very low birth weight neonates. *Thrombosis and Haemostasis* 1997;77:1002-1007. PMID: 9184418.
  43. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, **Michelson AD**. Nitric oxide released from activated platelets inhibits platelet recruitment. *Journal of Clinical Investigation* 1997;100:350-356. PMC: 508197.
  44. Furman MI, Benoit SE, Barnard MR, Valeri CR, Borbone ML, Becker RC, Hechtman HB, **Michelson AD**. Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease. *Journal of the American College of Cardiology* 1998;31:352-358. PMID: 9462579.
  45. Furman MI, Liu L, Benoit SE, Becker RC, Barnard MR, **Michelson AD**. The cleaved peptide of the thrombin receptor is a strong platelet agonist. *Proceedings of the National Academy of Sciences, U.S.A.* 1998;95:3082-3087. PMC: 19698.
  46. Peyton BD, Rohrer MJ, Furman MI, Barnard MR, Rodino LJ, Benoit SE, Hechtman HB, Valeri CR, **Michelson AD**. Patients with venous stasis ulceration have increased monocyte-platelet aggregation. *Journal of Vascular Surgery* 1998;27:1109-1116. PMID: 9652473.
  47. Himmelfarb J, Nelson S, McMonagle E, Holbrook D, Benoit SE, **Michelson AD**, Ault K. Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients. *American Journal of Kidney Diseases* 1998;32:132-138. PMID: 9669434.
  48. Khuri SF, Healey N, MacGregor H, Barnard MR, Szymanski IO, Birjiniuk V, **Michelson AD**, Gagnon DR, Valeri CR. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss following cardiopulmonary bypass. *Journal of Thoracic and Cardiovascular Surgery* 1999;117:172-184. PMID: 9869772.
  49. **Michelson AD**, Barnard MR, Khuri SF, Rohrer MJ, MacGregor H, Valeri CR. The effects of aspirin and hypothermia on platelet function in vivo. *British Journal of Haematology* 1999;104:64-68. PMID: 10027713.
  50. Pigazzi A, Heydrick S, Folli F, Benoit S, **Michelson A**, Loscalzo J. Nitric oxide inhibits thrombin receptor-activating peptide-induced phosphoinositide 3-kinase activity in human platelets. *Journal of Biological Chemistry* 1999;274:14368-14375. PMID: 10318860.
  51. Barnard MR, MacGregor H, Mercier R, Ragno G, Pivacek LE, Hechtman HB, **Michelson AD**, Valeri CR. Platelet surface P-selectin, platelet-granulocyte heterotypic aggregates, and plasma-soluble P-selectin during plateletpheresis. *Transfusion* 1999;39:735-741. PMID: 10413281.
  52. Barnard MR, MacGregor H, Ragno G, Pivacek LE, Khuri SF, **Michelson AD**, Valeri CR. Fresh, liquid-preserved, and cryopreserved platelets: adhesive surface receptors and membrane procoagulant activity.

- Transfusion* 1999;39:880-888. PMID: 15383025.
53. Kenet G, Freedman J, Shenkman B, Regina E, Brok-Simoni F, Holzman F, Vavva F, Brand N, **Michelson A**, Trolliet M, Loscalzo J, Inbal A. Plasma glutathione peroxidase deficiency and platelet insensitivity to nitric oxide in children with familial stroke. *Arteriosclerosis, Thrombosis, and Vascular Biology* 1999;19:2017-2023. PMID: 10446087.
  54. Powell CC, Rohrer MJ, Barnard MR, Peyton BD, Furman MI, **Michelson AD**. Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. *Journal of Vascular Surgery* 1999;30:844-850. PMID: 10550182.
  55. **Michelson AD**, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GP IIIa P1<sup>A</sup> polymorphisms display different sensitivities to agonists. *Circulation* 2000;101:1013-1018. PMID: 10704169.
  56. Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, **Michelson AD**. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. *Thrombosis and Haemostasis* 2000;84:492-498. PMID: 11019977.
  57. **Michelson AD**, Rajasekhar D, Bednarek FJ, Barnard MR. Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults. *Thrombosis and Haemostasis* 2000;84:689-694. PMID: 11057871.
  58. Furman MI, Nurden P, Berndt MC, Nurden AT, Benoit SE, Barnard MR, Ofosu FA, **Michelson AD**. The cleaved peptide of PAR1 results in a redistribution of the platelet surface GPIb-IX-V complex to the surface-connected canalicular system. *Thrombosis and Haemostasis* 2000;84:897-903. PMID: 11127874.
  59. Alugupalli KR, **Michelson AD**, Barnard MR, Robbins D, Coburn J, Baker EK, Ginsberg MH, Schwan TG, Leong JM. Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin  $\alpha_{IIb}\beta_3$  activation. *Molecular Microbiology* 2001;39:330-340. PMID: 11136454.
  60. Claytor RB, Li J-M, Furman MI, Garnette CSC, Rohrer MJ, Barnard MR, Krueger LA, Frelinger AL, **Michelson AD**. Laser scanning cytometry: a novel method for the detection of platelet-endothelial cell adhesion. *Cytometry* 2001;43:308-313. PMID: 11260598.
  61. Alugupalli KR, **Michelson AD**, Barnard MR, Leong JM. Serial determination of platelet counts in mice by flow cytometry. *Thrombosis and Haemostasis* 2001;86:668-671. PMID: 11522020.
  62. Frelinger AL, Furman MI, Krueger LA, Barnard MR, **Michelson AD**. Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. *Circulation* 2001;104:1374-1379. PMID: 11560852.
  63. Gardiner EE, De Luca M, McNally T, **Michelson AD**, Andrews RK, Berndt MC. Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G. *Blood* 2001;98:1440-1447. PMID: 11520793.
  64. **Michelson AD**, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. *Circulation* 2001;104:1533-1537. PMID: 11571248.
  65. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL, Goldberg R, **Michelson AD**. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. *Journal of the American College of Cardiology* 2001;38:1002-1006. PMID: 11583872.
  66. Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, **Michelson AD**. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: effects of dalteparin or unfractionated heparin in combination with abciximab. *American Heart Journal*

- 2001;142:790-798. PMID: 11685164.
67. Wheeler GL, Braden GA, Steinhubl SR, Kereiakes DJ, Kottke-Marchant K, **Michelson AD**, Furman MI, Mueller M, Moliterno DJ, Sane DC. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. *American Heart Journal* 2002;143:602-611. PMID: 11923796.
  68. Marciniak SJ, Mascelli MA, Furman MI, **Michelson AD**, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. *Thrombosis and Haemostasis* 2002;87:1020-1025. PMID: 12083481.
  69. Rohrer MJ, Claytor RB, Garnette CSC, Powell CC, Barnard MR, Furman MI, **Michelson AD**. Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux. *Cardiovascular Surgery* 2002;10:464-469. PMID: 12379404.
  70. Chen J, Dong J-F, Sun C, Bergeron A, McBride L, Pillai M, Barnard MR, Salmon J, **Michelson AD**, Bray PF. Platelet Fc $\gamma$ RIIA His131Arg polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation. *Journal of Thrombosis and Haemostasis* 2003;1:355-362. PMID: 12871511.
  71. Claytor RB, **Michelson AD**, Li J-M, Frelinger AL, Rohrer MJ, Garnette CSC, Barnard MR, Krueger LA, Furman MI. The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. *Journal of Vascular Surgery* 2003;37:440-445. PMID: 12563219.
  72. Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL, **Michelson AD**. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. *American Heart Journal* 2003;145:e6M1-e6M6. PMID: 12595861.
  73. Mitchell WB, Li J, Singh F, **Michelson AD**, Bussel J, Collier BS, French DL. Two novel mutations in the  $\alpha$ IIb calcium-binding domains identify hydrophobic regions essential for  $\alpha$ IIb $\beta$ 3 biogenesis. *Blood* 2003;101:2268-2276. PMID: 12424194.
  74. Frelinger AL, Furman MI, Barnard MR, Krueger LA, Dae MW, **Michelson AD**. Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. *American Journal of Cardiology* 2003;92:1099-1101. PMID: 14583364.
  75. Alugupalli KR, **Michelson AD**, Joris I, Schwan TG, Hodivala-Dilke, Hynes RO, Leong JM. Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis. *Blood* 2003;102:2843-2850. PMID: 12855586.
  76. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, **Michelson AD**. Release of soluble CD40L from platelets is regulated by glycoprotein IIb-IIIa and actin polymerization. *Journal of the American College of Cardiology* 2004;43:2319-2325. (Accompanying editorial: *Journal of the American College of Cardiology* 2004;43:2326-2328.) PMID: 15193700.
  77. Valeri CR, MacGregor H, Barnard MR, Summaria L, **Michelson AD**, Ragno G. In vitro testing of fresh and lyophilized reconstituted human and baboon platelets. *Transfusion* 2004;44:1505-1512. PMID: 15383025.
  78. Furman MI, Krueger LA, Linden ML, Fox ML, Ball SB, Barnard MR, Frelinger AL, **Michelson AD**. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. *Journal of Thrombosis and Haemostasis* 2005;3:312-320. PMID: 15670038.
  79. Valeri CR, MacGregor H, Barnard MR, Summaria L, **Michelson AD**, Ragno G. Survival of baboon biotin-X-N-hydroxysuccinimide and <sup>111</sup>In-oxine-labelled autologous fresh and lyophilized reconstituted platelets. *Vox Sanguinis* 2005;88:122-129. PMID: 15720610.
  80. O'Sullivan BP, Linden MD, Frelinger AL, Barnard MR, Spencer-Manzon M, Morris JE, Salem RO, Laposata M, **Michelson AD**. Platelet activation in cystic fibrosis. *Blood* 2005;105:4635-4641. PMID: 15705796.

81. Barnard MR, Linden MD, Frelinger AL, Li Y, Fox ML, Furman MI, **Michelson AD**. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. *Journal of Thrombosis and Haemostasis* 2005;3:2563-2570. PMID: 16241954.
82. Frelinger AL, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, **Michelson AD**. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway. A 700-patient study of aspirin resistance. *Circulation* 2006;113:2888-2896. (Accompanying editorial: *Circulation* 2006;113:2865-2867.) PMID: 16785341.
83. Mirkhel A, Peyster E, Sundeen J, Greene L, **Michelson AD**, Hasan A, Domanski M. Frequency of aspirin resistance in a community hospital. *American Journal of Cardiology* 2006;98:577-579. PMID: 16923439.
84. Linden MD, Whittaker P, Frelinger AL, Barnard MR, **Michelson AD**, Przyklenk K. Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. *Journal of Thrombosis and Haemostasis* 2006;4:2670-2677. PMID: 16995902.
85. **Michelson AD**, Linden MD, Furman MI, Li Y, Barnard MR, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. *Journal of Thrombosis and Haemostasis* 2007;5:75-81. PMID: 17002661.
86. Linden MD, Furman MI, Frelinger AL, Fox ML, Barnard MR, Li Y, Przyklenk K, **Michelson AD**. Indices of platelet activation and the stability of coronary artery disease. *Journal of Thrombosis and Haemostasis* 2007 5:761-765. PMID: 17371489.
87. Frelinger AL, III, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, **Michelson AD**. The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: influence of other blood cells, calcium, and aspirin. *Thrombosis and Haemostasis* 2007;98:192-200. PMID: 17598013.
88. Tarnow I, **Michelson AD**, Frelinger AL, III, Linden MD, Li Y, Fox ML, Barnard MR, O'Sullivan BP. Cystic fibrosis heterozygotes do not have increased platelet activation. *Thrombosis Research* 2007;121:159-162. PMID: 17532368.
89. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann F-J, **Michelson AD**, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Braunwald E, for the PRINCIPLE – TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation – thrombolysis in myocardial infarction 44 trial. *Circulation* 2007;116:2923-2932. PMID: 18056526.
90. Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP, Sanders SP, Sidi D, Bonnet D, Ewert P, Jennings LK, **Michelson AD**. Dosing of clopidogrel for platelet inhibition in infants and young children. Primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) trial. *Circulation* 2008;117:553-559. PMID: 18195173.
91. Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, **Michelson AD**. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. *Journal of Thrombosis and Haemostasis* 2008;6:359-365. PMID: 18021304.
92. Linden MD, Barnard MR, Frelinger AL, **Michelson AD**, Przyklenk K. Effect of adenosine A<sub>2</sub> receptor stimulation on platelet activation-aggregation: differences between canine and human models. *Thrombosis Research* 2008;121:689-698. PMID: PMC2346597.
93. Tarnow I, Kristensen AT, Krogh AKR, Frelinger AL, Barnard MR, **Michelson AD**. Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte-platelet aggregation and platelet activation. *Veterinary Immunology and Immunopathology* 2008;123:345-352. PMID: 18405981.

94. Trier DA, Gank KD, Kupferwasser D, Yount NY, French WJ, **Michelson AD**, Kupferwasser LI, Xiong YQ, Bayer AS, Yeaman MR. Platelet antistaphylococcal responses occur through P2X<sub>1</sub> and P2Y<sub>12</sub> receptor-induced activation and kinocidin release. *Infection & Immunity* 2008;76:5706-5713. PMCID: PMC2583569.
95. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, **Michelson AD**. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. *Journal of Thrombosis and Haemostasis* 2008;6:2035-2044. PMID: 18983514.
96. Bednarek FJ, Bean S, Barnard MR, Frelinger AL, **Michelson AD**. The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. *Thrombosis Research* 2009;124:42-45. PMID: 19026437.
97. Cattaneo M, Hayward CPM, Moffat KA, Pugliano MT, Liu Y, **Michelson AD**. Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. *Journal of Thrombosis and Haemostasis* 2009;7:1029. PMID: 19422455.
98. **Michelson AD**, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. *European Heart Journal* 2009;30:1753-1763. PMID: 19435740.
99. O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, **Michelson AD**, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD. Pharmacodynamic and clinical efficacy of clopidogrel and of prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. *The Lancet* 2009;374:989-997. PMID: 19726078.
100. Tarnow I, **Michelson AD**, Barnard MR, Frelinger AL, Aasted B, Jensen BR, Parving H-H, Rossing P, Tarnow L. Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. *Platelets* 2009;20:513-519. PMID: 19852691.
101. Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, **Michelson AD**. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. *Circulation* 2009;120:2586-2596. PMID: 19996015.
102. Przyklenk K, Frelinger AL, Linden MD, Whittaker P, Li Y, Barnard MR, Adams J, Morgan M, Al-Shamma, H, **Michelson AD**. Targeted inhibition of the serotonin 5HT<sub>2A</sub> receptor improves coronary patency in an *in vivo* model of recurrent thrombosis. *Journal of Thrombosis and Haemostasis* 2010;8:331-340. PMCID: PMC2916638.
103. Chang H, Yanachkov IB, **Michelson AD**, Li Y, Barnard MR, Wright GE, Frelinger AL. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y<sub>1</sub>, P2Y<sub>12</sub> and P2X<sub>1</sub> receptors. *Thrombosis Research* 2010;125:159-165. PMCID: PMC2826549.
104. Frelinger AL, Barnard MR, Fox ML, **Michelson AD**. The platelet activity after clopidogrel termination (PACT) study. *Circulation Cardiovascular Interventions* 2010;3:442-449. PMID: 20736449.
105. Lajer M, Tarnow I, **Michelson AD**, Jorsal A, Frelinger AL, Parving HH, Rossing P, Tarnow L. Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. *Platelets* 2010;21:525-532 PMID: 20701458.
106. Angiolillo DJ, Badimon JJ, Saucedo JF, Frelinger AL, **Michelson AD**, Jakubowski JA, Zhu B, Ojeh CK, Baker BA, Effron MB. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 trial. *European Heart Journal* 2011;32, 838-846. PMCID: PMC3069388.
107. Rahangdale S, Yeh SY, Novack V, Stevenson K, Barnard MR, Furman MI, Frelinger AL,

- Michelson AD**, Malhotra A. The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. *Journal of Clinical Sleep Medicine* 2011;7:172-178. PMCID: PMC3077345. (Accompanying editorial: *Journal of Clinical Sleep Medicine* 2011;7:179-180.)
108. Ferrer-Marin F, Chavda C, Lampa M, **Michelson AD**, Frelinger AL, Sola-Visner M. Effects of *in vitro* adult platelet transfusions on neonatal hemostasis. *Journal of Thrombosis and Haemostasis* 2011;9:1020–1028. PMCID: PMC3130591.
  109. Frelinger AL, **Michelson AD**, Wiviott SD, Trenk D, Neumann F-J, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Intrinsic platelet reactivity before P2Y<sub>12</sub> blockade contributes to residual platelet reactivity despite high-level P2Y<sub>12</sub> blockade by prasugrel or high-dose clopidogrel: results from PRINCIPLE-TIMI 44. *Thrombosis and Haemostasis* 2011;106:219-226. PMID: 21713327.
  110. Scheer FAJL, **Michelson AD**, Frelinger AL, Evoniuk H, Kelly EE, McCarthy M, Doamekpor LA, Barnard MR, Shea SA. The human endogenous circadian system causes greatest platelet activation during the biological morning independent of behaviors. *PLoS ONE* 2011;6(9): e24549. PMCID: PMC3169622.
  111. Psaila B, Bussel JB, Frelinger AL, Babula B, Linden MD, Li Y, Barnard MR, Tate C, Feldman EJ, **Michelson AD**. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. *Journal of Thrombosis and Haemostasis* 2011;9:2302–2310. PMCID: PMC3210015.
  112. Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, **Michelson AD**, Sabatine MS. Dosing clopidogrel based on *CYP2C19* genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. *JAMA* 2011;306:2221-2228. PMID: 22088980.
  113. Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, **Michelson AD**. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. *Journal of the American College of Cardiology* 2012;59:1304-1311. PMID: 22464259.
  114. Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K, Frelinger AL, **Michelson AD**. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. *Blood* 2012;119:4066-4072. (Accompanying editorial: *Blood* 2012;119:3876-3877.) PMCID: PMC3350368.
  115. Peters CG, **Michelson AD**, and Flaumenhaft R. Granule exocytosis is required for platelet spreading: differential sorting of  $\alpha$ -granules expressing VAMP-7. *Blood* 2012;120:199-206. PMCID: PMC3390958.
  116. Jennings LK, **Michelson AD**, Jacoski MV, Tyagi A, Grgurevich S, Li JS. Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: a comparative study of platelet aggregation response. *Platelets* 2012;23:430-8, 2012. PMID: 22309046.
  117. Chang H, Yanachkov B, Dix EJ, Li YF, Barnard MR, Wright GE, **Michelson AD**, Frelinger AL. Modified diadenosine tetraphosphates with dual specificity for P2Y<sub>1</sub> and P2Y<sub>12</sub> are potent antagonists of ADP-induced platelet activation. *Journal of Thrombosis and Haemostasis* 2012;10:2573-2580. PMID: 23083103.
  118. Frelinger, AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, **Michelson AD**. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (*CYP2C19*, *ABCB1*, *PON1*), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. *Journal of the American College of Cardiology* 2013;61:872-879. PMID: 23333143.
  119. Chang H, Shih LY, **Michelson AD**, Dunn P, Frelinger AL, Wang PN, Kuo MC, Lin TL, Wu JH,

- Tang TC. Clinical and laboratory significance of defective P2Y<sub>12</sub> pathway function in patients with myeloproliferative neoplasms: a pilot study. *Acta Haematologica* 2013;130:181-187. PMID: 23751441.
120. Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, **Michelson AD**, Frelinger AL. P2Y<sub>12</sub> receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity. *Journal of the American Heart Association (JAHA)* 2013;2:e000026. PMCID: PMC3698756.
  121. Smith BW, Rozelle SS, Leung A, Ubellacker J, Parks A, Nah SK, French D, Gadue P, Monti S, Chui DHK, Steinberg MH, Frelinger AL, **Michelson AD**, Theberge R, McComb ME, Costello CE, Kotton DN, Mostoslavsky G, Sherr DH, Murphy GJ. The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. *Blood* 2013;122:376-385. PMCID: PMC3716202.
  122. Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, Lussana F, Pugliano MT, **Michelson AD**. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. *Journal of Thrombosis and Haemostasis* 2013;11:1183-1189. PMID: 23574625.
  123. Darling CE, Sala Mercado JA, Quiroga-Castro W, Tecco GF, Zelaya FR, Conci EC, Sala JP, Smith CS, **Michelson AD**, Whittaker P, Welch RD, Przyklenk K. Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. *BMJ Open* 2014;4:e003883. doi:10.1136/bmjopen-2013-003883. PMCID: PMC3902349.
  124. Frelinger AL, Jakubowski JA, Brooks JK, Carmichael SL, Berny-Lang MA, Barnard MR, Heeney MM, **Michelson AD**. Platelet Activation and Inhibition in Sick cell disease (PAINS) study. *Platelets* 2014;25:27-35. doi:10.3109/09537104.2013.770136. PMID: 23469943.
  125. Chang H, Yanachkov IB, Dix EJ, Yanachkova M, Li Y, Barnard MR, Wright GE, **Michelson AD**, Frelinger AL, III. Antiplatelet activity, P2Y<sub>1</sub> and P2Y<sub>12</sub> inhibition, and metabolism in plasma of stereoisomers of diadenosine 5',5'''-P<sup>1</sup>,P<sup>4</sup>-dithio-P<sup>2</sup>,P<sup>3</sup>-chloromethylenetetraphosphate. *PLoS ONE* 2014;9:e94780. doi:10.1371/journal.pone.0094780. PMCID: PMC3983250.
  126. Hochholzer W, Ruff CT, Mesa RA, Mattimore JF, Cyr JF, Lei L, Frelinger AL, **Michelson AD**, Berg DD, Angiolillo DJ, O'Donoghue ML, Sabatine MS, Mega JL. Variability of individual platelet reactivity over time in patients treated with clopidogrel – insights from the ELEVATE-TIMI 56 trial. *Journal of the American College of Cardiology* 2014;64:361-368. PMID: 25060370. (Accompanying editorial: *Journal of the American College of Cardiology* 2014;64:369-371. PMID: 25060371.)
  127. Torres AS, Caiafaa A, Garner AL, Klopman S, LaPlante N, Morton C, Conway K, **Michelson AD**, Frelinger AL, Neculaes VB. Platelet activation using electric pulse stimulation: growth factor profile and clinical implications. *Journal of Trauma and Acute Care Surgery* 2014;77:S94-S100. PMID: 25159369.
  128. Berny-Lang MA, Darling CE, Frelinger AL, Barnard MR, Smith CS, **Michelson AD**. Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome? 2014, manuscript submitted. PMID: 24806286.

#### Other peer-reviewed publications

129. **Michelson AD**, Lammi AT. Haemolytic anaemia associated with acquired toxoplasmosis. *Australian Paediatric Journal* 1984;20:333-335. PMID: 6529393
130. **Michelson AD**, Marshall PC. Transient neurological disorder associated with transient erythroblastopenia of childhood. *American Journal of Pediatric Hematology/Oncology* 1987;9:161-163. PMID: 3592128.



131. Burke MC, Bernhard JD, **Michelson AD**. Chemotherapy-induced painful acral erythema in childhood: Burgdorf's reaction. *American Journal of Pediatric Hematology/Oncology* 1989;11:44-45. PMID: 2712242.
132. **Michelson AD**. Thrombocytopenia associated with environmental exposure to polyurethane. *American Journal of Hematology* 1991;38:145-146. PMID: 1951307
133. Barnard MR, **Michelson AD**. A morphologic question. *New England Journal of Medicine* 1995;333:1051
134. **Michelson AD**, Bovill E, Andrew M. Antithrombotic therapy in children. ACCP evidence-based clinical practice guidelines (4<sup>th</sup> edition). *Chest* 1995;108:506S-522S
135. **Michelson AD**. Flow cytometry: a clinical test of platelet function. *Blood* 1996;87:4925-4936. PMID: 8652804.
136. Andrew M, **Michelson AD**, Bovill T, Leaker M, Massicotte P, Marzinotto V, Brooker LA. The prevention and treatment of thromboembolic disease in children: a need for thrombophilia programs. *Journal of Pediatric Hematology/Oncology* 1997;19:7-22. PMID: 9065714.
137. Schmitz G, Rothe G, Ruf A, Barlage S, Tschöpe D, Clemetson KJ, Goodall AH, **Michelson AD**, Nurden AT, Shankey TV. European working group on clinical cell analysis: consensus protocol for the flow cytometric characterization of platelet function. *Thrombosis and Haemostasis* 1998;79:885-896. PMID: 9609215.
138. **Michelson AD**, Bovill E, Monagle P, Andrew M. Antithrombotic therapy in children. ACCP evidence-based clinical practice guidelines (5<sup>th</sup> edition). *Chest* 1998;114:748S-769S. PMID: 15383489.
139. Andrew M, **Michelson AD**, Bovill E, Leaker M, Massicotte MP. Medical progress. Guidelines for antithrombotic therapy in pediatric patients. *Journal of Pediatrics* 1998;132:575-588. PMID: 9580753.
140. Monagle P, **Michelson AD**, Bovill E, Andrew M. Antithrombotic therapy in children. ACCP evidence-based clinical practice guidelines (6<sup>th</sup> edition). *Chest* 2001;119:344S-370S. PMID: 15383489.
141. Monagle P, Chan A, Massicotte P, Chalmers E, **Michelson AD**. Antithrombotic therapy in children. ACCP evidence-based clinical practice guidelines (7<sup>th</sup> edition). *Chest* 2004;126:645S-687S. PMID: 15383489.
142. **Michelson AD**. Platelet function testing in cardiovascular diseases. *Circulation* 2004;110:e489-e493. PMID: 15533872.
143. **Michelson AD**, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, Pulcinelli FM, Cerletti C, Rao AK, on behalf of the Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. *Journal of Thrombosis and Haemostasis* 2005;3:1309-1311. PMID: 15892858.
144. Serebruany VL, Oshrine BR, Malinin AI, Atar D, **Michelson AD**, Ferguson JJ. Noncompliance in cardiovascular clinical trials. *American Heart Journal* 2005;150:882-886. PMID: 16290953.
145. O'Sullivan BP, **Michelson AD**. The inflammatory role of platelets in cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine* 2006;173:483-490. PMID: 16339920.
146. Harrison P, Frelinger AL, Furman MI, **Michelson AD**. Measuring antiplatelet drug effects in the laboratory. *Thrombosis Research* 2007;120:323-336. PMID: 17239428.
147. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, **Michelson AD**. Platelet function monitoring in patients with coronary artery disease. *Journal of the American College of Cardiology* 2007;50:1822-34. PMID: 17980247.
148. Monagle P, Chalmers E, Chan A, deVeber G, Kirkham F, Massicotte P, **Michelson AD**. Anti-thrombotic therapy in neonates and children: American College of Chest Physicians evidence-based clinical practice guidelines (8<sup>th</sup> edition). *Chest* 2008;133:887-968. PMID: 18574281.
149. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, **Michelson AD**, Peterson E, Wiviott S. Introduction: antiplatelet therapy and platelet function testing.

- Clinical Cardiology* 2008;31:I-1. PMID: 18481815.
150. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, **Michelson AD**, Peterson E, Wiviott S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes. *Clinical Cardiology* 2008;31:I-2 – I-9. PMID: 18481818.
  151. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, **Michelson AD**, Peterson E, Wiviott S. Assessing the current role of platelet function testing. *Clinical Cardiology* 2008;31:I-10 – I-16. PMID: 18481816.
  152. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, **Michelson AD**, Peterson E, Wiviott S. The problem of persistent platelet activation in acute coronary syndromes and following percutaneous coronary intervention. *Clinical Cardiology* 2008;31:I-17 – I-20. PMID: 18481817.
  153. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, **Michelson AD**, Peterson E, Wiviott S. Investigating the mechanisms of hyporesponse to antiplatelet approaches. *Clinical Cardiology* 2008;31:I-21 – I-27. PMID: 18481819.
  154. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, **Michelson AD**, Peterson E, Wiviott S. Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention. *Clinical Cardiology* 2008;31:I-28 – I-35. PMID: 18481820.
  155. Braunwald E, Angiolillo D, Bates E, Berger PB, Bhatt D, Cannon CP, Furman MI, Gurbel P, **Michelson AD**, Peterson E, Wiviott S. Conclusion: antiplatelet therapy and platelet function testing. *Clinical Cardiology* 2008;31:I-36.
  156. **Michelson AD**. Antiplatelet therapies for the treatment of cardiovascular disease. *Nature Reviews Drug Discovery* 2010;9:154-169. PMID: 20118963.
  157. Trenor CC, Chung RJ, **Michelson AD**, Neufeld EJ, Gordon CM, Laufer MR, Emans SJ. Hormonal contraception and thrombotic risk: a multidisciplinary approach. *Pediatrics* 2011;127:347-357. PMCID: PMC3025417.
  158. **Michelson AD**. Advances in antiplatelet therapy. *Hematology 2011* (American Society of Hematology Education Program Book), pp 62-69. PMID: 22160013.
  159. Fuster V, Bhatt DL, Califf RM, **Michelson AD**, Sabatine MS, Angiolillo DJ, Bates ER, Cohen DJ, Collier BS, Furie F, Hulot S-B, Mann KG, Mega JL, Musunuru K, O'Donnell CJ, Price MJ, Schneider DJ, Simon DI, Weitz JI, Williams MS, Hoots WK, Rosenberg YD, Hasan AAK. Guided antithrombotic therapy: current status and future research direction. Report on a National Heart, Lung, and Blood Institute Working Group. *Circulation* 2012;126:1645-1662. PMCID: PMC4086864.
  160. **Michelson AD**. Gray platelet syndrome. *Blood* 2013;121:250. PMID: 23427340.
  161. McCrindle BW, Li JS, Manliot C, Tweddell JS, Giglia TM, Massicotte MP, Monagle P, Krishnamurthy R, Mahaffey KW, **Michelson AD**, Verdun N, Almond CS, Newburger JW, Brandão LR, Esmon C, Manco-Johnson MJ, Ichord R, Ortel T, Chan AK, Portman R, Rose M, Strony J, Kaltman JR. Challenges and priorities for research: a report from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) working group on thrombosis in pediatric cardiology and congenital heart disease. *Circulation* 2014;130:1192-1203. PMID: 25266860.
  162. Siller-Matula JM, Trenk D, Krähenbühl S, **Michelson AD**, Delle-Karth G. Clinical implications of drug-drug interactions with P2Y<sub>12</sub> receptor inhibitors. *Journal of Thrombosis and Haemostasis* 2014, in press. PMID: 24406062

### Non-peer reviewed scientific or medical publications/materials in print or other media

#### **Reviews, chapters, monographs and editorials**

163. **Michelson AD**. Flow cytometric detection of distinct subpopulations of platelets in individual patients. *Progress in Clinical and Biological Research* 1988;283:131-136. PMID: 3211948.

164. **Michelson AD**, Barnard MR. Thrombin-induced changes in platelet membrane glycoproteins. *Progress in Clinical and Biological Research* 1988;283:159-162. PMID: 3211949.
165. **Michelson AD**. Pathomechanism of defective hemostasis during and after extracorporeal circulation: The role of platelets. In Friedel N, Hetzer R, Royston D (eds): *Blood Use in Cardiac Surgery*. Steinkopff Verlag, Darmstadt, p 16-26, 1991
166. **Michelson AD**. Thrombin-induced down-regulation of the platelet membrane glycoprotein Ib-IX complex. *Seminars in Thrombosis and Hemostasis* 1992;18:18-27. PMID: 1315453.
167. **Michelson AD**. Neonatal thrombosis and hemorrhage. In Loscalzo J, Schafer AI (eds): *Thrombosis and Hemorrhage*. Blackwell, Cambridge, p 999-1026, 1994
168. Khuri SF, **Michelson AD**, Valeri CR. Effects of cardiopulmonary bypass on hemostasis. In Loscalzo J, Schafer AI (eds): *Thrombosis and Hemorrhage*. Blackwell, Cambridge, p 1051-1073, 1994
169. **Michelson AD**. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry: methods and clinical applications. *Blood Coagulation and Fibrinolysis* 1994;5:121-131. PMID: 8180332.
170. **Michelson AD**. Bleeding associated with cardiopulmonary bypass in children. *International Journal of Pediatric Hematology/Oncology* 1994;1:147-158
171. **Michelson AD**, Roberts KB. Hemophilia and von Willebrand disease. In Roberts KB (ed): *Manual of Clinical Problems in Pediatrics*. 4th edition. Little, Brown, and Company, Boston, p 462-466, 1994
172. **Michelson AD**, Roberts KB. Idiopathic thrombocytopenic purpura. In Roberts KB (ed): *Manual of Clinical Problems in Pediatrics*. 4th edition. Little, Brown, and Company, Boston, p 466-470, 1994
173. **Michelson AD**. Manipulation of haemostasis during paediatric cardiopulmonary bypass. In Jonas R, Elliott M (eds): *Cardiopulmonary Bypass in Neonates, Infants and Young Children*. Butterworth-Heinemann, Oxford, p 110-123, 1994
174. Bovill EG, Andrew M, **Michelson AD**. Anticoagulation therapy in children. *Hematology* 1995. Education Program of the American Society of Hematology, Seattle, p 67-74, 1995
175. **Michelson AD**, Shattil SJ. The use of flow cytometry to study platelet activation. In Watson SP, Authi KS (eds): *Platelets. A Practical Approach*. Oxford University Press, Oxford, p 111-129, 1996
176. **Michelson AD**. Flow cytometric assessment of glycoprotein movements in platelets. *Platelets* 1997;8:105-115. PMID: 20297931.
177. **Michelson AD**, Valeri CR. Hypothermia and platelet dysfunction. In Tawes RL (ed): *Autotransfusion: Therapeutic Principles and Trends*. Appleton, Detroit, p 41-45, 1997
178. Rohrer MJ, Andrew M, **Michelson AD**. Hemorrhage, thrombosis, and antithrombotic therapy in children. In Loscalzo J, Schafer AI (eds): *Thrombosis and Hemorrhage*. Second edition, Williams & Wilkins, Baltimore, p 1027-1063, 1998
179. Khuri SF, **Michelson AD**, Valeri CR. Effects of cardiopulmonary bypass on hemostasis. In Loscalzo J, Schafer AI (eds): *Thrombosis and Hemorrhage*. Second edition, Williams & Wilkins, Baltimore, p 1091-1117, 1998
180. **Michelson AD**. Platelet function in the newborn. *Seminars in Thrombosis and Hemostasis* 1998;24:507-512. PMID: 10066145.
181. **Michelson AD**, Furman MI. Laboratory markers of platelet activation and their clinical significance. *Current Opinion in Hematology* 1999;6:342-348. PMID: 10468151.
182. **Michelson AD**, Barnard MR, Krueger LA, Frelinger AL, Furman MI. Evaluation of platelet function by flow cytometry. *Methods* 2000;21:259-270. PMID: 10873480.
183. **Michelson AD**. The relevance of platelet CD62 (P-selectin) testing. In Smit Sibinga CTh, Klein HG (eds). *Molecular Biology of Blood Transfusion*. Kluwer, Dordrecht, p 125 – 134, 2000
184. **Michelson AD**. Flow cytometric analysis of platelets. *Vox Sanguinis* 2000;78 (suppl 2):137-142. PMID: 10938943.
185. Furman MI, Frelinger AL, **Michelson AD**. Antithrombotic therapy in the cardiac catheterization

- laboratory: focus on antiplatelet agents. *Current Cardiology Reports* 2000;2:386-394. PMID: 10980905.
186. **Michelson AD**, Barnard MR, Krueger LA, Frelinger III AL, Furman MI. Evaluation of platelet function by flow cytometry. *Cytometry*. Purdue University Cytometry Laboratories, CD ROM vol. 5, 2000. PMID: 10873480.
  187. **Michelson AD**. GPIIb-IIIa antagonists. *Hematology 2000*. American Society of Hematology Education Program Book, San Francisco, p 228-233, 2000
  188. Loscalzo J, Freedman J, Inbal A, Keaney JF, **Michelson AD**, Vita JA. Nitric oxide insufficiency and arterial thrombosis. *Transactions of the American Clinical and Climatological Association* 2000;111:158-163. PMCID: PMC2194373.
  189. **Michelson AD**. Laboratory markers of platelet activation. In Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (eds): *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. Fourth edition, Lippincott Williams & Wilkins, Philadelphia, p 1101-1111, 2001
  190. **Michelson AD**, Barnard MR, Krueger LA, Frelinger AL, Furman MI. Flow cytometry. In **Michelson AD** (ed). *Platelets*. Academic Press/Elsevier Science, San Diego, p 297-315, 2002
  191. **Michelson AD**. The clinical approach to disorders of platelet number and function. In **Michelson AD** (ed). *Platelets*. Academic Press/Elsevier Science, San Diego, p 541-545, 2002
  192. Krueger LA, Barnard MR, Frelinger AL, III, Furman MI, **Michelson AD**. Immunophenotypic analysis of platelets. In Robinson JP, Darzynkiewicz Z, Dean PN, Dressler LG, Rabinovitch PS, Stewart CC, Tanke HJ, Wheelless LL (eds). *Current Protocols in Cytometry*. John Wiley & Sons, New York, 2002;1:6.10.1-6.10.17. PMID: 18770767.
  193. Krueger LA, Barnard MR, Frelinger III AL, Furman MI, **Michelson AD**. Preparation of samples for studying platelet function by flow cytometry. *Cytometry*. Purdue University Cytometry Laboratories, CD ROM vol. 6, 2002
  194. **Michelson AD**, Barnard MR, Krueger LA, Frelinger AL, Furman MI. Flow cytometric analysis of platelet function. In Gresele P, Page CP, Fuster V, Vermylen J (eds). *Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology, and Therapeutics*. Cambridge University Press, Cambridge, p 485-498, 2002
  195. Monagle P, Andrew M, **Michelson AD**. Hemorrhage, thrombosis, and antithrombotic therapy in children. In Loscalzo J, Schafer AI (eds): *Thrombosis and Hemorrhage*. Third edition, Williams & Wilkins, Baltimore, p 840-864, 2003
  196. Barnard MR, Krueger LA, Frelinger AL, III, Furman MI, **Michelson AD**. Whole blood analysis of leukocyte-platelet aggregates. In Robinson JP, Darzynkiewicz Z, Dean PN, Dressler LG, Rabinovitch PS, Stewart CC, Tanke HJ, Wheelless LL (eds). *Current Protocols in Cytometry*. John Wiley & Sons, New York, 2003;1:6.15.1-6.15.8. PMID: 18770779.
  197. Israels SJ, Rand ML, **Michelson AD**. Neonatal platelet function. *Seminars in Thrombosis and Hemostasis* 2003;29:363-371. PMID: 14517748.
  198. **Michelson AD**. How platelets work: platelet function and dysfunction. *Journal of Thrombosis and Thrombolysis* 2003;16:7-12. PMID: 14760205
  199. **Michelson AD**. Platelet inhibitor therapy: mechanism of action and clinical use. *Journal of Thrombosis and Thrombolysis* 2003;16:13-15
  200. Linden M, Frelinger AL, Barnard MR, Przyklenk K, Furman MI, **Michelson AD**. Application of flow cytometry to platelet disorders. *Seminars in Thrombosis and Hemostasis* 2004;30:501-511. PMID: 15497093.
  201. Furman MI, Frelinger AL, **Michelson AD**. GPIIb/IIIa inhibitor-induced dethrombosis. *Journal of Thrombosis and Thrombolysis* 2004;18:11-17. PMID: 15744548.
  202. **Michelson AD**. Platelet-derived microparticles in vascular disease. *Japanese Journal of Thrombosis and Hemostasis* 2005;16:240-246
  203. Eikelboom J, Feldman M, Mehta SR, **Michelson AD**, Oates JA, Topol E. Report of roundtable:

- aspirin resistance and its implications in clinical practice. *Medscape General Medicine* 2005;7(3)
204. Frelinger AL, **Michelson AD**. Editorial. Clopidogrel: linking evaluation of platelet response variability to mechanism of action. *Journal of the American College of Cardiology* 2005;46:646-647. PMID: 16098429.
  205. **Michelson AD**, Furman MI. Markers of platelet activation and granule secretion. In Quinn M, Fitzgerald D (eds). *Platelet Function: Assessment, Diagnosis, and Treatment*. Humana Press, Totowa, 2005, pp 301-314
  206. Linden ML, Frelinger AL, Przyklenk K, Furman MI, **Michelson AD**. Aspirin resistance: detection, mechanisms and clinical implications. *Current Cardiology Reviews* 2005;1:203-212
  207. **Michelson AD**. Platelet function testing in cardiovascular diseases. *Hematology* 2005;10:132-137. PMID: 16188654
  208. Israels SJ, **Michelson AD**. Antiplatelet therapy in children. *Thrombosis Research* 2006;8:75-83. PMID: 16709476.
  209. **Michelson AD**. Laboratory markers of platelet activation. In Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber S (eds): *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. Fifth edition, Lippincott Williams & Wilkins, Philadelphia, p 825-834, 2006
  210. **Michelson AD**. Aspirin resistance. *Journal of Pathophysiology of Haemostasis and Thrombosis* 2006;35:5-9
  211. **Michelson AD**. Evaluation of platelet function by flow cytometry. *Journal of Pathophysiology of Haemostasis and Thrombosis* 2006;35:67-82. PMID: 16855350.
  212. Kereiakes DJ, **Michelson AD**. Platelet activation and progression to complications. *Reviews in Cardiovascular Medicine* 2006;7:75-81. PMID: 16915126.
  213. **Michelson AD**. Platelet function disorders. In Arceci R, Hann I, Smith O (eds): *Pediatric Hematology*. Third edition, Blackwell Publishing, Oxford, p 562-582, 2006
  214. **Michelson AD**, Frelinger AL, Furman MI. Resistance to antiplatelet drugs. *European Heart Journal* 2006;8:G53-G58
  215. **Michelson AD**, Frelinger AL, Furman MI. Current options in platelet function testing. *American Journal of Cardiology* 2006;98[suppl]:4N-10N. PMID: 17097417.
  216. **Michelson AD**. Editorial. Arterial ischemic stroke in children: baby steps. *Circulation* 2006;111:2094-2095. PMID: 17101868.
  217. Wiviott SD, **Michelson AD**, Berger PB, Lepor NE, Kereiakes DJ. Therapeutic goals for effective platelet inhibition: a consensus document. *Reviews in Cardiovascular Medicine* 2006;7:214-225. PMID: 17224865.
  218. Przyklenk K, Darling CE, Volturo GA, **Michelson AD**. On-site assessment of platelet reactivity in the emergency department. *Emergency Medicine and Critical Care Review* 2006;2:28-30
  219. **Michelson AD**, Linden MD, Barnard MR, Furman MI, Frelinger AL. Flow cytometry. In **Michelson AD** (ed). *Platelets*. Second edition, Elsevier/Academic Press, San Diego, 2007, pp 545-563
  220. **Michelson AD**. The clinical approach to disorders of platelet number and function. In **Michelson AD** (ed). *Platelets*. Second edition, Elsevier/Academic Press, San Diego, 2007, pp 825-830
  221. **Michelson AD**, Newburger PN. Editorial. Platelets and leukocytes: aggregate knowledge. *Blood*, 2007;110:794-795
  222. **Michelson AD**. Monitoring antiplatelet therapy. *Sysmex Journal International* 2007;17(suppl. 2):29-36
  223. **Michelson AD**. P2Y<sub>12</sub> antagonism: promises and challenges. *Arteriosclerosis, Thrombosis and Vascular Biology* 2008;28:s33-s38. PMID: 18174449.
  224. Harrison P, **Michelson AD**. Monitoring antiplatelet therapy. In Bhatt DL (ed): *Platelets in Cardiovascular Disease*. Imperial College Press, London, 2008, pp 125-158

225. **Michelson AD**, Frelinger AL, Weitz JI. Laboratory assessment of platelet function and coagulation. In Angiolillo DJ, Kastrati A, Simon DI (eds). *Clinical Guide to the Use of Antithrombotic Drugs in Coronary Artery Disease*. Informa Healthcare, London, 2008, pp 19-31
226. **Michelson AD**, Frelinger AL. Thrombus formation. In Wakhloo AK, Gounis MJ, Lieber BB, Mericle RA, Linfante I (eds). *Thrombus and Stroke*. Informa Healthcare, 2008, pp 3-13
227. **Michelson AD**. New P2Y<sub>12</sub> antagonists. *Current Opinion in Hematology* 2009;16:371-377
228. **Michelson AD**, Frelinger AL. Laboratory assessment of platelet function and the effects of antiplatelet agents. In Wiviott SD (ed). *Antiplatelet Therapy in Ischemic Heart Disease*. American Heart Association Clinical Series, Wiley/Blackwell, Oxford, 2009, pp 15-29
229. **Michelson AD**. Methods for the measurement of platelet function. *American Journal of Cardiology* 2009;103[suppl]:20A-26A. PMID: 19166709.
230. **Michelson AD**. Editorial. New Developments in P2Y<sub>12</sub> Antagonists. *HemOnc Today* 2009;10(13): 4-6
231. Darling CE, **Michelson AD**, Volturo GA, Przyklenk K. Platelet reactivity and the identification of acute coronary syndromes in the emergency department. *Journal of Thrombosis and Thrombolysis* 2009;28:31-37. PMID: 18600429.
232. **Michelson AD**. The role of platelet function testing in the development of platelet inhibitors. In Freedman JE, Loscalzo J (eds). *New Therapeutic Agents in Thrombosis and Thrombolysis*, 3<sup>rd</sup> edition, Informa Healthcare, 2009, pp 99-115
233. Trenor CC, **Michelson AD**. Editorial. Thrombophilia and pediatric stroke. *Circulation* 2010;121:1795-1797. PMID: 20385934
234. Berny-Lang MA, Frelinger AL, Barnard MR, **Michelson AD**. Flow cytometry. In **Michelson AD** (ed). *Platelets*. Third edition, Elsevier/Academic Press, San Diego, 2013, pp 581-602
235. **Michelson AD**. The clinical approach to disorders of platelet number and function. In **Michelson AD** (ed). *Platelets*. Third edition, Elsevier/Academic Press, San Diego, 2013, pp 813-818
236. Harrison P, **Michelson AD**. Laboratory markers of platelet activation. In Marder, Aird, Bennett, Schulman S, White GC (eds). *Hemostasis and Thrombosis. Basic Principles and Clinical Practice*. 6<sup>th</sup> edition, Lippincott Williams & Wilkins, Philadelphia, 2013, pp 829-839
237. Chan AKC, Chalmers EA, **Michelson AD**. Bleeding in neonates and children. In Marder, Aird, Bennett, Schulman S, White GC (eds). *Hemostasis and Thrombosis. Basic Principles and Clinical Practice*. 6<sup>th</sup> edition, Lippincott Williams & Wilkins, Philadelphia, 2013, pp 1424-1433

#### Books/Textbooks for the medical or scientific community

238. **Michelson AD** (editor). *Platelets*. Academic Press/Elsevier Science, San Diego, 61 chapters, 956 pages, 2002. (*Best Book in Medical Science Award*, Association of American Publishers, 2002.)
239. **Michelson AD** (editor). *Platelets*. Second edition. Elsevier/Academic Press, San Diego, 71 chapters, 1343 pages, 2007
240. **Michelson AD** (editor). *Platelets*. Third edition. Elsevier/Academic Press, San Diego, 64 chapters, 1353 pages, 2013. (*Highly Commended Prize in the category of Internal Medicine*, British Medical Association [BMA] Medical Book Awards 2013.)

#### Letters to the Editor

241. **Michelson AD**. Inheritance of Diamond-Blackfan anaemia. *Medical Journal of Australia* 1982;2:409-410. PMID: 7177015
242. **Michelson AD**. The blood film in meningococcal disease. *Medical Journal of Australia* 1983;1:502. PMID: 6843440.
243. **Michelson AD**, Barnard MR. Flow cytometric detection of the redistribution of the GPIb-IX complex on thrombin-stimulated platelets is dependent on the type of antibody conjugate used. Response. *Blood*

1993;81:1408-1409

244. **Michelson AD**, Benoit SE, Barnard MR, Valeri CR, MacGregor H, Khuri SF, Loscalzo J, Kestin AS. Platelet aggregation abnormalities after cardiopulmonary bypass. Response. *Blood* 1994;83:300-301
245. Khuri SF, Valeri CR, Loscalzo J, **Michelson AD**. Heparin effect on platelets and fibrinolysis. Reply. *Annals of Thoracic Surgery* 1996;61:1590-1591
246. Bray PF, Goldschmidt-Clermont P, Furman MI, **Michelson AD**, Barnard MR, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Kickler T, Christie DF, Kundu S. Platelet glycoprotein IIIa P1<sup>A</sup> polymorphism and effects of aspirin on thrombin generation. *Circulation* 2001;103:e33-e34
247. Frelinger AL, Furman MI, Krueger LA, Barnard MR, **Michelson AD**. Activating effects of GPIIb/IIIa blockers: an intrinsic consequence of ligand-mimetic properties. Response. *Circulation* 105:180e-181e, 2002
248. Frelinger AL, Furman MI, Linden MD, Li Y, Fox ML, Barnard, MR, **Michelson AD**. Response to letter regarding article, "Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: A 700 patient study of aspirin resistance". *Circulation* 2006;115:e46
249. **Michelson AD**, Furman MI, Lau WC, McLaughlin TJ, Frelinger AL III. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance': reply to a rebuttal. *Journal of Thrombosis and Haemostasis* 2007;5:1089-1090. PMID: 17002661.
250. Li JS, Yow E, Berezny KY, Bokesch PM, Takahashi M, Graham TP, Sanders SP, Sidi D, Bonnet D, Ewert P, Jennings LK, **Michelson AD**. Response to letter regarding article "Dosing of clopidogrel for platelet inhibition in infants and young children: primary results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial". *Circulation* 2008;118:e121
251. Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, Furman MI, **Michelson AD**. Response to letter regarding article "Association of cyclooxygenase-1 dependent and independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization". *Circulation* 2010;122:e430
252. Psaila B, Bussel JB, Frelinger AL, **Michelson AD**. Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal. *Journal of Thrombosis and Haemostasis* 2013;11:1002–1003. PMID: 23496753
253. **Michelson AD**, Frelinger AL III, Psaila B, Bussel JB. Measurement of platelet function in thrombocytopenic patients. *Blood* e-Letter published April 25, 2014.  
[http://bloodjournal.hematologylibrary.org/content/123/10/1556/reply#bloodjournal\\_el\\_8796](http://bloodjournal.hematologylibrary.org/content/123/10/1556/reply#bloodjournal_el_8796)

**Professional educational materials or reports, in print or other media**



254. **Michelson AD**, Gurbel PA, Lepor NE, Kereiakes DJ. Resistance to oral antiplatelet therapies: definition, mechanism, clinical relevance and options for treatment. [www.plateletNEWS.org](http://www.plateletNEWS.org) (webcast), posted October 16, 2006
255. Bhatt DL, **Michelson AD**, Neumann F-J. Dual antiplatelet therapy: From TCT 2006 to clinical practice. [www.theheart.org](http://www.theheart.org) (webcast), posted November 1, 2006
256. **Michelson AD**. Measuring platelet activity. [www.plateletNEWS.org](http://www.plateletNEWS.org) (audio slide presentation), posted January 1, 2007
257. **Michelson AD**. New point-of-care methods for monitoring antiplatelet therapy. [www.theheart.org](http://www.theheart.org) (webcast), posted July 23, 2007
258. **Michelson AD**. Recent advances in the measurement of platelet inhibition. [www.theheart.org](http://www.theheart.org) (webcast), posted September 21, 2007
259. **Michelson AD**. Association of aspirin resistance and recurrent cardiovascular events: a recent meta-analysis. [www.plateletNEWS.org](http://www.plateletNEWS.org) (audio journal club), posted January 31, 2008

### Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

260. **Michelson AD**, Melnick B, Loscalzo J, Collier BS, Handin RI. Partial characterization of a binding site for von Willebrand's factor on glycosialicin. *Blood* 1983;62:262a. (Presented at the 25<sup>th</sup> Annual Meeting of the American Society of Hematology, San Francisco, December 5, 1983.)
261. Adelman B, Loscalzo J, **Michelson AD**, Handin RI. Fibrinolytic therapy inhibits platelet/von Willebrand's factor interactions. *Blood* 1983;62:296a. (Presented at the 25<sup>th</sup> Annual Meeting of the American Society of Hematology, San Francisco, December 6, 1983.)
262. **Michelson AD**, Adelman B, Ault KA, Handin RI. Assessment of platelet glycoprotein Ib by fluorescence-activated flow cytometry. *Circulation* 1984;70:II356 (Presented at the 57<sup>th</sup> Scientific Sessions of the American Heart Association, Miami Beach, November 15, 1984.)
263. Adelman B, Greenberg J, **Michelson AD**, Handin RI. Plasmin degradation of platelet glycoprotein Ib is dependent upon plasmin binding via lysine binding sites. *Circulation* 1984;70:II357. (Presented at the 57<sup>th</sup> Scientific Sessions of the American Heart Association, Miami Beach, November 15, 1984.)
264. Handin RI, Adelman B, Bockenstadt P, Loscalzo J, **Michelson AD**. Role of glycoprotein Ib in platelet adhesion to the vessel wall. *Thrombosis and Haemostasis* 1985;54:117. (Presented at the 10<sup>th</sup> International Congress on Thrombosis and Haemostasis, San Diego, July 17, 1985.)
265. **Michelson AD**, Isenstein LM, Adelman B. Glycoprotein Ib and glycosialicin content of stored platelet concentrates. *Blood* 1985;66:282a
266. **Michelson AD**. Flow cytometry detects subpopulations of platelets in children with chronic myeloid leukemia. *Clinical Research* 1986;34:465A
267. **Michelson AD**, Barnard MR. Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. *Blood* 1987;70:355a
268. **Michelson AD**, Adelman B, Carroll E, Barnard MR, Handin RI. Evidence for a large intraplatelet pool of glycoprotein Ib. *Blood* 1987;70:355a. (Presented at the 29<sup>th</sup> Annual Meeting of the American Society of Hematology, Washington, D.C., December 7, 1987.)
269. **Michelson AD**, Barnard MR, Rybak ME, Gore JM, Cola CA. In vivo infusion of recombinant tissue-type plasminogen activator results in a redistribution of platelet glycoprotein Ib stores. *Circulation* 1988;78:II620. (Presented at the 61<sup>st</sup> Scientific Sessions of the American Heart Association, Washington, D.C., November 16, 1988.)
270. **Michelson AD**, Barnard MR. The thrombospondin receptor on platelet membrane glycoprotein IV: Surface expression on resting platelets and modulation by thrombin. *Blood* 1988;72:332a. (Presented at the 30<sup>th</sup> Annual Meeting of the American Society of Hematology, San Antonio, December 5, 1988.)
271. **Michelson AD**, Barnard MR. The role of glycoprotein Ib in thrombin-induced modulation of platelet



- surface receptor expression. *Blood* 1989;74:172a. (Presented at the 31<sup>st</sup> Annual Meeting of the American Society of Hematology, Atlanta, December 4, 1989.)
272. Kestin AS, Errichetti A, Ellis PA, Muscente DL, **Michelson AD**. Acute effects of exercise on platelets of normal subjects: Activation state and response to thrombin in whole blood. *Blood* 1989;74:401a
  273. **Michelson AD**, Ellis PA, Viles AF, Barnard MR, Kestin AS. Thrombin-induced modulation of platelet surface receptor expression in whole blood. *Blood* 1989;74:404a
  274. **Michelson AD**, Barnard MR. Plasmin-induced redistribution of platelet GPIb. *Circulation* 1990;82:III661. (Presented at the 63<sup>rd</sup> Scientific Sessions of the American Heart Association, Dallas, November 14, 1990.)
  275. Kestin AS, Ellis PA, Barnard MR, Matic GB, **Michelson AD**. *In vivo* and *in vitro* modulation of platelet surface GPIb-IX complex and GPIV in whole blood. *Circulation* 1990;82:III662. (Presented at the 63<sup>rd</sup> Scientific Sessions of the American Heart Association, Dallas, November 14, 1990.)
  276. **Michelson AD**, Barnard MR, Ellis PA, Matic GB, Kestin AS. Activation-induced modulation of the platelet surface expression of glycoprotein IV *in vitro* and *in vivo*. *Thrombosis and Haemostasis* 1991;65:1070. (Presented at the XIII Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, July 1 - 2, 1991.)
  277. Kestin AK, Ellis PA, Errichetti A, Barnard MR, Rosner B, **Michelson AD**. The effect of strenuous exercise on platelet activation state and reactivity: Differences between physically trained and untrained subjects. *Thrombosis and Haemostasis* 1991;65:1117. (Presented at the XIII Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, July 4 - 5, 1991.)
  278. Yamamoto N, Greco NJ, Barnard MR, Tanoue K, Yamazaki H, Jamieson GA, **Michelson AD**. GPIb-dependent and GPIb-independent pathways of thrombin-induced platelet activation. *Thrombosis and Haemostasis* 1991;65:1151. (Presented at the XIII Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, July 4 - 5, 1991.)
  279. Rohrer MJ, Kestin A, Ellis PA, Barnard MR, **Michelson AD**. High dose heparin suppresses platelet degranulation. *Journal of Vascular Surgery* 1991;14:431. (Presented at the Eighteenth Annual Meeting of the New England Society for Vascular Surgery, Quebec, Canada, September 26 - 27, 1991.)
  280. Kestin AK, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, Birjiniuk V, Barnard MR, **Michelson AD**. The platelet function defect of cardiopulmonary bypass surgery. *Blood* 1991;78:144a. (Presented at the 33<sup>rd</sup> Annual Meeting of the American Society of Hematology, Denver, December 8, 1991.)
  281. **Michelson AD**, MacGregor H, Kestin AS, Barnard MR, Rohrer MJ, Valeri CR. Hypothermia-induced reversible inhibition of human platelet activation *in vitro* and *in vivo*. *Blood* 1991;78:389a. (Presented at the 33<sup>rd</sup> Annual Meeting of the American Society of Hematology, Denver, December 10, 1991.)
  282. Kamat SG, **Michelson AD**, Benoit SE, Moake JL, Rajasekhar D, Hellums JD, Kroll MH, Schafer AI. Fibrinolysis inhibits shear-induced platelet aggregation. *Circulation* 1992;86:I-734. (Presented at the 65<sup>th</sup> Scientific Sessions of the American Heart Association, New Orleans, November 18, 1992.)
  283. Kestin AS, Valeri CR, MacGregor H, Ellis PA, Giombetti M, **Michelson AD**. The effect of anemia on platelet activation in whole blood. *Blood* 1992;80:58a. (Presented at the 34<sup>th</sup> Annual Meeting of the American Society of Hematology, Anaheim, December 5, 1992.)
  284. **Michelson AD**, Benoit SE, Li J, Rohrer MJ, Kestin AS, Barnard MR. Thrombin-induced down-regulation of the platelet surface glycoprotein Ib-IX complex is reversible. *Blood* 1992;80:130a. (Presented at the 34<sup>th</sup> Annual Meeting of the American Society of Hematology, Anaheim, December 6, 1992.)
  285. Kestin AS, Rajasekhar D, Ellis PA, Arellano BB, Giombetti M, Bednarek FJ, **Michelson AD**. Thrombin reactivity of platelets: differences between normal neonates and adults. *Blood* 1992;80:500a

286. **Michelson AD**, Benoit SE, Breckwoldt WL, Barnard MR, Rohrer MJ, Loscalzo J. Endothelium-derived relaxing factor completely inhibits activation-dependent up-regulation of the GPIIb-IIIa complex, P-selectin, and CD63 in washed platelets but not whole blood. *Blood* 1992;80:501a
287. Rajasekhar D, Kestin AS, Ellis PA, Arellano BB, Giombetti MJ, Bednarek FJ, Barnard MR, **Michelson AD**. Platelet reactivity in normal neonates. *Clinical Research* 1993;41:315A and *Pediatric Research* 1993;33:285A. (Presented at the Joint Annual Meeting of the American Federation for Clinical Research, the American Society for Clinical Investigation, the Society for Pediatric Research, and the American Pediatric Society, Washington D.C., May 3, 1993.)
288. LaRosa CA, Rohrer MJ, Rodino LJ, Benoit SE, Barnard MR, **Michelson AD**. Human neutrophil cathepsin G is a potent platelet activator. *Journal of Vascular Surgery* 1993;17:1131. (Presented at the Annual Meeting of the Society for Vascular Surgery, Washington, D.C., June 8, 1993.)
289. Orchard MA, Goodchild CS, Prentice CRM, Davies JA, Benoit SE, Creighton-Kemsford LJ, Gaffney PJ, **Michelson AD**. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. *Thrombosis and Haemostasis* 1993;69:936. (Presented at the XIV Congress of the International Society on Thrombosis and Haemostasis, New York, July 4 - 9, 1993.)
290. Rajasekhar D, Kestin AS, Ellis PA, Arellano BB, Nelson MJ, Bednarek FJ, Barnard MR, **Michelson AD**. Platelet activation in the newborn. *Thrombosis and Haemostasis* 1993;69:1019. (Presented at the XIV Congress of the International Society on Thrombosis and Haemostasis, New York, July 4 - 9, 1993.)
291. **Michelson AD**, Benoit SE, Breckwoldt WL, Barnard MR, Rohrer MJ, Loscalzo J. Endothelium-derived relaxing factor completely inhibits activation-dependent up-regulation of platelet surface P-selectin, CD63, and the GPIIb-IIIa complex in a washed platelet system, but not in whole blood. *Thrombosis and Haemostasis* 1993;69:1334. (Presented at the XIV Congress of the International Society on Thrombosis and Haemostasis, New York, July 4 - 9, 1993.)
292. **Michelson AD**, Benoit SE, Barnard MR. Platelet activation results in a reversible decrease in the platelet surface expression of glycoprotein V. *Tissue Antigens* 1993;42:413. (Presented at the V<sup>th</sup> International Workshop on Human Leukocyte Differentiation Antigens, Boston, November 3 - 7, 1993.)
293. **Michelson AD**, Benoit SE, Barnard MR, MacGregor H, Valeri CR. A panel of monoclonal anti-platelet antibodies for the study of hemostasis and thrombosis in baboons. *Tissue Antigens* 1993;42:414. (Presented at the V<sup>th</sup> International Workshop on Human Leukocyte Differentiation Antigens, Boston, November 3 - 7, 1993.)
294. **Michelson AD**, Benoit SE, Barnard MR, MacGregor H, Valeri CR. Blood bank storage of platelet concentrates results in a loss of platelet surface GPIb (CD42b) and GPV but not GPIX (CD42a). *Tissue Antigens* 1993;42: 414. (Presented at the V<sup>th</sup> International Workshop on Human Leukocyte Differentiation Antigens, Boston, November 3 - 7, 1993.)
295. Greco NJ, Kornhauser RJ, Jamieson GA, Barnard MR, **Michelson AD**. Defining CD42 as a functional receptor for thrombin-induced platelet activation using anti-CD42 antibodies. *Tissue Antigens* 1993;42: 418. (Presented at the V<sup>th</sup> International Workshop on Human Leukocyte Differentiation Antigens, Boston, November 3 - 7, 1993.)
296. Ault KA, Mitchell J, Knowles C, Benoit SE, Rajasekhar D, Barnard MR, **Michelson AD**. Characterization of platelet binding of blind panel antibodies. *Tissue Antigens* 1993;42:454, 1993. (Presented at the V<sup>th</sup> International Workshop on Human Leukocyte Differentiation Antigens, Boston, November 3 - 7, 1993.)
297. Himmelfarb J, Ault KA, Holbrook D, McMonagle E, **Michelson A**, Hakim R. Hemodialysis (HD) increases plasma glyocalicin levels via cleavage of platelet glycoprotein Ib. *Journal of the American Society of Nephrology* 1993;4:353. (Presented at the 26<sup>th</sup> Annual Meeting of the American Society of Nephrology, Boston, November 14 - 17, 1993.)
298. LaRosa CA, Rohrer MJ, Benoit SE, Barnard MR, **Michelson AD**. Neutrophil cathepsin G modulates the platelet surface expression of the GPIb-IX complex by proteolysis of GPIb and by a cytoskeletal-

- mediated redistribution of the complex. *Blood* 1993;82:73a. (Presented at the 35<sup>th</sup> Annual Meeting of the American Society of Hematology, St. Louis, December 3 - 7, 1993.)
299. Rajasekhar D, Barnard MR, Bednarek FJ, Benoit SE, **Michelson AD**. Procoagulant activity of platelet-derived microparticles in whole blood: differences between neonates and adults. *Blood* 1993;82:163a. (Presented at the 35<sup>th</sup> Annual Meeting of the American Society of Hematology, St. Louis, December 3 - 7, 1993.)
  300. **Michelson AD**, Barnard MR, MacGregor H, Valeri CR. Procoagulant activity of platelet-derived microparticles formed during storage of platelet concentrates. *Blood* 1993;82:337a. (Presented at the 35<sup>th</sup> Annual Meeting of the American Society of Hematology, St. Louis, December 3 - 7, 1993.)
  301. **Michelson AD**, Barnard MR, MacGregor H, Rodino LJ, Valeri CR. Effect of ACD concentration and rotation on platelet aggregation during collection and storage of platelet concentrates in the blood bank. *Blood* 1993;82:399a. (Presented at the 35<sup>th</sup> Annual Meeting of the American Society of Hematology, St. Louis, December 3 - 7, 1993.)
  302. **Michelson AD**, MacGregor H, Barnard MR, Kestin AS, Valeri CR. Aspirin does not augment hypothermia-induced platelet dysfunction in vivo. *Blood* 1993;82:399a. (Presented at the 35<sup>th</sup> Annual Meeting of the American Society of Hematology, St. Louis, December 3 - 7, 1993.)
  303. Freedman JE, **Michelson AD**, Benoit SE, Barnard MR, Loscalzo J. Decreased platelet inhibition by nitric oxide in children with a history of vascular thrombosis. *Clinical Research* 1994;42:184A. (Presented at the Annual Meeting of the American Federation for Clinical Research, Baltimore, April 29 - May 2, 1994.)
  304. **Michelson AD**, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Valeri CR. *In vivo* tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. *Blood* 1994;84:320a. (Presented at the 36<sup>th</sup> Annual Meeting of the American Society of Hematology, Nashville, December 5, 1994.)
  305. Grabowski EF, Head C, Jang I-K, Gold H, Benoit SE, **Michelson AD**. Platelets are degranulated by some, but not all, contrast media. *Blood* 1994;84:686a
  306. **Michelson AD**, Khuri SF, Kestin AS, Loscalzo J, MacGregor H, Barnard MR, Valeri CR. The platelet function defect of cardiopulmonary bypass. *Proceedings of the ASAIO Cardiovascular Science and Technology Conference*, December 9 - 11, 1994. (Presented at the American Society for Artificial Internal Organs (ASAIO) Cardiovascular Science and Technology Conference, Washington, D.C., December 9, 1994.)
  307. Loscalzo J, **Michelson AD**, Khuri SF, Valeri CR. The effects of extracorporeal circulation on hemostasis: II Fibrinolysis. *Proceedings of the ASAIO Cardiovascular Science and Technology Conference*, December 9 - 11, 1994. (Presented at the American Society for Artificial Internal Organs (ASAIO) Cardiovascular Science and Technology Conference, Washington, D.C., December 9, 1994.)
  308. Rajasekhar D, Bednarek FJ, Barnard MR, **Michelson AD**. Platelet activation in very low birth weight (VLBW) neonates. *Pediatric Research* 1995;37:284A. (Presented at the Annual Meeting of the Society for Pediatric Research and the American Pediatric Society, San Diego, May 9, 1995.)
  309. **Michelson AD**, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Valeri CR. Circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. *Thrombosis and Haemostasis* 1995;73:1000. (Presented at the XV Congress of the International Society on Thrombosis and Haemostasis, Jerusalem, Israel, June 12, 1995.)
  310. **Michelson AD**, Rajasekhar D, Bednarek FJ, Barnard MR. Platelet activation in very low birth weight neonates. *Thrombosis and Haemostasis* 1995;73:1292. (Presented at the XV Congress of the International Society on Thrombosis and Haemostasis, Jerusalem, Israel, June 14, 1995.)
  311. Furman MI, Benoit SE, Becker RC, Borbone M, Weiner BH, **Michelson AD**. Thrombin receptor-mediated platelet reactivity is increased in stable coronary artery disease. *Circulation* 1995;92:I-343. (Presented at the 68<sup>th</sup> Scientific Sessions of the American Heart Association, Anaheim, November 13,

1995.)

312. **Michelson AD**, Benoit SE, Furman MI, Barnard MR, Nurden P, Nurden AT. Reversible cytoskeletal-mediated redistribution of platelet surface GPV. *Blood* 1995;86:454a. (Presented at the 37<sup>th</sup> Annual Meeting of the American Society of Hematology, Seattle, December 4, 1995.)
313. **Michelson AD**, Barnard MR, MacGregor H, CR Valeri. Evaluation of the in vivo function of transfused platelets or platelet substitutes in primates: novel three-color whole blood flow cytometric methods. *Frozen Platelets and Platelet Substitutes in Transfusion Medicine*, Uniformed Services University of the Health Sciences, Bethesda, March 1996, p. 46.
314. Grabowski EF, Boor SE, Rodino LJ, Dow C, Holt R, Gold H, Jang I-K, **Michelson AD**. Platelets are not degranulated by a nonionic dimeric contrast agent during diagnostic coronary angiography and coronary interventions. *Journal of the American College of Cardiology* 1996;27:355A. (Presented at the 45<sup>th</sup> Annual Scientific Session of the American College of Cardiology, Orlando, March 24 - 27, 1996.)
315. **Michelson AD**, Barnard MR, Bean S, Bednarek FJ. The platelet hyporeactivity of very low birth weight (VLBW) neonates is age-dependent. *Pediatric Research* 1996;39:290A. (Presented at the Annual Meeting of The Society for Pediatric Research and The American Pediatric Society, Washington, D.C., May 8, 1996.)
316. Furman MI, Benoit SE, Borbone M, Becker RC, **Michelson AD**. Monocyte-platelet aggregation is increased in stable coronary artery disease. *Circulation* 1996;94:I-81. (Presented at the 69<sup>th</sup> Scientific Sessions of the American Heart Association, New Orleans, November 11, 1996.)
317. Freedman JE, **Michelson AD**, Barnard MR, Alpert C, Keaney JF, Loscalzo J. Nitric oxide release from activated platelets inhibits platelet recruitment. *Circulation* 1996;94:I-461. (Presented at the 69<sup>th</sup> Scientific Sessions of the American Heart Association, New Orleans, November 12, 1996.)
318. Furman MI, Liu L, Benoit SE, Becker RC, Barnard MR, **Michelson AD**. The cleaved peptide of the thrombin receptor is a strong platelet agonist. *Circulation* 1996;94:I-580. (Presented at the 69<sup>th</sup> Scientific Sessions of the American Heart Association, New Orleans, November 13, 1996.)
319. Liu L, Furman M, Zhang Q, Spencer F, **Michelson A**, Gore J, Becker R. Clot-bound thrombin activates platelets as potent as fluid-phase thrombin. *Blood* 1996;88:48b
320. Liu L, Furman M, Zhang Q, Spencer F, **Michelson A**, Gore J, Becker R. Fibrinogen inhibits platelet activation by  $\alpha$ -thrombin and TRAP. *Blood* 1996;88:48b
321. Furman MI, Benoit SE, Borbone M, Becker RC, **Michelson AD**. Patients with stable coronary artery disease have increased platelet reactivity and circulating monocyte-platelet aggregates. *Thrombosis and Haemostasis* 1997;77:62. (Presented at the XVI Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, June 8, 1997.)
322. Grabowski EF, Boor SE, Laposata M, Johnson SM, Furman MI, Benoit SE, **Michelson AD**, Li C, Roth G. Platelet hyperaggregability and aspirin resistance in two brothers with syndrome X: a non-cyclooxygenase-dependent platelet defect. *Thrombosis and Haemostasis* 1997;77:71. (Presented at the XVI Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, June 8, 1997.)
323. Inbal A, Kenet G, Freedman JE, **Michelson AD**, Brand N, Loscalzo J. Impaired NO-mediated inhibition of platelet aggregation and P-selectin expression by plasma from patients with childhood stroke. *Thrombosis and Haemostasis* 1997;77:304. (Presented at the XVI Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy, June 9, 1997.)
324. **Michelson AD**. Clinical use of flow cytometry to assess platelet activation. *Cytometry (Communications in Clinical Cytometry)* 1997;30:344. (Presented at the Clinical Applications of Cytometry 12<sup>th</sup> Annual Meeting, Charleston, South Carolina, August 22, 1997.)
325. **Michelson AD**. Guidelines for antithrombotic therapy. *Journal of Pediatric Hematology/Oncology* 1997;19:357-358. (Presented at the 10<sup>th</sup> Annual Meeting of the American Society of Pediatric Hematology/Oncology, San Francisco, September 19, 1997.)

326. Barnard MR, MacGregor H, **Michelson AD**, Valeri CR. Optimization of collection and storage conditions prior to platelet cryopreservation. *Transfusion* 1997;37:8S. (Presented at the 50<sup>th</sup> Annual Meeting of the American Association of Blood Banks, Denver, October 19 - 21, 1997.)
327. Pivacek L, Ragno G, Barnard M, **Michelson AD**, Valeri CR. Measurement of in vivo red cell volume using biotin labeling in the baboon. *Transfusion* 1997;37:36S. (Presented at the 50<sup>th</sup> Annual Meeting of the American Association of Blood Banks, Denver, October 19 - 21, 1997.)
328. Barnard MR, MacGregor H, **Michelson AD**, Valeri CR. Cryopreserved platelets have more procoagulant activity and generate more thromboxane than liquid preserved platelets. *Transfusion* 1997;37:95S. (Presented at the 50<sup>th</sup> Annual Meeting of the American Association of Blood Banks, Denver, October 21, 1997.)
329. **Michelson AD**, Barnard MR, MacGregor H, Valeri CR. Function of cryopreserved platelets. *Blood* 1997;90:268a. (Presented at the 39<sup>th</sup> Annual Meeting of the American Society of Hematology, San Diego, December 8, 1997.)
330. Alugupalli KR, Barnard MR, Schwan TG, Coburn J, **Michelson AD**, Leong JM. Integrin binding and platelet activation by *Borrelia hermsii*, an agent of tick-borne relapsing fever. *Abstracts of the 98th General Meeting of the American Society for Microbiology*. American Society of Microbiology, Washington, DC, p 108, 1998. (Presented at the 98<sup>th</sup> General Meeting of the American Society for Microbiology, Atlanta, May 17, 1998.)
331. Powell C, Barnard M, Peyton B, Li J, Rohrer M, **Michelson A**. Monocyte, but not neutrophil, CD11b expression is increased throughout the circulation in patients with chronic venous insufficiency. Presented at the Surgical Forum of the American College of Surgeons, Orlando, October 25 – 30, 1998.
332. Furman MI, Nurden P, Berndt MC, Nurden AT, Benoit SE, Liu L, Rohrer MJ, Barnard MR, **Michelson AD**. The cleaved peptide of PAR1 results in a redistribution of platelet surface GPIb to the surface-connected canalicular system. *Circulation* 1998;98:I-523. (Presented at the 71<sup>st</sup> Scientific Sessions of the American Heart Association, Dallas, November 10, 1998.)
333. Bray PF, Furman MI, Coleman L, Hamlington J, Goldschmidt-Clermont P, Hendrix C, Mascelli MA, Barnard M, Kickler T, Christie D, Kundu S, **Michelson A**. Integrin  $\beta_3$  (GPIIIa) Pl<sup>A</sup> polymorphisms on platelets display different sensitivity to agonists and antagonists. *Blood* 1998;92:28a. (Presented at the 40<sup>th</sup> Annual Meeting of the American Society of Hematology, Miami Beach, December 5, 1998.)
334. Furman MI, Shilale EA, Barnard MR, Alugupalli K, Rohrer MJ, **Michelson AD**. Circulating monocyte-platelet aggregates are a marker of acute myocardial infarction in patients presenting to the emergency department with chest pain. *Blood* 1998;92:188a. (Presented at the 40<sup>th</sup> Annual Meeting of the American Society of Hematology, Miami Beach, December 6, 1998.)
335. Powell CC, Barnard MR, Peyton BD, Rohrer MJ, **Michelson AD**. Chronic venous insufficiency is associated with increased systemic platelet-monocyte aggregation. Presented at the Eleventh Annual Meeting of the American Venous Forum, Dana Point, California, February 18 – 21, 1999.
336. Claytor RB, Li J-M, Rohrer MJ, Frelinger AL, Garnette CSC, Barnard MR, Krueger LA, Furman MI, **Michelson AD**. Prolonged exposure of platelets to thrombin decreases platelet-endothelial cell adhesion. (Presented at the 10<sup>th</sup> Annual Meeting of the Society for Vascular Medicine and Biology, Washington, DC, June 4 - 5, 1999.)
337. Claytor B, Li J-M, Furman MI, Garnette CSC, Rohrer MJ, Barnard MR, Krueger L, Frelinger AL, **Michelson AD**. Laser scanning cytometry: a novel method for the detection of platelet-endothelial cell adhesion. *Thrombosis and Haemostasis* 1999;82:527. (Presented at the XVII Congress of the International Society on Thrombosis and Haemostasis, Washington, D.C., August 19, 1999.)
338. Kereiakes D, Mueller M, Sane D, Braden GA, Kottke-Marchant K, Topol EJ, Furman MI, **Michelson AD**. Use of the Ultegra-rapid platelet function assay to assess the degree of platelet inhibition in patients treated with abciximab. Results of a multicenter study. *Thrombosis and Haemostasis* 1999;82:646-647. (Presented at the XVII Congress of the International Society on Thrombosis and Haemostasis,

Washington, D.C., August 19, 1999.)

339. French DL, Li J, Scudder L, **Michelson AD**, Collier BS. Two new mutations within or surrounding the calcium-binding domains of GPIIb result in Glanzmann thrombasthenia. *Thrombosis and Haemostasis* 1999;82:744. (Presented at the XVII Congress of the International Society on Thrombosis and Haemostasis, Washington, D.C., August 20, 1999.)
340. **Michelson AD**. The relevance of platelet CD62P (P-selectin) testing. Abstract book: 24<sup>th</sup> International Symposium on Blood Transfusion, Groningen, Netherlands, p. 18, 1999. (Presented at the 24<sup>th</sup> International Symposium on Blood Transfusion, Groningen, Netherlands, October 7, 1999.)
341. Claytor RB, **Michelson AD**, Li J-M, Frelinger AL, Rohrer MJ, Garnette CSC, Barnard MR, Krueger L, Furman MI. The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than thrombin. (Presented at the 85<sup>th</sup> Clinical Congress of the American College of Surgeons, San Francisco, October 10 - 15, 1999.)
342. Kereiakes D, Mueller M, Sane D, Braden G, Kottke-Marchant K, Furman MI, **Michelson AD**. Use of the Ultegra-rapid platelet function assay to assess the degree of platelet inhibition in patients treated with abciximab. Results of a multicenter study. *Circulation* 1999;100:I-152. (Presented at the 72<sup>nd</sup> Scientific Sessions of the American Heart Association, Atlanta, November 8, 1999.)
343. Sane DC, Braden GA, **Michelson AD**, Furman MI, Mueller M, Kottke-Marchant K, Steinbuhl SR. Ultegra Rapid Platelet Function Assay (U-RPFA) correlates with the degree of abciximab platelet inhibition measured by receptor occupancy: results of a multicenter study. *Circulation* 1999;100:I-153. (Presented at the 72<sup>nd</sup> Scientific Sessions of the American Heart Association, Atlanta, November 8, 1999.)
344. Garnette CSC, Rohrer MJ, Valeri CR, Barnard MR, Frelinger AL, Claytor RB, Krueger LA, Hechtman HB, Furman MI, **Michelson AD**. Cathepsin G proteolyses platelet surface P-selectin and disaggregates leukocyte-platelet complexes: mechanism for the loss of surface P-selectin from circulating degranulated platelets. *Circulation* 1999;100:I-610. (Presented at the 72<sup>nd</sup> Scientific Sessions of the American Heart Association, Atlanta, November 10, 1999.)
345. Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, **Michelson AD**. GPIIb-IIIa antagonist-induced reduction in platelet procoagulant activity in whole blood: augmentation by thrombin inhibitors. *Circulation* 1999;100:I-681. (Presented at the 72<sup>nd</sup> Scientific Sessions of the American Heart Association, Atlanta, November 10, 1999.)
346. Furman MI, Krueger LA, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, **Michelson AD**. Tirofiban and eptifibatide, but not abciximab, induce leukocyte-platelet aggregation. *Circulation* 1999;100:I-681. (Presented at the 72<sup>nd</sup> Scientific Sessions of the American Heart Association, Atlanta, November 10, 1999.)
347. Steinbuhl S, Kottke-Marchant K, **Michelson AD**, Furman MI, Kereiakes D, Mueller M, Sane DC, Braden GA. Rapid bedside measurement of platelet aggregation in patients undergoing PCI and treated with abciximab: Results of a multi-center study of Ultegra-Rapid Platelet Function Assay (U-RPFA). *Circulation* 1999;100:I-856. (Presented at the 72<sup>nd</sup> Scientific Sessions of the American Heart Association, Atlanta, November 10, 1999.)
348. Frelinger AL, Furman MI, Krueger LA, Barnard MR, **Michelson AD**. Dissociation of GPIIb-IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation. *Blood* 1999;94:21a. (Presented at the 41<sup>st</sup> Annual Meeting of the American Society of Hematology, New Orleans, December 3 - 7, 1999.)
349. Bray PF, **Michelson AD**, Furman MI, Salmon J, Bolton E, Afshar-Kharghan V, Lopez JA. Correlating genetic variations in adhesive receptors with platelet function. *Blood* 1999;94:216a. (Presented at the 41<sup>st</sup> Annual Meeting of the American Society of Hematology, New Orleans, December 3 - 7, 1999.)
350. Krueger LA, **Michelson AD**, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, Furman MI.

- Leukocyte-platelet aggregation is augmented by GPIIb-IIIa antagonists tirofiban, eptifibatide and RGDS but not abciximab. *Cytometry* 2000;Supplement 10:159. (Presented at the XX<sup>th</sup> Congress of the International Society for Analytical Cytology (ISAC), Montpellier, France, May 20 - 25, 2000.)
351. Krueger LA, **Michelson AD**, Frelinger AL, Barnard MR, Mascelli MA, Nakada MT, Furman MI. Platelet procoagulant activity is diminished by GPIIb-IIIa antagonists in whole blood and is further diminished by thrombin inhibitors. *Cytometry* 2000;Supplement 10:159-160. (Presented at the XX<sup>th</sup> Congress of the International Society for Analytical Cytology (ISAC), Montpellier, France, May 20 - 25, 2000.)
  352. Furman MI, Barnard MR, Krueger LA, Fox ML, Lessard DM, Marchese P, Goldberg RJ, **Michelson AD**. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. *Circulation* 2000;102:II-498. (Presented at the 73<sup>rd</sup> Scientific Sessions of the American Heart Association, New Orleans, November 13, 2000.)
  353. Furman MI, Krueger LA, Barnard MR, **Michelson AD**. Circulating monocyte-platelet aggregates are a more sensitive marker of platelet activation than P-selective-positive platelets. *Circulation* 2000;102:II-777. (Presented at the 73<sup>rd</sup> Scientific Sessions of the American Heart Association, New Orleans, November 15, 2000.)
  354. Mitchell B, Li J, **Michelson AD**, Bussel J, Collier BS, French DL. Glanzmann thrombasthenia (GT) mutations within the second and third calcium-binding domains of  $\alpha$ IIb affect biogenesis of the  $\alpha$ IIb $\beta$ 3 receptor. *Blood* 2000;96:816a. (Presented at the 42<sup>nd</sup> Annual Meeting of the American Society of Hematology, San Francisco, December 1 - 5, 2000.)
  355. Frelinger AL, Mattson JC, Furman MI, Barnard MR, Krueger LA, Marchese PJ, Farrah D, O'Neill WW, **Michelson AD**. Monitoring tirofiban therapy in patients: effect of *ex vivo* anticoagulant. *Thrombosis and Haemostasis* Supplement July 2001 (abstract P377). (Presented at the XVIII Congress of the International Society on Thrombosis and Haemostasis, Paris, France, July 8, 2001.)
  356. Furman MI, **Michelson AD**, Krueger LA, Mueller MN, Broderick TM, Schneider J, Howard W, Fox ML, Barnard MR, Frelinger AL, Kereiakes DJ. Effects of 1/2 dose abciximab in the presence of either dalteparin or heparin on platelet inhibition, as determined by 3 independent assays. *Thrombosis and Haemostasis* Supplement July 2001 (abstract P382). (Presented at the XVIII Congress of the International Society on Thrombosis and Haemostasis, Paris, France, July 8, 2001.)
  357. **Michelson AD**, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of platelet activation than platelet surface P-selectin. *Thrombosis and Haemostasis* Supplement July 2001 (abstract OC2494). (Presented at the XVIII Congress of the International Society on Thrombosis and Haemostasis, Paris, France, July 11, 2001.)
  358. Gardiner EE, De Luca M, McNally T, **Michelson AD**, Andrews RK, Berndt MC. Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor PSGL-1 by neutrophil elastase and cathepsin G. *Thrombosis and Haemostasis* Supplement July, 2001 (abstract P2824). (Presented at the XVIII Congress of the International Society on Thrombosis and Haemostasis, Paris, France, July 11, 2001.)
  359. Rohrer MJ, Claytor RB, Garnette CSC, Powell CC, Barnard MR, Furman MI, **Michelson AD**. Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of the reflux. *Cardiovascular Surgery* 2001;9 (suppl 2):25-26. (Presented at the 25<sup>th</sup> World Congress of the International Society for Cardiovascular Surgery, Cancun, Mexico, September 9 - 13, 2001.)
  360. Kereiakes D, **Michelson A**, Krueger L, Mueller M, Broderick T, Schneider J, Howard W, Fox M, Barnard M, Furman M. Randomized comparison of dalteparin vs. unfractionated heparin in combination with abciximab during percutaneous coronary intervention: effects on leukocyte-platelet aggregation, platelet activation and GP IIb/IIIa receptor expression. *Circulation* 2001;104:II-38. (Presented at the 74<sup>th</sup> Scientific Sessions of the American Heart Association, Anaheim, November 12,

2001.)

361. Frelinger AL, Barnard MR, Furman MI, Krueger LA, **Michelson AD**. Combined effects of mild hypothermia and GPIIb-IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. *Circulation* 2001;104:II-706 - II-707. (Presented at the 74<sup>th</sup> Scientific Sessions of the American Heart Association, Anaheim, November 14, 2001.)
362. Krueger LA, Furman MI, Barnard MR, Marchese PJ, Frelinger AL, **Michelson AD**. Augmentation of platelet activation in the presence of GPIIb-IIIa receptor antagonists may be the result of murine monoclonal antibody-mediated platelet surface FcγRIIa receptor activation. *Cytometry* 2002;Suppl. 11, p 41. (Presented at the XXI Congress of the International Society of Analytical Cytology, San Diego, May 4 – 9, 2002.)
363. Furman MI, Krueger LA, Barnard MR, Fox ML, Frelinger AL, **Michelson AD**. GPIIb-IIIa antagonists modulate leukocyte-platelet aggregates in patients with ACS undergoing PCI. *Circulation* 2002;106:II-517. (Presented at the 75<sup>th</sup> Scientific Sessions of the American Heart Association, Chicago, November 19, 2002.)
364. Krueger LA, Furman MI, Barnard MR, Frelinger AL, **Michelson AD**. Release of soluble CD40L from platelets is regulated by fibrinogen binding to GPIIb-IIIa, actin polymerization, and a matrix metalloproteinase. *Blood* 2002;100:251a. (Presented at the 44<sup>nd</sup> Annual Meeting of the American Society of Hematology, Philadelphia, December 7, 2002.)
365. Frelinger AL, Mascelli MA, Jordan R, Marchese PJ, Barnard MR, Krueger LA, Furman MI, **Michelson AD**. Combined effects of GPIIb-IIIa antagonists, aspirin, apyrase and cytoskeletal inhibitors on preformed platelet aggregates. *Blood* 2002;100:256a. (Presented at the 44<sup>nd</sup> Annual Meeting of the American Society of Hematology, Philadelphia, December 7, 2002.)
366. Frelinger AL, Marchese PJ, Barnard MR, Krueger LA, Fox ML, Furman MI, **Michelson AD**. Flow cytometric assessment of aspirin and NSAID effects on platelet function and leukocyte-platelet aggregation. *Blood* 2002;100:704a. (Presented at the 44<sup>nd</sup> Annual Meeting of the American Society of Hematology, Philadelphia, December 9, 2002.)
367. Krueger LA, Furman MI, Barnard MR, Frelinger AL, **Michelson AD**. Augmentation of platelet activation in the presence of GPIIb-IIIa antagonists can result from antibody-mediated FcγRIIa receptor activation. *Blood* 2002;100:62b.
368. **Michelson AD**, Krueger LA, Barnard MR, Fox ML, Frelinger AL, Furman MI. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. *Journal of Thrombosis and Haemostasis* 2003;1 (July Supplement): P1767. (Presented at the XIX Congress of the International Society on Thrombosis and Haemostasis, Birmingham, United Kingdom, July 17, 2003.)
369. O'Sullivan BP, Linden MD, Frelinger AL, Spencer M, Barnard MR, **Michelson AD**. Increased circulating activated platelets and platelet reactivity in cystic fibrosis. *Blood* 2003;102:786a. (Presented at the 45<sup>th</sup> Annual Meeting of the American Society of Hematology, San Diego, December 8, 2003.)
370. Linden MD, Przyklenk K, Barnard MR, Frelinger AL, Furman MI, **Michelson AD**. Molecular characterization of platelet activation in an *in vivo* canine model of unstable angina. *Blood* 2003;102:64b.
371. Linden M, **Michelson AD**, Frelinger AL, Barnard M, Furman M, Przyklenk K. Preconditioning ischemia favorably attenuates platelet aggregation: insight into molecular mechanisms. *Journal of Molecular and Cellular Cardiology* 2004;37:296. (Presented at the International Society for Heart Research 2004 World Congress, Brisbane, Australia, August 7 – 11, 2004.)
372. Frelinger AL, Linden MD, Furman MI, Li Y, Fox ML, Barnard MR, Barringhaus K, Przyklenk K, **Michelson AD**. Aspirin resistance is associated with markers of platelet activation and is not accounted for by non-compliance or aspirin underdosing. *Circulation* 2004;110:III-216. (Presented at



- the 77<sup>th</sup> Scientific Sessions of the American Heart Association, New Orleans, November 9, 2004.)
373. Linden MD, Furman MI, **Michelson AD**, Fox ML, Barnard MR, Li Y, Barringhaus KG, Przyklenk K, Frelinger AL. Indices of platelet activation as markers of recent myocardial infarction. *Circulation* 2004;110:III-450-451. (Presented at the 77<sup>th</sup> Scientific Sessions of the American Heart Association, New Orleans, November 8, 2004.)
  374. **Michelson AD**. Platelet-derived microparticles in vascular disease. *Japanese Journal of Thrombosis and Hemostasis* 2004;15:415
  375. Frelinger AL, Linden MD, Furman MI, Fox ML, Barnard MR, Li Y, Barringhaus K, Przyklenk K, **Michelson AD**. Patients with coronary artery disease have an increased incidence of aspirin resistance: association of PFA-100 closure time with clinical findings. *Blood* 2004;104:514a. (Presented at the 46<sup>th</sup> Annual Meeting of the American Society of Hematology, San Diego, December 5, 2004.)
  376. **Michelson AD**, Linden MD, Furman MI, Barnard MI, Fox ML, Lau WC, McLaughlin TJ, Frelinger AL. Pre-existent variability in platelet response to ADP accounts for "clopidogrel resistance". *Journal of Thrombosis and Haemostasis* 2005;3 (Supplement 1):P0955. (Presented at the XX Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 8, 2005.)
  377. Linden MD, Frelinger AL, Barnard MR, Furman MI, **Michelson AD**. A novel mechanism of action of clopidogrel: inhibition of monocyte procoagulant activity. *Journal of Thrombosis and Haemostasis* 2005;3 (Supplement 1):P0357. (Presented at the XX Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 9, 2005.)
  378. Frelinger AL, Linden MD, Furman MI, Li Y, Fox ML, Barnard MR, **Michelson AD**. Clinical "aspirin resistance" is associated with increased cyclooxygenase-independent platelet activation. *Journal of Thrombosis and Haemostasis* 2005;3 (Supplement 1):P0954. (Presented at the XX Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 9, 2005.)
  379. Linden MD, **Michelson AD**, Frelinger AL, Barnard MR, Furman MI, Przyklenk K. Preconditioning ischemia favorably attenuates platelet activation: insights into molecular mechanisms. *Journal of Thrombosis and Haemostasis* 2005;3 (Supplement 1):P0955. (Presented at the XX Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 9, 2005.)
  380. Linden MD, O'Sullivan BP, Frelinger AL, Barnard MR, Spencer-Manzon M, Laposata M, **Michelson AD**. Increased platelet activation in cystic fibrosis: a role for cAMP/adenylate cyclase but not for Mead acid or platelet CFTR. *Journal of Thrombosis and Haemostasis* 2005;3 (Supplement 1):P0361. (Presented at the XX Congress of the International Society on Thrombosis and Haemostasis, Sydney, Australia, August 10, 2005.)
  381. Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, **Michelson AD**. The active metabolite of prasugrel (CS-747) inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: leukocyte-platelet and platelet-platelet aggregation and platelet surface P-selectin and activated GPIIb-IIIa. *Circulation* 2005;112:II-389. (Presented at the 78<sup>th</sup> Scientific Sessions of the American Heart Association, Dallas, November 14, 2005.)
  382. Linden MD, Frelinger AL, Furman MI, Krueger LA, Li Y, Fox ML, Hughes A, Lown J, Barnard MR, Przyklenk K, **Michelson AD**. Detection and mechanisms of GPIIb-IIIa antagonist induced thrombocytopenia: role for antibody induced platelet activation. *Blood* 2005;106:472a. (Presented at the 47<sup>th</sup> Annual Meeting of the American Society of Hematology, New Orleans, December 2 – 6, 2005.)
  383. Frelinger AL, III, Jakubowski JA, Li Y, Barnard MR, Fox ML, Linden MD, Sugidachi A, Winters KJ, Furman MI, **Michelson AD**. The active metabolite of prasugrel (CS-747) inhibits ADP-stimulated

- thrombo-inflammatory markers of platelet activation: modulation by other blood cells and calcium, but not by aspirin. *Journal of the American College of Cardiology* 2006;47(suppl 1):364A. (Presented at the 55<sup>th</sup> Annual Scientific Session of the American College of Cardiology, Atlanta, March 14, 2006.)
384. Linden MD, **Michelson AD**, Barnard MR, Frelinger AL, Furman MI, Przyklenk K. Does adenosine A<sub>2</sub> receptor stimulation trigger the favorable ‘anti-platelet’ effect of preconditioning ischemia? *Arteriosclerosis Thrombosis Vascular Biology* 2006;26:e-46. (Presented at the 7<sup>th</sup> Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association, Denver, April 27 – 29, 2006.)
  385. Linden MD, **Michelson AD**, Barnard MR, Frelinger AL, Furman MI, Przyklenk K. *In vitro* adenosine A<sub>2</sub> receptor stimulation inhibits platelet activation in humans. *Arteriosclerosis Thrombosis Vascular Biology* 2006;26:e-58. (Presented at the 7<sup>th</sup> Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association, Denver, April, 2006.)
  386. Li JS, Berezny KY, Yow E, Bokesch PM, Takahashi M, Graham TP, Sanders SP, Jennings LK, **Michelson AD**. Optimal dose of clopidogrel for platelet inhibition in children: primary results of the PICOLO trial. *Circulation* 2006;114:II-450. (Presented at the 79<sup>th</sup> Scientific Sessions of the American Heart Association, Chicago, November 13, 2006.)
  387. Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Sugidachi A, Winters KJ, Furman MI, **Michelson AD**. The active metabolite of prasugrel inhibits platelet procoagulant activities. *Circulation* 2006;114:II-699. (Presented at the 79<sup>th</sup> Scientific Sessions of the American Heart Association, Chicago, November 15, 2006.)
  388. Przyklenk K, Linden MD, Frelinger AL, **Michelson AD**. Targeted inhibition of serotonin 5-HT<sub>2A</sub> receptors attenuates recurrent platelet-mediated thrombosis in an *in vivo* model of unstable angina. Presented at the XXI Congress of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland, July 11, 2007
  389. Tarnow I, O’Sullivan BP, Frelinger AL, Linden MD, Li Y, Fox ML, Barnard MR, **Michelson AD**. Cystic fibrosis heterozygotes do not have increased platelet activation. Presented at the XXI Congress of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland, July 11, 2007
  390. Przyklenk K, Linden MD, Frelinger AL, Teegarden B, Adams J, **Michelson AD**. Targeted inhibition of the serotonin 5-HT<sub>2A</sub> receptor improves coronary patency in an *in vivo* model of recurrent thrombosis. *Circulation* 2007;116:II-206. (Presented at the 80<sup>th</sup> Scientific Sessions of the American Heart Association, Orlando, Florida, November 4 – 7, 2007.)
  391. Psaila B, Bussel JB, Linden MD, Li Y, Barnard MR, Tate CM, Page LK, Frelinger AL, **Michelson AD**. *In vivo* effects of eltrombopag on human platelet function. *Blood* 2007;110:391a-392a. (Presented at the 49<sup>th</sup> Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 8, 2007.)
  392. Psaila B, Bussel JB, Linden MD, Li Y, Barnard MR, Tate CM, Page LK, Feldman EJ, Frelinger AL, **Michelson AD**. Comparison of platelet function and bleeding in thrombocytopenic patients with immune thrombocytopenic purpura (ITP) and chemotherapy-induced thrombocytopenia (CIT). *Blood* 2007;110:624a. (Presented at the 49<sup>th</sup> Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 9, 2007.)
  393. Chang H, Yanachkov IB, **Michelson AD**, Li Y, Barnard MR, Wright GE, Frelinger AL. Modified diadenosine tetraphosphonate derivatives synergistically inhibit platelet activation via both P2Y<sub>1</sub> and P2Y<sub>12</sub>. *Journal of the American College of Cardiology* 2008;51:A281. (Presented at the 57<sup>th</sup> Annual Scientific Session of the American College of Cardiology, Chicago, Illinois, March 30, 2008.)
  394. Frelinger AL, Li Y, Linden MD, Barnard MR, Fox ML, Furman MI, **Michelson AD**. Lack of association between cyclooxygenase-1-dependent platelet function assays and adverse clinical outcomes in 700 consecutive aspirin-treated patients presenting for cardiac catheterization. *Journal of the American College of Cardiology* 2008;51:A370. (Presented at the 57<sup>th</sup> Annual Scientific Session

of the American College of Cardiology, Chicago, Illinois, April 1, 2008.)

395. Tarnow L, **Michelson AD**, Barnard MR, Frelinger AL, Jensen BR, Aasted B, Parving H-H, Rossing P, Tarnow I. Type 1 diabetic nephropathy is associated with increased circulating activated platelets and platelet hyperreactivity. *Diabetologia* 2008;51(Suppl 1):S487. (Presented at the 44<sup>th</sup> Annual Meeting of the European Association for the Study of Diabetes [EASD], Rome, Italy, September 8 – 11, 2008.)
396. Frelinger AL, **Michelson AD**, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD. Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 trial. *Circulation* 2008;118:S\_814. (Presented at the 81<sup>st</sup> Scientific Sessions of the American Heart Association, New Orleans, Louisiana, November 11, 2008.)
397. Frelinger AL, **Michelson AD**, Wiviott SD, Trenk D, Neumann F-J, Miller DL, Jakubowski JA, Costigan TM, McCabe CH, Antman EM, Braunwald E. Intrinsic platelet variability in response to ADP before exposure to thienopyridines contributes to the variability in residual platelet reactivity to ADP after treatment with clopidogrel or prasugrel: results from PRINCIPLE-TIMI 44. *Circulation* 2008;118:S\_814. (Presented at the 81<sup>st</sup> Scientific Sessions of the American Heart Association, New Orleans, Louisiana, November 11, 2008.)
398. Frelinger AL, **Michelson AD**, Braunwald E, Trenk D, Neumann F-J, Miller DL, Jakubowski JA, Cairns R, Murphy SA, McCabe CH, Antman EM, Wiviott SD. Comparison of the effects of prasugrel and high dose clopidogrel on *in vivo* and *in vitro* platelet activation: results from PRINCIPLE-TIMI 44. *Circulation* 2008;118:S\_814. (Presented at the 81<sup>st</sup> Scientific Sessions of the American Heart Association, New Orleans, Louisiana, November 11, 2008.)
399. Frelinger AL, Li Y, Linden MD, Tarnow I, Barnard MR, Fox ML, **Michelson AD**. Aspirin “resistance”: role of pre-existent platelet reactivity and correlation between tests. *Circulation* 2008;118:S\_821. (Presented at the 81<sup>st</sup> Scientific Sessions of the American Heart Association, New Orleans, Louisiana, November 11, 2008.)
400. Chang H, Yanachkov IB, **Michelson AD**, Li Y, Barnard MR, Wright GE, Frelinger AL. Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y<sub>1</sub>, P2Y<sub>12</sub> and P2X<sub>1</sub> receptors. *Blood* 2008;112:5368
401. Darling C, Welch R, Yong R, Volturo G, **Michelson A**, Przyklenk K. Point-of-care measurement of platelet reactivity in the emergency department may assist in the early risk assessment of potential acute coronary syndromes. *Academic Emergency Medicine* 2009;16:S72. (Presented at the 2009 Society for Academic Emergency Medicine Annual Meeting, New Orleans, Louisiana, May 14 – 17, 2009.)
402. Scheer FAJL, Evoniuk H, Kelly EE, Hahn M, Hu K, Malhotra A, Barnard MR, Frelinger AL, **Michelson AD**, Shea SA. Effect of circadian system and behavioral stressors on platelet activity and reactivity: implications for the morning peak in cardiovascular incidents. *SLEEP* 2009;32:A47. (Presented at the 23<sup>rd</sup> Annual Meeting of the Associated Professional Sleep Societies, Seattle, Washington, June 6 – 11, 2009.)
403. Angiolillo DJ, Badimon J, Saucedo JF, Frelinger AL, **Michelson AD**, Jakubowski JA, Ojeh CK, Baker B, Zhu B, Effron MB. Comparison of prasugrel with clopidogrel on platelet function in coronary artery disease patients with type 2 diabetes mellitus – third Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS-3). *Circulation* 2009;120:S1027. (Presented at the 82<sup>nd</sup> Scientific Sessions of the American Heart Association, Orlando, Florida, November 15, 2009.)
404. Wilson SR, Angiolillo DJ, Frelinger AL, O'Donoghue M, Neumann F-J, **Michelson AD**, Miller DL, Luo J, McCabe CH, Antman EM, Braunwald E, Wiviott S. Platelet function in diabetes mellitus: observations from the PRINCIPLE-TIMI 44 trial. *Circulation* 2009;120:S548-549. (Presented at the 82<sup>nd</sup> Scientific Sessions of the American Heart Association, Orlando, Florida, November 18, 2009.)

405. Frelinger AL, Barnard MR, Fox ML, **Michelson AD**. The Platelet Activity after Clopidogrel Termination (PACT) study. *Circulation* 2009;120:S1145. (Presented at the 82<sup>nd</sup> Scientific Sessions of the American Heart Association, Orlando, Florida, November 18, 2009.)
406. Angiolillo DJ, Jakubowski JA, Frelinger AL, Zafar MU, Saucedo JF, **Michelson AD**, Zhu B, Ojeh CK, Baker BA, Effron MB. Lack of rebound in platelet reactivity following cessation of prasugrel or clopidogrel in type 2 diabetes mellitus patients with coronary artery disease: insights from OPTIMUS-3. (P2315: Presented at the European Society of Cardiology [ESC] Congress 2010, Stockholm, Sweden, August 28 – September 1, 2010.)
407. Bussel JB, Frelinger AL, Mitchell WB, Pinheiro MP, Barnard MR, Lampa M, Psaila B, Boulad N, Tamary H, **Michelson AD**. Platelet function and response to thrombopoietin mimetics in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. *Blood* 2010;116:1429. (Presented at the 52<sup>nd</sup> Annual Meeting of the American Society of Hematology, Orlando, Florida, December 4, 2010.)
408. Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, **Michelson AD**. Clopidogrel pharmacokinetics and pharmacodynamics vary widely, independent of CYP2C19 polymorphisms, diet, smoking, proton pump inhibitors and other co-medications. *Journal of the American College of Cardiology (JACC)* 2011;57:E927. (Presented at the 60<sup>th</sup> Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, April 3, 2011.)
409. Frelinger AL, Lee RD, Mulford DJ, Wu J, Bhatt DL, **Michelson AD**. A randomized, open-label, 2-period, crossover design study to assess the steady-state effects of dextansoprazole, lansoprazole, esomeprazole or omeprazole on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy subjects. *Journal of the American College of Cardiology (JACC)* 2011;57:E1098. (Presented at the 60th Annual Scientific Session of the American College of Cardiology, New Orleans, Louisiana, April 4, 2011.)
410. Frelinger AL, Jakubowski JA, Sugidachi A, Barnard MR, **Michelson AD**. The active metabolite of prasugrel augments GPIIb-IIIa antagonist inhibition of platelet activation and aggregation: complementary roles for inhibition of P2Y<sub>12</sub> and GPIIb-IIIa. *Journal of Thrombosis and Haemostasis* 2011;9(Suppl 2):339. (Presented at the XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23 – 28, 2011.)
411. Chang H, Shih L-Y, Dunn P, **Michelson AD**, Frelinger AL, Wang P-N, Kuo M-C, Lin T-L, Wu J-H, Tang T-C Increased platelet counts correlate with decreased function of platelet P2Y<sub>12</sub> receptors in patients with myeloproliferative neoplasm. *Journal of Thrombosis and Haemostasis* 2011;9(Suppl 2):777. (Presented at the XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23 – 28, 2011.)
412. Ferrer-Marin F, Chavda C, Lampa M, **Michelson AD**, Frelinger III AL, Sola-Visner M. Effects of in-vitro adult platelet transfusions on neonatal hemostasis. *Journal of Thrombosis and Haemostasis* 2011;9(Suppl 2):793. (Presented at the XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23 – 28, 2011.)
413. Harney KM, McSweeney J, **Michelson AD**, Neufeld EJ, Trenor CC. Pediatric anticoagulation: similar bleeding but fewer thromboembolic complications than adults. *Journal of Thrombosis and Haemostasis* 2011;9(Suppl 2):892. (Presented at the XXIII Congress of the International Society on Thrombosis and Haemostasis, Kyoto, Japan, July 23 – 28, 2011.)
414. Frelinger AL, Jakubowski JA, Brooks JK, Nigam A, Berny-Lang MA, Barnard MR, Heeney MM, **Michelson AD**. In vivo platelet activation and its in vitro inhibition by prasugrel's active metabolite in adolescents with sickle cell disease. *Blood* 2011;118:2141. (Presented at the 53<sup>rd</sup> Annual Meeting of the American Society of Hematology, San Diego, California, Florida, December 10 – 13, 2011.)
415. Flaumenhaft RC, **Michelson AD**, Peters CG. Platelet spreading requires exocytosis of a subpopulation of  $\alpha$ -granules expressing VAMP-7. *Blood* 2011;118:3248. (Presented at the 53<sup>rd</sup> Annual Meeting of the American Society of Hematology, San Diego, California, Florida, December

10 – 13, 2011.)

416. Frelinger AL, III, Jakubowski JA, Brooks JK, Zayas SL, Berny-Lang MA, Barnard MR, Heeney MH, **Michelson AD**. Platelet activation and inhibition in sickle cell disease (PAINS) study. *Blood* 2012;120:5147
417. Frelinger AL, III, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, **Michelson AD**. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (*CYP2C19*, *ABCB1*, *PON1*), non-compliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. *Blood* 2012;120:4356
418. Frelinger AL, III, Chang H, Dix EJ, Yanachkova M, Li Y, Barnard MR, Wright GE, **Michelson AD**, Yanachkov IB. Antiplatelet activity, P2Y<sub>1</sub> and P2Y<sub>12</sub> inhibition, and metabolism in plasma of diastereomers of the Ap4A analog diadenosine-5',5'''-P<sub>1</sub>,P<sub>4</sub>-dithio-P<sub>2</sub>,P<sub>3</sub>-chloromethylenetetraphosphate. *Journal of Thrombosis and Haemostasis* 2013;11(Suppl. 2):495. (Presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, July 1, 2013.)
419. Gerrits AJ, Barnard MR, Fitzpatrick MG, Berny-Lang MA, **Michelson AD**, Frelinger AL, III. Use of high-sensitivity flow cytometry for the characterization of a lyophilized platelet-derived hemostatic agent. *Journal of Thrombosis and Haemostasis* 2013;11(Suppl. 2):511. (Presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, July 1, 2013.)
420. Berny-Lang MA, Darling CE, Frelinger AL, Barnard MR, Gerrits AJ, **Michelson AD**. Does the immature platelet function (IPF) in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome? *Journal of Thrombosis and Haemostasis* 2013;11(Suppl. 2):731. (Presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, July 2, 2013.)
421. Brun C, Frelinger AL, Daali Y, Zufferey A, **Michelson A**, Combescure C, Fontana P, Reny J-L. Aspirin response: how to explain striking differences in serum TxB<sub>2</sub> levels across clinical studies and what use for serum TxB<sub>2</sub>? *Journal of Thrombosis and Haemostasis* 2013;11(Suppl. 2):761. (Presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands, July 3, 2013.)
422. Carreras ET, Hochholzer W, Frelinger AL, Hoffman EB, O'Donoghue ML, Wiviott SD, Angiolillo DJ, **Michelson AD**, Sabatine MS, Mega JL. Diabetes mellitus, CYP2C19 genotype, and pharmacodynamic response to clopidogrel dosing: insights from the ELEVATE-TIMI 56 trial. *Circulation* 2013;128: A12325. (Presented at the American Heart Association Scientific Sessions, Dallas, Texas, November 19, 2013.)
423. Gerrits AJ, Leven E, Frelinger AL, Berny-Lang MA, Tamary H, Revel-Vilk S, Carmichael SL, Mitchell WB, **Michelson AD**, Bussel JB. Effects of eltrombopag on thrombocytopenia, platelet function and bleeding in patients with Wiskott-Aldrich syndrome/X-Linked thrombocytopenia. *Blood* 2013;122:3536. (Presented at the 55<sup>th</sup> Annual Meeting of the American Society of Hematology, New Orleans, Louisiana, December 9, 2013.)
424. Frelinger AL, Gerrits AJ, Berny-Lang MA, Brown T, Carmichael SL, Neufeld EJ, **Michelson AD**, Grace RF. Association of platelet function markers, independent of platelet count, with bleeding score in patients with immune thrombocytopenia. *Blood* 2013;122:3534. (Presented at the 55<sup>th</sup> Annual Meeting of the American Society of Hematology, New Orleans, Louisiana, December 9, 2013.)
425. Frelinger AL, III, Torres AS, Caiafa A, Morton C, Berny-Lang MA, Gerrits AJ, Carmichael SL, Neculaes VB, **Michelson AD**. Therapeutic platelet-rich plasma: characterization of platelet activation and procoagulant markers, growth factor release, and cell proliferation following pulse electric field stimulation. *Journal of Thrombosis and Haemostasis* 2014;12(Suppl 1):76. 10.1111/jth.12588.

(Presented at the 60<sup>th</sup> Annual Meeting of the Scientific and Standardization Committee (SSC) of the International Society on Thrombosis and Haemostasis, Milwaukee, Wisconsin, June 23 - 26, 2014.)

## Narrative Report

My time is divided between research (80%) and clinical work (20%), with teaching overlapping both of these areas. My academic career has focused on platelet and thrombosis research, with my contributions encompassing basic, translational, and clinical research.

My research has included five areas:

- 1) *Studies of activated platelets*. For example, I developed novel methods for in vivo tracking of platelets and used these methods to demonstrate that circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function (*PNAS* 1996;93:11877-11882). This frequently-cited paper overturned the long-held, standard dogma that activated (degranulated) platelets are rapidly cleared from the circulation.
- 2) *Nitric oxide*. We demonstrated that platelet-derived nitric oxide markedly inhibits platelet recruitment (*J Clin Invest* 1997;100:359-356). Furthermore, we provided the first evidence in humans of a thrombotic disorder caused by a lack of nitric oxide (*J Clin Invest* 1996;97:979-987).
- 3) *Measurement of platelet function in patients*. My research group pioneered the application of flow cytometry to the study of platelets (*Blood* 1996;87:4925-4936) and has published more than 50 original research articles on this topic in high-impact peer-reviewed journals.
- 4) *Antiplatelet therapy*. For example, we conducted one of the very few randomized clinical trials of antithrombotic therapy in children (*Circulation* 2008;117:553-559).
- 5) *Evidence-based clinical practice guidelines*. I was the primary author of the first evidenced-based clinical practice guidelines for antithrombotic therapy in children (published by the Consensus Conference on Antithrombotic and Thrombolytic Therapy) (*Chest* 1995;108:506S-522S). I was subsequently the first or senior author on successive evidence-based clinical practice guidelines on antithrombotic therapy in children in 1998, 2001, 2004, and 2008 (by which time these pediatric evidence-based guidelines had grown to 82 journal pages). These guidelines are recognized nationally and internationally as the gold standard for antithrombotic therapy in children.

I am the editor of the textbook *Platelets* (Elsevier/Academic Press), which integrates the entire field of platelet biology, pathophysiology and clinical medicine into a comprehensive source of knowledge about platelets for clinicians, pathologists, and scientists. The first edition of *Platelets*, published in 2002, was the winner of the *Best Book in Medical Science* award from the Association of American Publishers and was called “landmark” by the *New England Journal of Medicine*. The 64-chapter, 1353-page third edition of *Platelets*, published in 2013, was the winner of the *Highly Commended Prize* in the category of Internal Medicine, British Medical Association (BMA) Medical Book Awards. This book, and the now biennial international platelet research conference that I co-organize ([www.platelets2014.org](http://www.platelets2014.org)), has, on a world-wide scale, brought together and catalyzed interactions between the many and disparate research and clinical groups with an interest in platelets, including biologists, pathologists, hematologists, cardiologists, stroke physicians, and blood bankers – as well as students and fellows in these fields.

My particular clinical expertise is in pediatric hemostasis and thrombosis – which synergizes with my research interests. My local teaching and mentoring of students, residents, fellows and junior faculty at Boston Children’s Hospital takes place in the following settings: the pediatric hematology clinic, the pediatric hematology inpatient service, the interdisciplinary pediatric thrombosis and hemostasis rounds (which I founded and chair), tutorials, lectures and at the research benches of the Center for Platelet

Research Studies. In addition, my teaching is national and international: I have been an invited speaker at over 170 major medical conferences both nationwide and worldwide (United States, Canada, United Kingdom, Germany, France, Italy, Spain, Austria, the Netherlands, Belgium, Switzerland, Denmark, Norway, Greece, Turkey, Israel, Japan, Australia).